LANXESS Solutions US (CEMJQ) 10-K 25 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data in Millions, unless otherwise specified	Dec. 31, 2014	Jan. 31, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	Chemtura CORP
Entity Central Index Key	1091862
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$2.30
Entity Common Stock, Shares Outstanding		69.3
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Operations
NET SALES	$467	$558	$609	$556	$544	$569	$590	$528	$2,190	$2,231	$2,196
COSTS AND EXPENSES
Cost of goods sold									1,682	1,721	1,615
Selling, general and administrative									255	229	246
Depreciation and amortization									102	101	100
Research and development									36	40	41
Facility closures, severance and related costs	19		4	2	14	3	11	14	25	42	11
Gain on sale of business	-529								-529
Equity loss											4
OPERATING INCOME									619	98	179
Interest expense									-45	-60	-64
Loss on early extinguishment of debt	-7					50			-7	-50	-1
Other income, net									12	8	15
Earnings (loss) from continuing operations before income taxes									579	-4	129
Income tax benefit (expense)									192	-18	-26
Earnings (loss) from continuing operations									771	-22	103
Earnings (loss) from discontinued operations, net of tax									1	25	-3
Loss on sale of discontinued operations, net of tax			-4	-5	-31	-3	-146		-9	-180
Net earnings (loss)									763	-177	100
Less: Net loss attributed to non-controlling interests											1
Net earnings (loss) attributable to Chemtura									763	-177	101
BASIC PER SHARE INFORMATION - ATTRIBUTABLE TO CHEMTURA:
Earnings (loss) from continuing operations, net of tax (in dollars per share)	$8.57	$0.17	$0.46	$0.10	$0.13	($0.45)	$0.27	($0.18)	$8.55	($0.23)	$1.04
Earnings (loss) from discontinued operations, net of tax (in dollars per share)				$0.01	($0.03)	$0.07	$0.26	($0.05)	$0.01	$0.26	($0.02)
Loss on sale of discontinued operations, net of tax (in dollars per share)			($0.04)	($0.05)	($0.32)	($0.03)	($1.48)		($0.10)	($1.84)
Net earnings (loss) attributable to Chemtura	$8.57	$0.17	$0.42	$0.06	($0.22)	($0.41)	($0.95)	($0.23)	$8.46	($1.81)	$1.02
DILUTED PER SHARE INFORMATION - ATTRIBUTABLE TO CHEMTURA:
Earnings (loss) from continuing operations, net of tax (in dollars per share)	$8.44	$0.17	$0.46	$0.10	$0.13	($0.45)	$0.27	($0.18)	$8.43	($0.23)	$1.04
Earnings (loss) from discontinued operations, net of tax (in dollars per share)				$0.01	($0.03)	$0.07	$0.26	($0.05)	$0.01	$0.26	($0.02)
Loss on sale of discontinued operations, net of tax (in dollars per share)			($0.04)	($0.05)	($0.32)	($0.03)	($1.46)		($0.10)	($1.84)
Net earnings (loss) attributable to Chemtura (in dollars per share)	$8.44	$0.17	$0.42	$0.06	($0.22)	($0.41)	($0.93)	($0.23)	$8.34	($1.81)	$1.02
Basic weighted - average shares outstanding (in shares)	82	89.4	93.2	96.3	96.6	97.5	98.6	98.2	90.2	97.7	98.2
Diluted weighted - average shares outstanding (in shares)	83.3	90.7	94.4	97.8	98.1	97.5	99.7	98.2	91.5	97.7	98.8
AMOUNTS ATTRIBUTABLE TO CHEMTURA STOCKHOLDERS:
Earnings (loss) from continuing operations, net of tax	703	15	43	10	13	-44	27	-18	771	-22	103
Earnings from discontinued operations, net of tax				1	-3	7	26	-5	1	25	-2
Loss on sale of discontinued operations, net of tax			-4	-5	-31	-3	-146		-9	-180
Net Income (Loss) Available to Common Stockholders, Basic									$763	($177)	$101

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Consolidated Statements of Comprehensive (Loss) Income
Net earnings (loss)	$763
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments net of income tax benefit (expense) of $10, $(3) and $(4)	-73
Unrecognized pension and other post-retirement benefit costs - net of income tax benefit (expense) of $39, $(16) and $14	-39
Unrealized loss on available for sale securities	-5
Unrealized loss on available for sale securities	-5
Comprehensive income (loss) income	646
Comprehensive income (loss) income attributable to Chemtura	$646

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Balance Sheets
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Tax	$10	($3)	($4)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax	$39	($16)	$14

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
CURRENT ASSETS
Cash and cash equivalents	$392	$549
Accounts receivable	251	234
Inventories	329	346
Other current assets	238	151
Assets held for sale	6	245
Total current assets	1,216	1,525
NON-CURRENT ASSETS
Property, plant and equipment	704	717
Goodwill	172	179
Intangible assets, net	99	114
Deferred tax asset - non-current	313	25
Other assets	163	144
Total Assets	2,667	2,704
CURRENT LIABILITIES
Short-term borrowings	18	117
Accounts payable	146	148
Accrued expenses	170	176
Below market obligation - current	38
Income taxes payable	24	5
Liabilities held for sale	9	38
Total current liabilities	405	484
NON-CURRENT LIABILITIES
Long-term debt	556	781
Pension and post-retirement health care liabilities	318	246
Below market obligation - non-current	185
Deferred tax liability - non-current	25	37
Other liabilities	124	160
Total liabilities	1,613	1,705
EQUITY
Common stock - $.01 par value, authorized - 500.0 shares, issued - 100.5 shares in 2014 and 2013	1	1
Additional paid-in capital	4,383	4,375
Accumulated deficit	-2,262	-3,025
Accumulated other comprehensive loss	-397	-280
Treasury stock at cost - 28.8 shares in 2014 and 4.0 shares in 2013	-672	-73
Total Chemtura stockholders' equity	1,053	998
Non-controlling interests	1	1
Total equity	1,054	999
Total Liabilities and Equity	$2,667	$2,704

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, except Per Share data, unless otherwise specified
Consolidated Balance Sheets
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, Authorized shares	500	500
Common stock, Issued shares	100.5	100.5
Treasury stock at cost, shares	28.8	4

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)	$763	($177)	$100
Adjustments to reconcile net earnings (loss) to net cash (used in) provided by operating activities:
Loss on sale of discontinued operations	9	180
Gain on sale of business	-529
Impairment charges		7	47
Agrochemical Manufacturing supply agreements	-6
Release of translation adjustment from liquidation of entities		-13	-21
Loss on early extinguishment of debt	7	50	1
Depreciation and amortization	102	123	139
Stock-based compensation expense	14	14	24
Deferred tax (benefit) expense	-274	1	3
Excess tax benefit from share-based payment arrangements	-5
Other non-cash transactions	8	-1
Changes in assets and liabilities, net:
Accounts receivable	-89	-20	-8
Inventories	-31	-13	-1
Other current assets	-27	-14	-4
Other assets	6	-18
Accounts payable	4	20	30
Accrued expenses	-37	-18	-3
Income taxes payable	19	5	-14
Pension and post-retirement health care liabilities	-27	-59	-79
Other liabilities	12	15	1
Other	3	-3	3
Net cash (used in) provided by operating activities	-78	79	218
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net	984	357	9
Payments for acquisitions, net of cash acquired		-3
Capital expenditures	-113	-170	-149
Net cash provided by (used in) investing activities	871	184	-140
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt	19	481	125
Payments on long term debt, includes premium on tendering of notes	-350	-502
(Payments on) proceeds from other short-term borrowings, net	-1	-1	-3
Payments for debt issuance and refinancing costs		-12	-2
Common shares acquired	-618	-54	-20
Proceeds from exercise of stock options	10	8	5
Excess tax benefit from share-based payment arrangements	5
Net cash (used in) provided by financing activities	-935	-80	105
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents	-15	1	2
Change in cash and cash equivalents	-157	184	185
Cash and cash equivalents at beginning of year	549	365	180
Cash and cash equivalents at end of year	$392	$549	$365

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Parent Company	Non Controlling Interests	Total
In Millions, unless otherwise specified
Balance at Dec. 31, 2011	$1	$4,353	($2,949)	($346)	($22)	$1,037	$9	$1,046
Balance (in shares) at Dec. 31, 2011	96.3
Increase (Decrease) in Stockholders' Equity
Net earnings			101			101	-1	100
Other comprehensive income (loss)				-82		-82		-82
Issuance of reorganized Chemtura common stock		1				1		1
Issuance of reorganized Chemtura common stock (in shares)	2.1
Dividends attributable to the non-controlling interest							-1	-1
Share-based compensation		24				24		24
Stock options exercised		1			4	5		5
Stock options exercised (in shares)	0.3
Common shares acquired					-20	-20		-20
Common shares acquired (in shares)	-1.4
Other issuances		-13			8	-5		-5
Other issuances (in shares)	0.7
Balance at Dec. 31, 2012	1	4,366	-2,848	-428	-30	1,061	7	1,068
Balance (in shares) at Dec. 31, 2012	98
Increase (Decrease) in Stockholders' Equity
Net earnings			-177			-177		-177
Other comprehensive income (loss)				148		148		148
Dividends attributable to the non-controlling interest							-6	-6
Share-based compensation		14				14		14
Stock options exercised		1			7	8		8
Stock options exercised (in shares)	0.5
Common shares acquired					-54	-54		-54
Common shares acquired (in shares)	-2.4
Other issuances		-6			4	-2		-2
Other issuances (in shares)	0.4
Balance at Dec. 31, 2013	1	4,375	-3,025	-280	-73	998	1	999
Balance (in shares) at Dec. 31, 2013	96.5
Increase (Decrease) in Stockholders' Equity
Net earnings			763			763		763
Other comprehensive income (loss)				-117		-117		-117
Share-based compensation		14				14		14
Stock options exercised		1			13	14		14
Stock options exercised (in shares)	0.6
Common shares acquired					-618	-618		-618
Common shares acquired (in shares)	-25.8							-25.8
Other issuances		-7			6	-1		-1
Other issuances (in shares)	0.4
Balance at Dec. 31, 2014	$1	$4,383	($2,262)	($397)	($672)	$1,053	$1	$1,054
Balance (in shares) at Dec. 31, 2014	71.7

NATURE_OF_OPERATIONS_AND_SUMMA

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	1)  NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Operations
	Chemtura Corporation, together with our consolidated subsidiaries, is a chemical company dedicated to delivering innovative, performance-driven engineered specialty chemical solutions which are used as additives, ingredients or intermediates which add value to our customers’ end products.  We are committed to global sustainability through “greener technology” and developing engineered chemical solutions that meet our customers’ evolving needs.  We operate in a wide variety of end-use industries, including automotive, building and construction, electronics, energy lubricants, packaging and transportation. We are a leader in many of our key product lines and transact business in more than 80 countries.
	With the completion of the sale of our Chemtura AgroSolutions business in 2014 and our antioxidant and UV stabilizer (“Antioxidants”) and Consumer Products businesses in 2013, we have completed our transformation into an operating company focused primarily on serving the global specialty chemical market.
	Our principal executive offices are located in Philadelphia, Pennsylvania and Middlebury, Connecticut.
	When we use the terms “Corporation,” “Company,” “Chemtura,” “Registrant,” “We,” “Us” and “Our,” unless otherwise indicated or the context otherwise requires, we are referring to Chemtura Corporation and our consolidated subsidiaries.
	Basis of Presentation
	The accompanying Consolidated Financial Statements include the accounts of Chemtura and our wholly-owned and majority-owned subsidiaries that we control.  Other affiliates in which we have a 20% to 50% ownership interest or a non-controlling majority interest are accounted for in accordance with the equity method.  Other investments in which we have less than 20% ownership are recorded at cost.  All significant intercompany balances and transactions have been eliminated in consolidation.
	Our Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from these estimates.
	Certain prior year amounts have been reclassified to conform to the current year’s presentation.  These changes did not have a material impact on previously reported results of operations, cash flows or financial position.
	Accounting Policies
	Revenue Recognition
	Substantially all of our revenues are derived from the sale of products.  Revenue is recognized when risk of loss and title to the product is transferred to the customer.  Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities with the collected taxes recorded as current liabilities until remitted to the respective governmental authorities.  Our products are sold subject to various shipping terms.  Our terms of delivery are included on our sales invoices and order confirmation documents.
	We record the revenue and costs associated with our supply agreements for our Agrochemical Manufacturing segment on a gross basis.  Additionally, included in revenue for this segment is the recognition of the below market contract obligation associated with these supply agreements, on a straight-line basis based on our estimate of the timing of shipments.
	Customer Rebates
	We accrue for the estimated cost of customer rebates as a reduction of sales.  Customer rebates are primarily based on customers achieving defined sales targets over a specified period of time.  We estimate the cost of these rebates based on the likelihood of the rebate being achieved and recognize the cost as a deduction from sales when such sales are recognized.
	Rebate programs are monitored on a regular basis and adjusted as required.  Customer rebates are included as a reduction to accounts receivable on our Consolidated Balance Sheet.  Activity in customer rebate accounts is a follows:
	(In millions)		2014			2013			2012
	Balance, January 1		$	10		$	14		$	14
	Charged to costs and expenses		37			36			8
	Payments to customers		(40		)	(40		)	(8		)
	Other(1)		(5		)	—			—
	Balance, December 31		$	2		$	10		$	14
		-1		Relates to the sale of Chemtura AgroSolutions in November 2014.
	Operating Costs and Expenses
	Cost of goods sold (“COGS”) includes all costs incurred in manufacturing goods, including raw materials, direct manufacturing costs and manufacturing overhead.  COGS also includes warehousing, distribution, engineering, purchasing, customer service, environmental, health and safety functions, and shipping and handling costs for outbound product shipments.  Selling, general and administrative (“SG&A”) expenses include costs and expenses related to the following functions and activities: selling, advertising, legal, provision for doubtful accounts, corporate facilities and corporate administration.  SG&A also includes accounting, information technology, finance and human resources, excluding direct support in manufacturing operations, which is included as COGS.  Research and development (“R&D”) expenses include basic and applied research and development activities of a technical and non-routine nature.  R&D costs are expensed as incurred.  COGS, SG&A and R&D expenses exclude depreciation and amortization expenses which are presented on a separate line in our Consolidated Statements of Operations.
	Other Income (Expense), Net
	Other income (expense), net includes:
	(In millions)		2014			2013			2012
	Foreign exchange gain (loss)		$	10		$	(7	)	$	(6	)
	Interest income		3			3			5
	Release of cumulative foreign currency translation adjustments from liquidation of entities		—			13			21
	Reorganization items, net		(1		)	(1		)	(5		)
			$	12		$	8		$	15
	Allowance for Doubtful Accounts
	The allowance for doubtful accounts reflects a reserve representing our estimate of the amounts that may not be collectible.  In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserves, including historical data, experience, customer types, credit worthiness, and economic trends.  From time to time, we may adjust our assumptions for anticipated changes in any of these or other factors expected to affect collection.  Allowances for doubtful accounts are included as a reduction to accounts receivable in our Consolidated Balance Sheet.  Activity in allowance for doubtful accounts is a follows:
	(In millions)		2014			2013			2012
	Balance, January 1		$	11		$	11		$	15
	Charged to costs and expenses		8			2			2
	Write-offs		(3		)	(1		)	(6		)
	Other(1)		(14		)	(1		)	—
	Balance, December 31		$	2		$	11		$	11
		-1		Relates to the sale of Chemtura AgroSolutions in November 2014.
	Inventory Valuation
	Inventories are valued at the lower of cost or market.  Cost is determined using the first-in, first-out (“FIFO”) method.
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation.  Depreciation expense is principally computed on the straight-line method using the following ranges of asset lives: land improvements - 3 to 20 years; buildings and improvements - 2 to 40 years; machinery and equipment - 2 to 25 years; information systems and equipment - 2 to 10 years; and furniture, fixtures and other - 1 to 10 years.  See Note 5 — Property, Plant and Equipment for further information.
	Renewals and improvements that significantly extend the useful lives of the assets are capitalized.  Capitalized leased assets and leasehold improvements are depreciated over the shorter of their useful lives or the remaining lease term.  Expenditures for maintenance and repairs are charged to expense as incurred.
	Intangible Assets
	Patents, trademarks and other intangibles assets are being amortized principally on a straight-line basis using the following ranges for their estimated useful lives: patents - 10 to 20 years; trademarks - 30 to 40 years; customer relationships - 15 to 30 years; production rights - 10 years; and other intangibles - 5 to 50 years.  See Note 6 — Goodwill and Intangible Assets for further information.
	Marketable Securities
	We apply the provision of ASC Topic 360 - Investments - Debt and Equity Securities (“ASC 320”), in evaluating and accounting for marketable securities.  Our primary marketable security is 2 million shares of Platform Specialty Products Corporation (“Platform”) common stock of which was acquired as part of the sale of our Chemtura AgroSolutions business in 2014.  The stock is restricted from trading for a period of six months from the date of sale.  We have deemed these securities to be considered available-for-sale.  The valuation of these securities is based upon Level 2 valuation techniques.  As of December 31, 2014. the value of the shares of $45 million was included in Other Current Assets on our Consolidated Balance Sheet.  Changes in the valuation of these securities is included in Accumulated Other Comprehensive Loss (“AOCL”) on our Consolidated Balance Sheet.
	Asset Retirement Obligation
	We apply the provisions of ASC Topic 410, Asset Retirements and Environmental Obligations (“ASC 410”), which requires us to make estimates regarding future events in order to record a liability for asset retirement obligations in the period in which a legal obligation is created.  Such liabilities are recorded at fair value, with an offsetting increase to the carrying value of the related long-lived assets.  The fair value is estimated by discounting projected cash flows over the estimated life of the assets using our credit adjusted risk-free rate applicable at the time the obligation is initially recorded.  In future periods, the liability is accreted to its present value and the capitalized cost is depreciated over the useful life of the related asset.  We also adjust the liability for changes resulting from revisions to the timing of future cash flows or the amount of the original estimate.  Upon retirement of the long-lived asset, we either settle the obligation for its recorded amount or incur a gain or loss.
	Our asset retirement obligations are primarily the result of legal obligations for the removal of leasehold improvements and restoration of premises to their original condition upon termination of leases; legal obligations to close brine supply, brine disposal, waste disposal and hazardous waste injection wells and the related pipelines at the end of their useful lives; and decommissioning and decontamination obligations that are legally required to be fulfilled upon closure of our manufacturing facilities.
	During 2014 and 2013, accretion expense recorded to COGS was $3 million.  At December 31, 2014, $3 million of the asset retirement obligation balance was included in accrued expenses and $13 million was included in other liabilities in our Consolidated Balance Sheet.  At December 31, 2013, $3 million of the asset retirement obligation balance was included in accrued expenses and $13 million was included in other liabilities in our Consolidated Balance Sheet.
	Recoverability of Long-Lived Assets and Goodwill
	We evaluate the recoverability of the carrying value of long-lived assets, excluding goodwill, whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Under such circumstances, we assess whether the projected undiscounted cash flows of our long-lived assets are sufficient to recover the existing unamortized cost of our long-lived assets.  If the undiscounted projected cash flows are not sufficient, we calculate the impairment amount by discounting the projected cash flows using our weighted-average cost of capital.  The amount of the impairment is written off against earnings in the period in which the impairment is determined.
	We have elected to perform our annual goodwill impairment procedures for all of our reporting units in accordance with ASC Subtopic 350-20, Intangibles — Goodwill and Other - Goodwill (“ASC 350-20”) as of July 31, or sooner, if events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below the carrying value.  We estimate the fair value of our reporting units utilizing income and market approaches through the application of discounted cash flow and market comparable methods (Level 3 inputs as described in Note 14 — Financial Instruments and Fair Value Measurements).  The assessment is required to be performed in two steps: step one to test for a potential impairment of goodwill and, if a potential impairment is identified, step two to measure the impairment loss through a full fair valuation of the assets and liabilities of the reporting unit utilizing the acquisition method of accounting.  We concluded that no goodwill impairment existed in any of our reporting units based on our reviews in 2014 and 2013.
	Income Taxes
	We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities using enacted rates. The effect of a change in tax rates on deferred tax assets is recognized in income in the period that includes the enactment date.
	We recognize the financial statement effects of an uncertain income tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We accrue for other tax contingencies when it is probable that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated.
	Provision is made for taxes on undistributed earnings of foreign subsidiaries and related companies to the extent that such earnings are not deemed to be indefinitely reinvested.
Valuation allowances are established when we determine that it is more likely than not that the results of future operations will not generate sufficient taxable income to realize our deferred tax assets. We consider the scheduled reversal of deferred tax assets and liabilities, projected future taxable income, and tax planning strategies in making this assessment. Thus, changes in future results of operations could result in adjustments to our valuation allowances.
Environmental Liabilities
Each quarter, we evaluate and review our estimates for future remediation, operation and management costs directly related to environmental remediation, to determine appropriate environmental reserve amounts.  For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments to implement the remediation plan will occur. In regards to remediation costs, we accrue on an undiscounted basis, for a period of generally no more than 10 years, those costs which are probable and estimable.  At sites where we expect to incur ongoing operations and maintenance expenditures, we accrue on an undiscounted basis, for a period of generally no more than 10 years, those costs which are probable and estimable.
Below-Market Obligation
Contemporaneously with the sale of our Chemtura AgroSolutions business we entered into supply agreements with Platform to manufacture products of that business.  The supply agreements were designed to recover the cash costs incurred to manufacture the products under the agreements and do not include reimbursement for depreciation and amortization of property, plant and equipment we have retained to perform under these supply agreements.  As such, we have determined that the supply agreements with Platform are below-market. To determine the undiscounted value of this obligation we utilized a Level 3 fair value technique.  Our fair value calculation was based upon taking the reduction in selling prices on a before and after basis factoring in the the favorable cost benefit of reduced SG&A, R&D and distribution expense.  Historical volumes under the supply agreements are anticipated to represent the requirements of Platform on a going forward basis.  We did not consider depreciation or amortization as these amounts are not reimbursable under the terms of the supply agreements.  We applied a growth factor to each year to represent inflation over the terms of the supply agreements.  We discounted the calculated loss of profits for those products over the period of the supply agreements by applying our internal weighted average cost of capital to determine the amount of the initial obligation.
Accretion of the obligation to its undiscounted fair value and the recognition of the below market contract obligation is taken to net sales on a straight-line basis over the estimated 6 year life of the supply agreements based on the estimated timing of shipments on an annual basis.
Litigation and Contingencies
In accordance with guidance now codified under ASC Topic 450, Contingencies and ASC Topic 460, Guarantees, we record in our Consolidated Financial Statements amounts representing our probable and estimable liability for claims, litigation and guarantees.  As information about current or future litigation or other contingencies becomes available, management assesses whether such information warrants the recording of additional expenses relating to those contingencies.  See Note 15 - Legal Proceedings and Contingencies for further information.
Stock-Based Compensation
We recognize compensation expense for stock-based awards issued over the requisite service period for each separately vesting tranche, as if multiple awards were granted.  Stock-based compensation expense is measured at the date of grant, based on the fair value of the award.  We used the Monte-Carlo simulation model to determine the fair value of performance shares.  We used the Black-Scholes option-pricing model to determine the fair value of nonqualified stock options.  See Note 12 - Stock Incentive Plans for further information.
Translation of Foreign Currencies
Balance sheet accounts denominated in foreign currencies are translated at the current rate of exchange as of the balance sheet date, while revenues and expenses are translated at average rates of exchange during the periods presented.  The cumulative foreign currency adjustments resulting from such translation are included in accumulated other comprehensive loss. Upon complete or substantial liquidation of any of our subsidiaries, the value of the cumulative translation adjustment of such subsidiaries prior to their liquidation is reported in net earnings.
Derivatives and Hedging
Our activities expose our earnings, cash flows and financial condition to a variety of market risks, including the effects of changes in foreign currency exchange rates, interest rates and energy prices.  We maintain a risk management strategy that may utilize derivative instruments to mitigate risk against foreign currency movements and to manage energy price volatility.  We do not enter into derivative instruments for trading or speculative purposes.
We have exposure to changes in foreign currency exchange rates resulting from transactions entered into by us and our foreign subsidiaries in currencies other than their functional currency (primarily trade payables and receivables).  We are also exposed to currency risk on intercompany transactions (including intercompany loans).  We manage these currency risks on a consolidated basis, which allows us to net our exposure.
There were no outstanding derivatives at December 31, 2014.
Cash Flows
Cash and cash equivalents include bank term deposits with original maturities of three months or less.
In March 2009, Chemtura and 26 of our affiliates filed for relief under Chapter 11 of Title 11 of the United States Code (“Chapter 11”) the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”).  In November 2010, the Bankruptcy Court entered an order confirming our plan of reorganization (the “Plan”).  In 2012, we settled approximately $5 million in cash relating to our Chapter 11 cases.  The $5 million paid in 2012, was paid from restricted cash.  Additionally, in 2012 we issued approximately $26 million of common stock for the settlement of liabilities in accordance with the Plan.
Cash payments included interest payments of $46 million in 2014, $57 million in 2013 and $58 million in 2012.  Cash payments also included income tax payments, net of refunds of $68 million in 2014, $21 million in 2013 and $45 million in 2012.
Accounting Developments
In March 2013, the FASB issued ASU No. 2013-05, Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (“ASU 2013-05”).  The amendments in ASU 2013-05 address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity.  The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted).  The adoption of this amendment did not have a material impact on our financial statements.
In July 2013, the FASB issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, providing guidance on the presentation of unrecognized tax benefits in the financial statements as either a reduction to a deferred tax asset or either a liability to better reflect the manner in which an entity would settle at the reporting date any additional income taxes that would result from the disallowance of a tax position when net operating loss carryforwards, similar tax losses or tax credit carryforwards exist.  The amendments in this ASU do not require new recurring disclosures and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.  The adoption of this guidance did not have a material impact on our financial statements.
In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.  This guidance improves GAAP by more faithfully representing when a company or other organization discontinues its operations. ASU 2014-08 changed the criteria for reporting a discontinued operation.  Under the new guidance, a disposal of part of an organization that has a major effect on its operations and financial results is a discontinued operation.  ASU 2014-08 is effective on a prospective basis for interim and annual periods beginning on or after December 15, 2014 although early adoption is permitted.  We chose not to early adopt this standard in the quarter ended June 30, 2014 when evaluating the sale of our Chemtura AgroSolutions business as a discontinued operation.  See Note 2 - Divestitures and Acquisitions for our analysis of that transaction.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers.  This ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective.  The new standard is effective on January 1, 2017.  Early application is not permitted.  The standard permits the use of either the retrospective or cumulative effect transition method.  We are evaluating the effect that the ASU will have on our consolidated financial statements and related disclosures.  We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.
Risks and Uncertainties
Our revenues are largely dependent on the continued operation of our manufacturing facilities.  There are many risks involved in operating chemical manufacturing plants, including the breakdown, failure or substandard performance of equipment, operating errors, natural disasters, the need to comply with directives of, and maintain all necessary permits from, government agencies as well as potential terrorist attacks.  Our operations can be adversely affected by raw material shortages, labor force shortages or work stoppages and events impeding or increasing the cost of transporting our raw materials and finished products.  The occurrence of material operational problems, including but not limited to the events described above, may have a material adverse effect on the productivity and profitability of a particular manufacturing facility.  With respect to certain facilities, such events could have a material effect on Chemtura as a whole.
Our operations are also subject to various hazards incident to the production of industrial chemicals.  These include the use, handling, processing, storage and transportation of certain hazardous materials.  Under certain circumstances, these hazards could cause personal injury and loss of life, severe damage to and destruction of property and equipment, environmental damage and suspension of operations.  Claims arising from any future catastrophic occurrence at any one of our facilities may result in us being named as a defendant in lawsuits asserting potential claims.
We perform ongoing credit evaluations of our customers’ financial condition including an assessment of the impact, if any, of prevailing economic conditions.  We generally do not require collateral from our customers.  We are exposed to credit losses in the event of nonperformance by counterparties on derivative instruments when utilized.  The counterparties to these transactions are major financial institutions, which may be adversely affected by global economic impacts.  However, we consider the risk of default to be minimal.
International operations are subject to various risks which may or may not be present in U.S. operations.  These risks include political instability, the possibility of expropriation, restrictions on dividends and remittances, instabilities of currencies, requirements for governmental approvals for new ventures and local participation in operations such as local equity ownership and workers’ councils.  Currency fluctuations between the U.S. dollar and the currencies in which we conduct business have caused and will continue to cause foreign currency transaction gains and losses, which may be material.  Any of these events could have an adverse effect on our international operations.

DIVESTITURES_AND_ACQUISITIONS

DIVESTITURES AND ACQUISITIONS	12 Months Ended
	Dec. 31, 2014
DIVESTITURES AND ACQUISITIONS
DIVESTITURES AND ACQUISITIONS
	2)  DIVESTITURES AND ACQUISITIONS
	Divestitures
	Chemtura AgroSolutions Business
	On November 3, 2014 we sold our Chemtura AgroSolutions business to Platform under a Stock and Asset Purchase Agreement (“SAPA”) for approximately $1 billion, consisting of $950 million in cash and 2 million shares of Platform’s common stock. The purchase price is subject to customary post-closing adjustments, primarily for working capital.  The agreement specified a value of working capital based upon a twelve-month average against which working capital would be measured.  To the extent working capital at closing was lower than this value, Platform would be compensated for the difference.  If working capital was higher, we would be compensated.  The impact of some of these adjustments was estimated in the cash paid at closing.  Under the terms of the SAPA, we will retain most of the property, plant and equipment used to manufacture products of the Chemtura AgroSolutions business and will continue to manufacture products for Platform under several supply agreements and a tolling agreement (collectively, the “supply agreements”) with minimum terms of between two and four years.  In alignment with the change in the nature of operations, we changed the name of this segment to Agrochemical Manufacturing.
	The supply agreements with Platform are designed to recover the cash costs incurred to manufacture the products under the agreement.  Because of this, the supply agreements are considered below-market contracts for their full term.  We have recorded an obligation of $230 million as of November 3, 2014, on a discounted basis, which represents the loss of profit on these products over the terms of the supply agreements, including contractual obligations to continue to supply for a period of up to 2 years after the termination of the contracts.  The recognition of this obligation, along with the accretion of the obligation to its undiscounted value of $345 million as of November 3, 2014, will be recorded as net sales on a straight-line basis over the term of each supply agreement based on our estimate of the timing of shipments.  Although the recognition of this obligation will be recorded as net sales to the Agrochemical Manufacturing segment over this period, this recognition will not generate cash flows during the term of the supply agreements.  As of December 31, 2014, the remaining below market obligation, on a discounted basis was $223 million of which $38 million and $185 million was the current and long-term portions, respectively.
	In connection with the sale, we entered into a transitional services agreement which requires us to provide various support services to Platform for periods ranging from 6 months to one year.  These services are reimbursable by Platform.
	We evaluated the transaction and determined that as of April 30, 2014, upon signing of the SAPA, those assets that form part of the transaction under the SAPA met the criteria to be reported as assets held for sale and we ceased recording depreciation and amortization on these assets as of that date.  As of December 31, 2014, we had not transferred ownership of our wholly-owned subsidiary in Russia and our 15% investment in Certis Europe B.V. to Platform as provided in the SAPA due to customary pending approvals.  The value ascribed to these investments as part of the purchase price was received at the closing in 2014.  We have reported the assets and liabilities, along with the proceeds received for these investments, as assets and liabilities held for sale on our December 31, 2014 consolidated balance sheet.  As of January 31, 2015, we have closed on the sale of our subsidiary in Russia.
	We further evaluated whether the Chemtura AgroSolutions business met the criteria to be presented as a discontinued operation under the provisions of ASC 205-20-45.  Due to the significant gross cash flows associated with the post-closing supply agreements, we concluded that the Chemtura AgroSolutions business did not meet the criteria to be presented as a discontinued operation.  As a result, the historical results of the Chemtura AgroSolutions business through the date of sale as well as the results associated with the supply agreements from the date of sale will be presented in continuing operations as the Agrochemical Manufacturing segment.
	We recognized a pre-tax gain on the sale of the business of $529 million in operating income, which included a $3 million non-cash gain related to the release of accumulated other comprehensive loss (“AOCL”) associated with the release of cumulative translation adjustments of the entities sold.
	The following is a summary of the assets and liabilities sold or settled related to the Chemtura AgroSolutions business as of November 3, 2014 and the assets and liabilities held for sale as of December 31, 2014 and December 31, 2013.
	(In millions)		December 31, 2014			November 3, 2014			December 31, 2013
	Cash and cash equivalents		$	—		$	7		$	—
	Accounts receivable, net		3			158			128
	Inventories, net		1			94			71
	Other current assets		—			8			7
	Property, plant and equipment		—			11			8
	Intangible assets, net		—			32			28
	Other assets		2			3			3
	Assets		6			313			245
	Accounts payable		—			21			24
	Accrued expenses		9			30			13
	Income taxes payable		—			4			1
	Liabilities		9			55			38
	Net Assets		$	(3	)	$	258		$	207
	The following table reconciles the adjusted cash proceeds to the pre-tax gain on the sale:
	(In millions)		2014
	Cash consideration		$	950
	Pre-closing working capital and other adjustments		28
	Cash proceeds		978
	Platform Stock (1)		51
	Less direct items:
	Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effect		258
	Below market supply contract		230
	Transaction costs and other (2)		21
	Post-closing adjustments, obligations and other, net		(6		)
	Less non-cash items:
	Release of AOCL - cumulative translation adjustment		(3		)
	Pre-tax gain on sale of Chemtura AgroSolutions		$	529
	(1) Represents 2 million shares of PSP common stock at $26.00 per share discounted for the value of a restriction to sell of $1 million.
	(2) Transaction costs include success fees to a financial adviser, legal fees and other direct costs incurred to sell the business since October 1, 2014.
	Divestitures Reported as Discontinued Operations
	Consumer Divestiture
	In December 2013, we sold our investment in the dedicated legal entities that constituted our Consumer Products business, including dedicated manufacturing plants in the U.S. and South Africa, to KIK Customer Products Inc. (“KIK”) for $300 million and the assumption by KIK of pension and other liabilities totaling approximately $8 million.  The purchase price was subject to customary post-closing adjustments, primarily for working capital and assumed pension liabilities.  The agreement specified a value of working capital based upon a twelve-month average against which working capital would be measured.  To the extent working capital at closing was lower than this value, KIK would be compensated for the difference.  If working capital was higher, we would be compensated.  The impact of some of these adjustments was estimated in the cash paid at closing.  In March 2014, KIK made an advance payment of $9 million ahead of the final adjustments.  In July 2014, the parties reached agreement on the post-closing working capital and indebtedness adjustments.  The remaining payment of $5 million due from KIK was received in July 2014.
	In connection with the sale, we entered into a transition services agreement to provide various support services and a supply contract with KIK to supply products from our Adrian, MI facility.  Under the terms of the supply contract, KIK had the option, exercisable for a period of six-months following the closing date, to purchase the net assets of the Adrian facility at a price that is below the carrying value of the net assets.  Accordingly, as of December 31, 2013, we concluded the net assets of the Adrian facility met the criteria to be classified as assets held for sale and we recorded an impairment charge in December 2013 of $7 million to write-down the property, plant and equipment to its fair value less the costs to sell.  The option expired un-exercised as of June 30, 2014 and the assets and liabilities are now classified as held and used in both the current and prior periods.  See Note 3 - Restructuring and Asset Impairment for a further discussion of initiatives related to that plant.
	In 2014, we recognized a pre-tax loss of $8 million ($8 million after-tax), primarily for transaction costs and post-closing adjustments and obligations.  In 2013, we recognized a pre-tax loss of $24 million ($25 million after-tax), which included a $39 million non-cash gain related to the release of accumulated other comprehensive loss (“AOCL”) associated with the release of cumulative translation adjustments of the entities sold and the pension obligations transferred.
	While the transaction represented the sale of stock in the dedicated legal entities that constituted the Consumer Products business, the below chart presents the underlying assets and liabilities of those legal entities as assets and liabilities of discontinued operations.  Earnings and direct costs associated with our Consumer Products business have been presented as earnings (loss) from discontinued operations, net of tax in our Consolidated Statements of Operations for the current and comparative periods.  All applicable disclosures included in the accompanying footnotes have been updated to reflect the Consumer Products business as a discontinued operation.
	(In millions)		December 31, 2013
	Cash and cash equivalents		$	13
	Accounts receivable, net		55
	Inventories, net		64
	Current domestic tax assets reversed upon sale		7
	Other current assets, includes foreign deferred tax assets		8
	Property, plant and equipment		63
	Intangible assets, net		195
	Other assets		5
	Assets		410
	Accounts payable		16
	Accrued expenses		14
	Income taxes payable		—
	Pension and post-retirement health care liabilities		6
	Domestic tax liabilities reversed upon sale		44
	Other liabilities, includes foreign deferred tax liabilities		32
	Liabilities		112
Net Assets		$	298
The following table reconciles the adjusted cash proceeds to the pre-tax loss on the sale:
(In millions)		2014			2013
Cash consideration					$	300
Working capital and other adjustments		$	(3	)	(36		)
Cash proceeds					264
Less direct items:
Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effect					335
Transaction costs and other (1)		5			10
Post-closing adjustments, obligations and other, net					(18		)
Less non-cash items:
Release of AOCL - pension					5
Release of AOCL - cumulative translation adjustment					(44		)
Pre-tax loss on sale of discontinued operations		$	(8	)	$	(24	)
	-1		Transaction costs include legal fees and other direct costs incurred to sell the business since October 1, 2013.
Antioxidant Divestiture
In April 2013, we sold substantially all the assets of our Antioxidant business (the “Antioxidant Sale”) to SK Blue Holdings, Ltd. (“SK”), an affiliate of SK Capital Partners III, L.P., and Addivant USA Holdings Corp (“Addivant”) for $97 million, $9 million in preferred stock issued by Addivant and the assumption by SK and Addivant of pension, environmental and other liabilities totaling approximately $91 million.  Additionally, we paid $2 million in cash as part of a pre-closing adjustment.  We received the final payment for the remaining working capital adjustment of $4 million in March 2014.
Included as part of the consideration, we received 9.2 million shares of Series A Preferred Stock of Addivant with a face value of $9 million.  These shares accrue dividends at escalating rates beginning at 7% in the first year and up to 11% in the third year and beyond which are payable upon declaration and which become preferential payments in liquidation if not declared and paid by Addivant.  Addivant did not declare any dividends through December 31, 2014.
In connection with the sale, we entered into several ancillary agreements, including site sharing and supply agreements, a distribution agreement and a transition services agreement.
In 2014, we recognized a pre-tax loss of $1 million ($1 million after-tax) primarily related to the final settlement of the working capital component of the transaction.  In 2013, we recognized a pre-tax loss of $164 million ($155 million after-tax), which included $121 million of non-cash charges related to the release of AOCL associated with the pension obligations transferred, the release of cumulative translation adjustments and the release of our non-controlling interest in a Korean joint venture.
Earnings and direct costs associated with the Antioxidant business for the periods prior to the date of the sale have been presented as earnings (loss) from discontinued operations, net of tax for the current and comparative periods.  All applicable disclosures included in the accompanying footnotes have been updated to reflect the Antioxidant business as a discontinued operation.
The following is a summary of the assets and liabilities sold or settled related to the Antioxidant business as of April 30, 2013.
(In millions)		April 30, 2013
Cash and cash equivalents		$	2
Accounts and trade receivable, net		70
Inventories, net		76
Other current assets		2
Property, plant and equipment		48
Intangible assets, net		14
Other assets		32
Assets		244
Accounts payable		39
Accrued expenses		2
Income taxes payable		—
Pension and post-retirement health care liabilities		81
Other liabilities		11
Liabilities		133
Net Assets		$	111
Assets sold or settled consisted primarily of plant facilities located at Morgantown, West Virginia, Bay Minette, Alabama, Waldkraiburg, Germany and Catenoy, France; our shares in the Asia Stabilizers joint venture, located in Korea, a previously controlled consolidated entity; our shares in Gulf Stabilizers Industries, located in Saudi Arabia, a previously 49% owned equity method investment; certain dedicated operating equipment located at Latina, Italy and Elmira, Canada; intangible assets and working capital associated with the Antioxidants business.
We retained ownership of certain manufacturing assets that will be used to meet our obligations under the supply agreements in Canada, Italy, the United States, Taiwan, Mexico, and Brazil.  The minimum terms of the supply agreements range from two to five years.  Based on the terms of the supply agreements and the forecasted costs to meet our obligations under those agreements, we have fair valued the supply agreements using Level 3 fair value techniques and included a $13 million charge in 2013 to the loss on sale of discontinued operations in our Consolidated Statement of Operations.
The following table reconciles the adjusted cash proceeds to the pre-tax loss on the sale:
(In millions)		2014			2013
Cash consideration					$	97
Working capital and other adjustments					(10		)
Post-closing adjustments		$	(1	)	(2		)
Cash proceeds					85
Preferred stock					9
Less direct items:
Net assets sold or settled					111
Transaction costs and other (1)					5
Post-closing obligations and other, net					8
Fair value of supply agreements					13
Less non-cash items:
Release of AOCL - pension					122
Release of AOCL - cumulative translation adjustment					6
Release of non-controlling interest					(7		)
Pre-tax loss on sale of discontinued operations		$	(1	)	$	(164	)
	-1		Transaction costs include legal fees and other direct costs incurred to sell the business since April 1, 2013.
Discontinued Operations - Consumer Products (“Consumer”) and Antioxidant Divestitures
Earnings (loss) from discontinued operations for the years ended December 31, 2014, 2013 and 2012 and the loss from the sale of discontinued operations for the year ended December 31, 2014 and 2013 consists of the following:
		Year Ended
(In millions)		2014			2014			2014			2013			2013			2013			2012			2012			2012
		Consumer			Antioxidant			Total			Consumer			Antioxidant			Total			Consumer			Antioxidant			Total
Net sales		$	—		$	—		$	—		$	408		$	123		$	531		$	433		$	387		$	820
Earnings (loss) from discontinued operations:
Pre-tax earnings (loss)		$	1		$	—		$	1		$	24		$	4		$	28		$	33		$	(45	)	$	(12	)
Income tax (expense) benefit		—			—			—			(3		)	—			(3		)	(2		)	11			9
Earnings (loss), net of taxes		1			—			1			21			4			25			31			(34		)	(3		)
Net loss attributable to non-controlling interests		—			—			—			—			—			—			—			1			1
Earnings (loss), net of taxes - attributable to Chemtura		$	1		$	—		$	1		$	21		$	4		$	25		$	31		$	(33	)	$	(2	)
Loss on sale of discontinued operations:
Pre-tax loss		$	(8	)	$	(1	)	$	(9	)	$	(24	)	$	(164	)	$	(188	)
Income tax (expense) benefit (a)		—			—			—			(1		)	9			8
Net loss		$	(8	)	$	(1	)	$	(9	)	$	(25	)	$	(155	)	$	(180	)
(a) Income tax expense on the sale of our Consumer Products business is primarily a cash tax charge for estimated U.S. Federal alternative minimum tax and state taxes. Deferred taxes in our non-U.S. entities are included in the calculation of the pre-tax loss on sale.  However, the reversal of deferred tax assets and liabilities of our U.S. entities are included in tax expense, reflecting the election made to treat the sale of stock of the U.S. legal entities in the transaction as a sale of assets.  The reversal of these U.S. net deferred tax liabilities increased the value of our consolidated U.S. net deferred tax assets against which we provide a valuation allowance.  The result was that there was no net deferred tax expense.  The income tax benefit on the sale of our Antioxidant business is primarily related to the domestic tax impacts of the release of AOCL related to pensions that was not offset by a valuation allowance and reduced by tax expense in various foreign jurisdictions.
A portion of certain functional and other expenses that are managed company-wide that are allocated to the Antioxidant and Consumer Products businesses have not or will not transfer directly under the respective sale agreements.  As such, in historic periods these costs are shown as part of continuing operations in the corporate segment and not included under earnings (loss) from discontinued operations, net of tax.  These costs are as follows:
(In millions)		2013			2012
Antioxidant		$	6		$	13
Consumer Products		14			13
Amortization expense (a)		(8		)	(14		)
Net increase in Corporate Segment		$	12		$	12
(a) Our Corporate segment included amortization expense which related directly to the Antioxidant and Consumer Products businesses which is now included in earnings (loss) from discontinued operations, net of tax.
Other Dispositions
Tetrabrom Joint Venture Divestiture
On November 28, 2011, we sold our 50% interest in Tetrabrom Technologies Ltd. for net consideration of $38 million.  The consideration was be paid in equal annual installments over a three-year period starting in 2012.  In April 2012, we purchased two forward contracts with a notional amount totaling $25 million to reduce the risk of currency exposure related to the remaining two annual installments of proceeds from the sale of our 50% interest in Tetrabrom Technologies Ltd. in 2011.  We used fair value accounting methods for these contracts.  One contract expired in the second quarter of 2013 and the second contract expired in the second quarter of 2014.  We have recorded realized gains of less than $1 million in 2014 and 2013 on these forward contracts.
ISEM Alliance
During 2013 we sold, in two separate transactions, two product lines of our investment in ISEM S.r.l. (“ISEM”), a strategic research and development alliance with Isagro S.p.A., for a sum of €38 million ($51 million).  Our remaining investment in ISEM was dissolved during the fourth quarter of 2014.
Acquisitions
Terminated Solaris Acquisition
In September 2012, we announced that we entered into a Business Transfer Agreement (“BTA”) with Solaris ChemTech Industries Limited (“Solaris ChemTech”), an Indian Company, and Avantha Holdings Limited, an Indian Company and the parent company of Solaris ChemTech (collectively, “Solaris”) to purchase from Solaris certain assets used in the manufacture and distribution of bromine and bromine chemicals.  In September 2014, the BTA was terminated due to the inability to satisfy certain conditions precedent to the closing and the changes in bromine market conditions since 2012.  Neither party incurred any early termination penalties.
DayStar Acquisition
In May 2013, we purchased the remaining 50% interest in DayStar Materials, LLC (“Daystar”), a joint venture with UP Chemical Co. Ltd. (“UP Chemical”) and DayStar became a consolidated entity.  The purchase price was $3 million in cash which approximated the fair value of the remaining share of the assets and liabilities, primarily inventory and fixed assets, as of the purchase date.  In addition, we reimbursed UP Chemical for a $3 million loan they had made to DayStar.

RESTRUCTURING_AND_ASSET_IMPAIR

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES	12 Months Ended
	Dec. 31, 2014
RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES
RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES
	3)  RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES
	Restructuring
	In April 2012, our Board approved a restructuring plan providing for, among other things, the closure of our Antioxidant business manufacturing facility in Pedrengo, Italy.  The Board also approved actions to improve the operating effectiveness of certain global corporate functions.  This plan was intended to achieve significant gains in efficiency and costs.  The total cost of the restructuring plan was estimated to be approximately $40 million of which approximately $6 million consisted of non-cash charges.  During 2012, we recorded pre-tax charges of $33 million which included $4 million for accelerated depreciation of property, plant and equipment included in depreciation and amortization, $2 million for accelerated asset retirement obligations included in cost of goods sold (“COGS”), $12 million for severance and professional fees related to corporate initiatives, $5 million for severance and other obligations related to the Pedrengo closure and $10 million reflecting the write-off of a receivable for which collection is no longer probable as a result of the restructuring actions.  We recorded an additional pre-tax charge of $1 million in 2013, primarily for accelerated depreciation and relocation costs related to the Pedrengo closure.  All charges related to the Pedrengo closure have been included in loss from discontinued operations, net of tax, as this plant formed part of our Antioxidants business.  The Pedrengo plant ceased operations on March 31, 2013 and asset retirement work has been completed.  We have retained this property under the terms of the sale of the Antioxidants business and anticipate selling it after all remediation work is completed.
	In February 2013, our Board approved a restructuring plan providing for, among other things, actions to reduce stranded costs related to divestitures.  This plan is expected to preserve pre-divestiture operating margins following our portfolio changes.  On October 9, 2013, the Board approved additional restructuring actions to consolidate our business’ organizational structure in an effort to streamline the organization and gain efficiencies and additional cost savings.  In December 2013, we substantially completed employee communications and the consultation process regarding the closure of our Droitwich, UK facility and consolidation of those operations into our Perth Amboy, NJ facility, in order to improve our competitiveness in the current economic environment.  We recorded a pre-tax charge of $44 million in 2013, which included $27 million for severance and related costs, $15 million for professional fees, $1 million for accelerated depreciation of property, plant and equipment and $1 million for accelerated asset retirement obligations.  We recorded a pre-tax charge of $7 million in 2014 which included $1 million related to severance and professional fees, and $5 million for accelerated depreciation of property, plant and equipment, and $1 million for accelerated asset retirement obligations.
	In June 2014, as a result of KIK not exercising its option to purchase the net assets of the Adrian, MI facility, our Board of Directors (the “Board”) approved the closure of this facility, which is expected to occur in mid-2015.  Additionally, during the second quarter of 2014, our management approved further actions to consolidate our business’ organizational structure, which are in line with the restructuring actions approved by the Board in 2013.  We expect the total cost of these initiatives to be approximately $7 million to $9 million, of which we recorded a pre-tax charge of $4 million in 2014, which included $3 million for severance and related costs and $1 million for accelerated asset retirement obligations related to the Adrian facility.  We expect to incur the remaining costs primarily for decommissioning and accelerated depreciation by mid-2015.
	In November 2014, the Board approved a restructuring plan to reduce manufacturing costs, eliminate stranded costs arising from the sale of our Chemtura AgroSoultions business, and reduce SG&A costs.  The primary action being implemented to achieve this plan is headcount reductions.  The total cash costs approved by the Board to implement this plan is $37 million, of which $21 million has been incurred in the fourth quarter of 2014 for severance and related costs. The remainder could be incurred during 2015 as additional actions are finalized.
	A summary of the changes in the liabilities established for restructuring programs is as follows:
	(In millions)	Severance and			Other Facility			Total
		Related Costs			Closure Costs
	Balance at January 1, 2012	$	1		$	—		$	1
	Facility closure, severance and related costs
	Continuing operations	6			5			11
	Discontinued operations	6			—			6
	Cash payments	(5		)	(5		)	(10		)
	Balance at December 31, 2012	8			—			8
	Facility closure, severance and related costs:
	Continuing operations	27			15			42
	Discontinued operations	—			1			1
	Cash payments	(19		)	(14		)	(33		)
	Reclassifications	(2		)	—			(2		)
	Balance at December 31, 2013	14			2			16
	Facility closure, severance and related costs:
	Continuing operations	22			3			25
	Cash payments	(15		)	(5		)	(20		)
	Balance at December 31, 2014	$	21		—			$	21
	At December 31, 2014, the balance of these reserves was included in accrued expenses in our Consolidated Balance Sheet. The remaining liability for prior year initiatives is not material.  At December 31, 2013, $15 million of these reserves were included in accrued expenses and $1 million was included in accounts payable in our Consolidated Balance Sheet.
	Asset Impairments
	In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC 350”) and ASC Topic 360, Property, Plant and Equipment (“ASC 360”), we recorded pre-tax charges totaling $7 million in 2013 and $47 million in 2012 to earnings (loss) from discontinued operations, net of tax in our Consolidated Statements of Operations.
	We continually monitor and evaluate business and competitive conditions that affect our operations and reflects the impact of these factors in our financial projections.  If permanent or sustained changes in business or, competitive conditions occur, they can lead to revised projections that could potentially give rise to impairment charges.
	During the third quarter of 2012, we completed an assessment of an initiative to monetize portfolio assets relating to our Antioxidant business.  As of September 30, 2012, we considered it more-likely-than-not that the initiative would become effective before the end of 2012.  In performing the impairment analysis, we probability weighted the possible outcomes of the initiative as of September 30, 2012.  Based on this analysis, the expected undiscounted cash flows were insufficient to recover the carrying values of  assets of the component of the segment to which the initiative relates.  We estimated the fair value using various income and market approaches to calculate the impairment charge.  We recorded an asset impairment charge included in loss from discontinued operations, net of tax on our Consolidated Statement of Operations of $35 million, of which $26 million related to property, plant and equipment, net and $9 million related to intangible assets, net included in non-current assets of discontinued operations on our Consolidated Balance Sheets.
	In November 2012, we entered into an asset purchase agreement to sell our Antioxidant business and determined that discontinued operations treatment applied.  Accordingly, we compared the carrying value of the net assets to be sold to their estimated fair value based on the proceeds expected to be received per the asset purchase agreement less the estimated costs to sell.  As a result, in the fourth quarter of 2012 we recorded an additional asset impairment charge of $11 million included in loss from discontinued operations, net of tax on our Consolidated Statement of Operations to write-down the long-lived assets of the Antioxidant business to their estimated fair value, of which $9 million relates to property, plant and equipment and $2 million related to intangible assets that are classified as non-current assets of discontinued operations on the Consolidated Balance Sheets.
	During the first two quarters of 2013, we completed an assessment of the possible sale of the Consumer Products business.  As of March 31, 2013 and June 30, 2013, we considered it more-likely-than-not that the initiative would become effective during 2013.  In performing the impairment analysis, we probability weighted the possible outcomes of the initiative as of March 31, 2013 and June 30, 2013.  Based on this analysis, the expected undiscounted cash flows were sufficient to recover the carrying values of assets of the Consumer Products business.  As a result, we concluded that no impairment existed at March 31, 2013 or June 30, 2013.
	In September 2013, when we met the criteria to record assets held for sale, we again performed an impairment analysis of the Consumer Products Business.  We probability weighted the fair value less cost to sell under different fair value models, as a proxy for an agreed upon purchase price, and found the fair value less cost to sell was sufficient to recover the carrying value of the net assets to be sold as of September 30, 2013.  As a result, we concluded that no impairment existed at September 30, 2013.
	On December 31, 2013, we completed a stock sale of our investment in dedicated legal entities of our Consumer Products business.  In connection with the sale we entered into a supply contact with KIK to supply products from our Adrian, MI facility.  Under the terms of the supply contract, KIK has the option, exercisable for a period of six-months following the closing date, to purchase the net assets of the Adrian facility at a price that is below the carrying value of the net assets.  Accordingly, we concluded that the net assets of the Adrian facility met the criteria to be classified as assets held for sale and based on the expected selling price we recorded an impairment charge in December 2013 of $7 million to write-down the property, plant and equipment to its estimated fair value which is included in earnings from discontinued operations, net of tax in our Consolidated Statement of Operations.The option expired un-exercised as of June 30, 2014 and the assets are now classified as held and used in both the current and prior periods.
	During the third quarter of 2014, the Industrial Engineered Products segment performed a strategic review of the organometallics business included in this segment.  As a result, we performed an impairment analysis of the organometallics asset group in which we probability weighted the possible outcomes of the base business case and various initiatives identified in the strategic review.  Based on this analysis, the estimated undiscounted cash flows were sufficient to recover the carrying value of the net assets of the asset group.  As a result we concluded that no impairment existed at September 30, 2014.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2014
INVENTORIES
INVENTORIES
	4)  INVENTORIES
	(In millions)	2014		2013
	Finished goods	$	200	$	223
	Work in process	35		35
	Raw materials and supplies	94		88
		$	329	$	346
	Included in the above net inventory balances are inventory obsolescence reserves of approximately $13 million and $19 million at December 31, 2014 and 2013, respectively.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT
	5)  PROPERTY, PLANT AND EQUIPMENT
	(In millions)	2014		2013
	Land and improvements	$	71	$	74
	Buildings and improvements	209		212
	Machinery and equipment	1,248		1,225
	Information systems and equipment	167		171
	Furniture, fixtures and other	22		24
	Construction in progress	82		94
		1,799		1,800
	Less: accumulated depreciation	1,095		1,083
		$	704	$	717
	Depreciation expense from continuing operations amounted to $87 million, $82 million and $80 million for 2014, 2013 and 2012, respectively.  Depreciation expense from continuing operations includes accelerated depreciation of certain fixed assets associated with our restructuring programs of $4 million for 2014 and $1 million for 2013.

GOODWILL_AND_INTANGIBLE_ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS
	6)  GOODWILL AND INTANGIBLE ASSETS
	Goodwill
	Our remaining goodwill relates to the Industrial Performance Products segment.  Changes in the carrying amount of goodwill were as follows:
	(In millions)	Gross Goodwill			Accumulated			Net Goodwill
					Impairments
	Balance at December 31, 2012	$	267		$	(90	)	$	177
	Foreign currency translation	2			—			2
	Balance at December 31, 2013	269			(90		)	179
	Foreign currency translation	(7		)	—			(7		)
	Balance at December 31, 2014	$	262		$	(90	)	$	172
	Intangible Assets
	Our intangible assets (excluding goodwill) are comprised of the following:
		2014									2013
	(In millions)	Gross			Accumulated			Net			Gross		Accumulated			Net
		Value			Amortization			Intangibles			Value		Amortization			Intangibles
	Patents	$	26		$	(17	)	$	9		$	33	$	(21	)	$	12
	Trademarks	44			(13		)	31			45		(12		)	33
	Customer relationships	41			(20		)	21			42		(18		)	24
	Production rights	45			(41		)	4			45		(36		)	9
	Other	72			(38		)	34			74		(38		)	36
	Total	$	228		$	(129	)	$	99		$	239	$	(125	)	$	114
	Amortization expense from continuing operations related to intangible assets amounted to $15 million in 2014, $19 million in 2013 and $20 million in 2012.  Estimated amortization expense of intangible assets for the next five fiscal years is as follows: $12 million (2015), $8 million (2016), $8 million (2017) $7 million (2018) and $7 million (2019).

DEBT

DEBT	12 Months Ended
	Dec. 31, 2014
DEBT
DEBT
	7)  DEBT
	Our debt is comprised of the following:
		2014					2013
	(In millions)	Carrying			Fair Value		Carrying			Fair Value
		Value					Value
	5.75% Senior Notes due 2021, with an effective interest rate of 5.93% in 2014 and 5.83% in 2013	$	450		$	439	$	450		$	456
	7.875% Senior Notes due 2018, net of unamortized discount of $1 million in 2013 with an effective interest rate of 8.90% in 2013	—			—		100			108
	Term Loan due 2016, net of unamortized discount of less than $1 million in 2014 and $2 million 2013 with an effective interest rate of 3.78% in 2014 and 5.39% in 2013	82			82		316			320
	Other borrowings	42			42		32			32
	Total Debt	574			$	563	898			$	916
	Less: Other short-term borrowings	(18		)			(7		)
	Less: Current portion of Term Loan	—					(110		)
	Total Long-Term Debt	$	556				$	781
	Financing Facilities
	2021 Senior Notes
	In July 2013, we completed a registered public offering of $450 million of 5.75% Senior Notes due 2021 (the “2021 Senior Notes”).  The purpose of the 2021 Senior Notes was to fund the tender for any and all of our outstanding $455 million aggregate principal amount of 7.875% Senior Notes due 2018 (the “2018 Senior Notes”) pursuant to our Offer to Purchase and Consent Solicitation Statement (the “Offer to Purchase”), pay expenses related to the offering and prepay a portion of our senior secured term loan facility due 2016 (the “Term Loan”).
	In July 2013, we completed the purchase of $354 million of the 2018 Senior Notes tendered in response to the Offer to Purchase.  In addition, we used the balance of the proceeds from the offering of the 2021 Senior Notes, after completing the purchase of the 2018 Senior Notes tendered and paying transaction costs, of approximately $45 million and approximately $5 million of cash on hand to prepay $50 million of principal of our Term Loan.
	At any time prior to July 15, 2016, we are permitted to redeem some or all of the 2021 Senior Notes at a redemption price equal to 100% of the principal amount thereof plus a make-whole premium (as defined in the indenture governing the 2021 Senior Notes (the “2021 Indenture”)) and accrued and unpaid interest up to, but excluding, the redemption date.  At any time after July 15, 2016, we are permitted to redeem some or all of the 2021 Senior Notes at any time, with the redemption prices being, prior to July 15, 2017, 104.313% of the principal amount; on or after July 15, 2017 and prior to July 15, 2018, 102.875% of the principal amount; on or after July 15, 2018 and prior to July 15, 2019, 101.438% of the principal amount; and thereafter 100% of the principal amount, in each case plus any accrued and unpaid interest to the redemption date.  In addition, prior to July 15, 2016, we may redeem up to 35% of the 2021 Senior Notes from the proceeds of certain equity offerings at a redemption price of 105.75% plus accrued but unpaid interest to the redemption date.  If we experience certain kinds of changes in control, as defined in the 2021 Indenture, we may be required to offer to repurchase all of the 2021 Senior Notes at a redemption price (subject to limitations as described in the 2021 Indenture) equal to 101% of the aggregate principal amount plus accrued and unpaid interest.
	Our 2021 Senior Notes contain covenants that limit our ability to enter into certain transactions, such as incurring secured debt and subsidiary debt and entering into sale and lease-back transactions.
	Our 2021 Senior Notes are subject to certain events of default, including, among others, breach of other agreements in the 2021 Indenture; any guarantee of a significant subsidiary ceasing to be in full force and effect; a default by us or our restricted subsidiaries under any bonds, debentures, notes or other evidences of indebtedness of a certain amount, resulting in its acceleration; and certain events of bankruptcy or insolvency.
	2018 Senior Notes
	In August 2010, we completed a $455 million private placement offering under Securities and Exchange Commission (“SEC”) Rule 144A for the 2018 Senior Notes at an issue price of 99.269% in reliance on an exemption pursuant to Section 4(2) of the Securities Act of 1933.  The 2018 Senior Notes were exchanged in June 2011 for identical registered 2018 Senior Notes.
	In July 2013, we purchased in a tender $354 million of the $455 million outstanding balance with proceeds from the 2021 Senior Notes offering.  In the third quarter of 2013, we recorded a $50 million loss on the early extinguishment of debt.  The loss included $42 million for the difference between the principal amount of the 2018 Senior Notes tendered and the sum of the tender offer consideration and consent payments.  The loss also included $8 million for the write-off of unamortized capitalized financing costs and original issuance discount with respect to the 2018 Senior Notes purchased under the tender.
	In December 2014, we called the remaining 2018 Senior Notes of $101 million, repurchasing them with proceeds from the sale of our Agrochemical Manufacturing business.  In the fourth quarter of 2014, we recorded a $6 million loss on the early extinguishment of debt which included a tender premium of $4 million and the write-off of unamortized capitalized financing costs and original issuance discount with respect to the 2018 Senior Notes of $2 million.
	Term Loan
	In August 2010, we entered into the Term Loan due in 2016 with Bank of America, N.A., as administrative agent, and other lenders party thereto for an aggregate principal amount of $295 million with an original issue discount of 1%.  The Term Loan permitted us to increase the size of the facility with an accordion feature by up to $125 million.  On October 31, 2012, we exercised the accordion feature of our Term Loan and borrowed the additional $125 million for the purpose of funding potential investment opportunities and for general corporate purposes.  During 2013, we repaid $102 million of the Term Loan with proceeds from the 2021 Senior Notes offering and cash on hand.
	In October 2013, we entered into Amendment No. 2 to the Term Loan which, among other things, reduced the interest rate and LIBOR floor on the term loans outstanding under the Term Loan agreement and permitted additional flexibility under certain of our operating covenants (including but not limited to additional flexibility for debt, investments, restricted payments and dispositions) in the Term Loan agreement.  The amendment became effective on October 30, 2013.
	In January 2014, we repaid an additional $110 million of the Term Loan with proceeds from the sale of the Consumer Products business.  In light of this transaction, we classified the $110 million as short-term borrowings in our Consolidated Balance Sheet as of December 31, 2013.  In November 2014, we repaid an additional $126 million of our Term Loan with proceeds from the sale of our Agrochemical Manufacturing business.  In 2014, we recorded a $1 million loss on the early extinguishment of debt which included the write-off of unamortized capitalized financing costs and original issuance discount with respect to the Term Loan.
	Borrowings under the amended Term Loan bear interest at a rate per annum equal to, at our election, (i) 1.75% plus the Base Rate (defined as the higher of (a) the Federal Funds rate plus 0.5%; (b) Bank of America’s published prime rate; and (c) the Eurodollar Rate plus 1%) or (ii) 2.75% plus the Eurodollar Rate (defined as the higher of (a) 0.75% and (b) the current LIBOR adjusted for reserve requirements).
	The Term Loan is secured by a first priority lien on substantially all of our U.S. tangible and intangible assets (excluding accounts receivable, inventory, deposit accounts and certain other related assets), including, without limitation, real property, equipment and intellectual property, together with a pledge of the equity interests of our first tier subsidiaries and the guarantors of the Term Loan, and a second priority lien on substantially all of our U.S. accounts receivable and inventory.
	Our obligations as borrower under the Term Loan are guaranteed by certain of our U.S. subsidiaries.
	The Term Loan contains covenants that limit, among other things, our ability to enter into certain transactions, such as creating liens, incurring additional indebtedness or repaying certain indebtedness, making investments, paying dividends, and entering into acquisitions, dispositions and joint ventures.
	Additionally, the Term Loan requires that we meet certain financial maintenance covenants including a maximum Secured Leverage Ratio (net of unrestricted cash, as defined in the agreement) of 2.5:1.0 and a minimum Consolidated Interest Coverage Ratio (as defined in the agreement) of 3.0:1.0.  Additionally, the Term Loan contains a covenant related to the repayment of excess cash flow (as defined in the agreement).  As of December 31, 2014, we were in compliance with the covenant requirements of the Term Loan.
	The Term Loan is subject to certain events of default, applicable to Chemtura, the guarantors and their respective subsidiaries, including, nonpayment of principal, interest, fees or other amounts, violation of covenants, material inaccuracy of representations and warranties (including the existence of a material adverse event as defined in the agreement), cross-default to material indebtedness, certain events of bankruptcy and insolvency, material judgments, certain ERISA events, a change in control, and actual or asserted invalidity of liens or guarantees or any collateral document, in certain cases subject to the threshold amounts and grace periods set forth in the Term Loan agreement.
	ABL Facility
	In November 2010, we entered into a five-year senior secured revolving credit facility available through 2015 (the “ABL Facility”) with Bank of America, N.A., as administrative agent and the other lenders party thereto for an amount up to $275 million, subject to availability under a borrowing base, and included a $125 million letter of credit sub-facility.
	In December 2013, we amended and restated the ABL Facility.  The new five-year senior secured revolving credit facility available through 2018 provides for $175 million available to our domestic subsidiaries (the “US ABL Facility”) and €60 million available to Chemtura Sales Europe B.V., a Netherlands subsidiary (the “Foreign ABL Facility”, and together with the US ABL Facility, the “2018 ABL Facility”), subject in each case to availability under a borrowing base.  The 2018 ABL Facility provides a $125 million letter of credit sub-facility.
	The revolving loans under the 2018 ABL Facility will bear interest at a rate per annum which, at our option, can be either: (a) a base rate (which varies depending on the currency in which the loans are borrowed) plus a margin of between 0.50% and 1.00% for loans denominated in U.S. dollars or between 1.50% and 2.00% for loans denominated in other currencies, in each case based on the average excess availability under the 2018 ABL Facility for the preceding quarter; or (b) the current reserve adjusted Eurocurrency Rate plus a margin of between 1.50% and 2.00% based on the average excess availability under the 2018 ABL Facility for the preceding quarter.
	Our obligations (and the obligations of the other borrowing subsidiaries) under the US ABL Facility will continue to be guaranteed on a secured basis by all of the existing domestic subsidiaries that were borrowers or guarantors prior to the amendment of the 2015 ABL Facility, and by certain of our future direct and indirect domestic subsidiaries (collectively, the “US Loan Parties”).  The obligations under the Foreign ABL Facility are guaranteed on a secured basis by Chemtura Europe GmbH, a Swiss subsidiary, and are guaranteed and secured on a junior priority basis by the US Loan Parties.
	The obligations and guarantees under the US ABL Facility will continue to be secured by (i) a first-priority security interest in the US Loan Parties’ existing and future inventory and accounts receivable, together with general intangibles relating to inventory and accounts receivable, contract rights under agreements relating to inventory and accounts receivable, documents relating to inventory, supporting obligations and letter-of-credit rights relating to inventory and accounts receivable, instruments evidencing payment for inventory and accounts receivable; money, cash, cash equivalents, securities and other property held by the Administrative Agent or any lender under the US ABL Facility; deposit accounts, credits and balances with any financial institution with which any US Loan Party maintains deposits and which contain proceeds of, or collections on, inventory and accounts receivable; books, records and other property related to or referring to any of the foregoing and proceeds of any of the foregoing (the “US ABL Priority Collateral”); and (ii) a second-priority security interest in substantially all of the US Loan Parties’ other assets (the “Term Loan Priority Collateral”), including (x) 100% of the capital stock of US Loan Parties’ direct domestic subsidiaries held by the US Loan Parties and 100% of the non-voting capital stock of the US Loan Parties’ direct foreign subsidiaries held by the US Loan Parties, and (y) 65% of the voting capital stock of the US Loan Parties’ direct foreign subsidiaries (to the extent held by the US Loan Parties), in each case subject to certain exceptions set forth in the 2018 ABL Facility Agreement and the related loan documentation.  The obligations and guarantees under the Foreign ABL Facility are secured by (i) a first priority security interest on certain of Chemtura Sales Europe B.V., a Netherlands accounts receivable and receivables collection accounts and certain of Chemtura Europe GmbH’s inventory; (ii) a second-priority security interest in the US ABL Priority Collateral; and (iii) a third-priority security interest in the Term Loan Priority Collateral; in each case subject to certain exceptions set forth in the 2018 ABL Facility and the related loan documentation.
	Mandatory prepayments of the loans under the US ABL Facility (and cash collateralization of outstanding letters of credit) shall be required (i) to the extent the usage of the US ABL Facility exceeds the lesser of (x) the borrowing base for the US ABL Facility and (y) the then effective commitments under the US ABL Facility, and mandatory prepayments of the loans under the Foreign ABL Facility shall be required (i) to the extent the usage of the Foreign ABL Facility exceeds the lesser of (x) the borrowing base for the Foreign ABL Facility and (y) the then effective commitments under the Foreign ABL Facility. Mandatory prepayments of the loans under the 2018 ABL Facility (and cash collateralization of outstanding letters of credit) shall also be required, subject to exceptions, thresholds and reinvestment rights, with the proceeds of certain sales or casualty events of assets on which the 2018 ABL Facility have a first priority security interest (but, solely during a cash dominion period).
	The 2018 ABL Facility Agreement contains certain affirmative and negative covenants (applicable to us, the other borrowing subsidiaries, the guarantors and their respective subsidiaries other than unrestricted subsidiaries), including, without limitation, covenants requiring financial reporting and notices of certain events, and covenants imposing limitations on incurrence of indebtedness and guaranties; liens; loans and investments; asset dispositions; dividends, redemptions, and repurchases of stock and prepayments, redemptions and repurchases of certain indebtedness; mergers, consolidations, acquisitions, joint ventures or creation of subsidiaries; material changes in business; transactions with affiliates; restrictions on distributions from restricted subsidiaries and granting of negative pledges; changes in accounting and reporting; sale leasebacks; and speculative transactions, and a springing financial covenant requiring a minimum trailing four quarter fixed charge coverage ratio of 1.0 to 1.0 at all times during (A) any period from the date when the amount available for borrowings under the 2018 ABL Facility falls below the greater of (i) $25 million and (ii) 10% of the aggregate commitments to the date such available amount has been equal to or greater than the greater of (i) $25 million and (ii) 10% of the aggregate commitments for 30 consecutive days, or (B) any period from the date when the amount available for borrowings under the US ABL Facility falls below the greater of (i) $18 million and (ii) 10% of the aggregate commitments under the US ABL Facility to the date such available amount has been equal to or greater than the greater of (i) $18 million and (ii) 10% of the aggregate commitments under the US ABL Facility for 30 consecutive days.
	The 2018 ABL Facility Agreement contains certain events of default (applicable to us, the other borrowers, the guarantors and their respective restricted subsidiaries), including nonpayment of principal, interest, fees or other amounts, violation of covenants, material inaccuracy of representations and warranties, cross-default to material indebtedness, certain events of bankruptcy and insolvency, material judgments, certain ERISA events, a change in control, and actual or asserted invalidity of liens or guarantees or any collateral document, in certain cases subject to the threshold amounts and grace periods set forth in the 2018 ABL Facility Agreement.
	At December 31, 2014 and 2013, we had no borrowings under the 2018 ABL Facility, but we had $15 million and $14 million at December 31, 2014 and 2013 of outstanding letters of credit (primarily related to insurance obligations, environmental obligations and banking credit facilities) which utilizes available capacity under the facility.  At December 31, 2014 and 2013, we had approximately $211 million and $237 million, respectively, of undrawn availability under the 2018 ABL Facility.
	Other Facilities
	In December 2012, we entered into a CNY 250 million (approximately $40 million) 5 year secured credit facility available through December 2017 (the “China Bank Facility”) with Agricultural Bank of China, Nantong Branch (“ABC Bank”).  The China Bank Facility is being used for funding construction of our manufacturing facility in Nantong, China.  The China Bank Facility is secured by land, property and machinery of our subsidiary Chemtura Advanced Materials (Nantong) Co., Ltd.  The loans under the China Bank Facility bear interest at a rate determined from time to time by ABC Bank base on the prevailing People Bank of China Lending Rate.  At December 31, 2014 and 2013, we had borrowings of $27 million and $17 million, respectively, under the China Bank Facility.  Repayments of principal will be made in semi-annual installments from December 2014 through December 2017.  In December 2014 and January 2015, we repaid $5 million and $15 million, respectively, of the China Bank Facility with proceeds from the sale of the Chemtura AgroSolutions business.
	In March 2013, we entered into a promissory note in the principal sum of $7 million with a term of six years bearing interest at a rate of 5.29% per annum to finance the cost of certain information technology software licenses.  The principal is to be repaid in equal monthly installments over its term.
	Maturities
	At December 31, 2014, the scheduled maturities of debt are as follows: 2015 - $18 million; 2016 - $87 million; 2017 - $11 million; 2018 - $2 million and thereafter $450 million.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2014
LEASES
LEASES
	8)  LEASES
	At December 31, 2014, minimum rental commitments, primarily for buildings, land and equipment under non-cancelable operating leases, net of sublease income, amounted to $8 million (2015), $7 million (2016), $6 million (2017), $5 million (2018), $4 million (2019), $10 million (2020 and thereafter) and $40 million in the aggregate.  Sublease income is not significant in future periods.  Rental expenses under operating leases were $23 million (2014), $23 million (2013) and $24 million (2012).
	Future minimum lease payments under capital leases at December 31, 2014 were not significant.
	Real estate taxes, insurance and maintenance expenses are generally our obligations and, accordingly, were not included as part of rental payments.  It is expected that in the normal course of business, leases that expire will be renewed or replaced by similar leases.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
INCOME TAXES
INCOME TAXES
	9)  INCOME TAXES
	The components of earnings (loss) from continuing operations before income taxes and the income tax expense (benefit) are as follows:
	(In millions)		2014			2013			2012
	Pre-tax Earnings (Loss) from Continuing Operations:
	Domestic		$	388		$	(105	)	$	26
	Foreign		191			101			103
			$	579		$	(4	)	$	129
	Income Tax Expense (Benefit)
	Domestic
	Current		$	34		$	—		$	—
	Deferred		(274		)	(1		)	—
			(240		)	(1		)	—
	Foreign
	Current		48			17			23
	Deferred		—			2			3
			48			19			26
	Total
	Current		82			17			23
	Deferred		(274		)	1			3
			$	(192	)	$	18		$	26
	The expense (benefit) for income taxes from continuing operations differs from the Federal statutory rate for the following reasons:
	(In millions)		2014			2013			2012
	Income tax (benefit) expense at the U.S. statutory rate		$	203		$	(1	)	$	45
	Foreign rate differential		(45		)	(17		)	(4		)
	Valuation allowances		(389		)	21			(25		)
	U.S. tax on foreign earnings		92			26			28
	Foreign withholding		40			—			—
	Nondeductible reorganizational expenses		—			—			1
	Nondeductible expenses, other		1			7			2
	Nondeductible stock compensation		1			1			1
	Depletion		(3		)	(3		)	(3		)
	Income tax credits		(85		)	(6		)	(18		)
	State income taxes, net of federal benefit		(12		)	—			—
	Taxes attributable to prior periods		(10		)	(11		)	(1		)
	Other, net		15			1			—
	Income tax (benefit) expense		$	(192	)	$	18		$	26
	Due to the sale of our Chemtura AgroSolutions business, we generated and utilized approximately $85 million of foreign tax credits in the current year which was used to offset U.S. tax on foreign earnings and we also utilized approximately $141 million of federal and state net operating losses that had previously been offset by a valuation allowance.
	We recognize deferred tax assets and liabilities for future tax consequences arising from differences between the carrying amounts of existing assets and liabilities under GAAP and their respective tax bases, and for net operating loss carryforwards and tax credit carryforwards.  We evaluate the recoverability of our deferred tax assets, by jurisdiction, as of the end of each quarter, weighing all positive and negative evidence, and are required to establish or maintain a valuation allowance for these assets if we determine that it is more likely than not that some or all of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.
	As of December 31, 2013, we had a valuation allowance against our U.S. deferred tax assets of $506 million. After weighing all of the evidence, we determined that the positive evidence in favor of releasing the valuation allowance, particularly the evidence that was objectively verifiable, outweighed the negative evidence against releasing the allowance as of December 31, 2014. Therefore, we concluded that it is more likely than not that our U.S. deferred tax assets will be realized, except the deferred tax assets relating to certain long lived assets, pre-bankruptcy foreign tax and general business credits, and certain state net operating losses.  As a result, we released net $404 million of the valuation allowance, including $141 million related to the release of a valuation allowance against the Chemture AgroSolutions sale, of our U.S. deferred tax assets as of December 31, 2014.  Of the net $404 million reduction in the total U.S. valuation allowance during 2014, $406 million was recorded to the income tax benefit in our Consolidated Statements of Operations and $2 million was recorded to other comprehensive loss in our Consolidated Balance Sheet.
	The positive evidence that weighed in favor of releasing the U.S. valuation allowance as of December 31, 2014 and ultimately outweighed the negative evidence against releasing the allowance included the following:
		·		At December 31, 2014, our U.S. operations had a 3 year cumulative pretax income of $258 million (including discontinued operations).
		·		At December 31, 2014, our U.S. operations had a three year cumulative income of $38 million after excluding the contribution of the three businesses we divested in the period 2013-2014, the expense incurred to divest those businesses and of the gain/loss on those divestitures as well as including the benefit of lower interest expense arising from the pay down of debt with a portion of the proceeds from the divestitures.
		·		The pay down of both third party and intercompany debt during 2013 and 2014 has reduced the interest expense (both third party and interest paid on loans from our foreign subsidiaries) of our U.S. operations by $18 million compared to what was incurred in 2013 and $36 million compared to what was incurred in 2012.
		·		Our U.S. operations benefit from significant foreign source income from their international operations.  A review of historic receipts of foreign source income, adjusted to exclude income from the divested businesses, or that arose from intercompany lending that has now been repaid, indicates that the U.S. operations can reasonably expect $15-20 million of recurring foreign source income annually.  The benefit of the foreign source income reduces the value of U.S. pretax income that is required to fully utilize the U.S. federal NOL released each year by an equal amount.
		·		Our U.S. Federal NOLs have a 20 year carryforward period and will expire in 2029 and 2030.
		·		The U.S. federal NOL utilization is based on U.S. federal taxable income, which is comprised of pretax income, permanent items and reversals of temporary differences.  As of December 31, 2014, we will need to generate approximately $725 million of pretax income over the next 16 years to realize all of our federal NOLs and absorb reversing temporary differences. The amount of pretax income needed to utilize the federal NOL is significantly less than our projected U.S. pretax income for the same time period.  We believe our U.S. deferred tax liabilities will reverse in the same time period as our U.S. deferred tax assets.
		·		The profitability of our U.S. operations are driven by the performance of our Great Lakes Solutions products manufactured in the U.S.  Performance is expected to progressively improve in 2015 and in subsequent years initially led by our manufacturing and SG&A cost reduction programs.  A significant portion of  the actions to reduce manufacturing and SG&A costs (primarily reductions in headcount) have already been taken and in conjunction with improvement in manufacturing efficiencies and yields, will yield cost reductions of $26 million annually in the U.S..
		·		We are not relying on any tax planning strategies as a source of U.S. income necessary to utilize our U.S. federal NOLs.
	The negative evidence that was considered in our determination that positive evidence is greater than negative evidence was the following:
		·		We disposed of two profitable businesses in 2013 (Consumer Products) and 2014 (Chemtura AgroSolutions).  However, we have already eliminated the stranded costs associated with the Consumer Products business and we anticipate that we will eliminate the stranded cost associated with the Chemtura Agrosolutions business by the end of the first quarter of 2015.  We have used a portion of the net after-tax sale proceeds to repay debt, reducing U.S. interest expense.  We have also transferred pension liabilities to the buyers of the Antioxidants and Consumer Products business.  We also refinanced a significant portion of our debt in 2013, further reducing interest expense from that in 2012 and prior years.
		·		If we exclude the profit contribution of the Antioxidants, Consumer Products and Chemtura AgroSolutions businesses, U.S. operations incurred a loss in both 2013 and 2014.  However, as indicated in positive evidence, these results adjusted for lower third party and intercompany interest expense in the U.S., eliminated costs incurred by the U.S. in support of the international operations of these businesses and the release of the obligations and the accretion related to the below market nature of the Supply Agreements, U.S. operations would have been profitable in these periods and was profitable in 2012.
		·		In 2012 and 2013, our forecast of pretax income of our U.S. operations was not fully achieved.  However, the achievement of U.S. pretax income forecasts in full is not required to fully utilize the Company’s U.S. deferred tax assets as they become available to offset U.S. taxable income.
		·		At September 30, 2014 and December 31, 2013, our U.S. operations had a three-year cumulative loss of $105 million and $89 million, respectively, (including discontinued operations).  The cumulative loss was eliminated by the gain on the sale of our Chemtura AgroSolutions business in the quarter ended December 31, 2014.
		·		As a result of our emergence from Chapter 11 Bankruptcy in 2010, we will be subject to annual U.S. federal NOL limitations under Internal Revenue Code (“IRC”) Section 382 in the future.  Our federal NOL annual limitation will be $72 million in 2015 and $59 million annually in the period 2016-2023 and $46 million in 2024.
		·		At December 31, 2014, Chemtura had a deferred tax asset related to Low Income Housing credits (“LIH”) in the amount of $23 million; post 1998 LIH credits have a 20 year carry forward (the oldest is pre-2003 in the amount of  $10 million).  LIH credits are not available for use until all pre-Chapter 11 federal NOLs are utilized.  Therefore, we do not believe it is more likely than we will utilize pre-Chapter 11 LIH credits before they expire.
	We had valuation allowances related to U.S. operations of $102 million, $506 million and $605 million at December 31, 2014, 2013 and 2012, respectively.  We had valuation allowances related to our foreign subsidiaries of $25 million, $23 million and $23 million at December 31, 2014, 2013 and 2012, respectively.  A valuation allowance has been provided for deferred tax assets where it is more likely than not these assets will expire before we are able to realize their benefit.  Of the $402 million reduction in the total valuation allowance during 2014, $404 million was recorded to the income tax benefit in our Consolidated Statements of Operations and $2 million was recorded to other comprehensive loss in our Consolidated Balance Sheet.  Of the $99 million reduction in the total valuation allowance during 2013, $57 million was recorded to the income tax expense in our Consolidated Statements of Operations and $42 million was recorded to other comprehensive loss in our Consolidated Balance Sheet.  During 2013, due to the sale of our Antioxidants business, the value of the pension deferred asset and the associated valuation allowance both decreased by $33 million.
	The components of the deferred tax assets and liabilities are as follows:
	(In millions)		2014			2013
	Deferred tax assets:
	Pension and other post-retirement liabilities		$	83		$	61
	Net operating loss carryforwards		253			387
	Other accruals		3			15
	Below market contracts, net of discount		82			—
Tax credit carryforwards		66			128
Accruals for environmental remediation		23			29
Intangibles		2			5
Inventories and other		15			20
Financial instruments		1			1
Total deferred tax assets		528			646
Valuation allowance		(127		)	(529		)
Net deferred tax assets after valuation allowance		401			117
Deferred tax liabilities:
Unremitted foreign earnings of subsidiaries		(11		)	(36		)
Property, plant and equipment		(63		)	(72		)
Other		(13		)	(11		)
Total deferred tax liabilities		(87		)	(119		)
Net deferred tax asset (liability) after valuation allowance		$	314		$	(2	)
Net current and non-current deferred taxes from each tax jurisdiction are included in the following accounts:
(In millions)		2014			2013
Net current deferred taxes
Other current assets		$	34		$	10
Other current liabilities		(8		)	(3		)
Net non-current deferred taxes
Other assets		313			25
Other liabilities		(25		)	(34		)
The components of our gross net operating loss (“NOL”) are as follows:
(In millions)		2014			2013
Federal NOL		$	591		$	974
State NOL		$	929		$	1,034
Foreign NOL		$	181		$	141
State and foreign NOL and credits expire over the period 2015-2034, foreign tax credits expire over the period 2016-2020. low income housing credits expire over the period 2019-2030 and federal NOL expire over the period 2029-2030.  As a result of our emergence from Chapter 11 bankruptcy in 2010, we are subject to future annual federal NOL limitations under Internal Revenue Code (“IRC”) Section 382.  Our federal annual limitations on the release of our NOLs are $72 million in 2015 and $59 million annually in the period 2016-2023 and $ 46 million in 2024, subject to adjustment upon audit, if any.  At December 31, 2014, we had federal and state tax credit carryforwards of $63 million and $3 million, respectively.  At December 31, 2013, we had federal and state tax credit carryforwards of $125 million and $3 million, respectively.
We anticipate that we will repatriate the undistributed earnings of certain foreign subsidiaries.  For the year ended December 31, 2014, we decreased by $25 million the amount of the net deferred tax liability we provide for the U.S. tax consequences of these repatriations, primarily due to the repatriations completed in 2014 as a result of  the sale of our Chemtura AgroSolutions business.  For the year ended December 31, 2013, we increased by $18 million, the amount of the net deferred tax liability we provide for the U.S. tax consequences of these repatriations.  In 2013, this increase has been offset by an equal increase to our foreign tax credits, and as such, had no effect on the tax expense recognized in our Consolidated Statements of Operations.  We consider undistributed earnings of all other foreign subsidiaries to be indefinitely invested in their operations. At December 31, 2014, such undistributed earnings deemed to be indefinitely reinvested in foreign operations amounted to $747 million.
We also have not recognized a deferred tax liability for the difference between the book basis and tax basis of investments in the common stock of foreign subsidiaries.  Such differences relate primarily to the unremitted earnings of both Witco’s and Great Lakes’ foreign subsidiaries prior to their mergers with us.  The basis difference in subsidiaries of Witco, acquired on September 1, 1999, is approximately $89 million and the basis difference in subsidiaries of Great Lakes, acquired on July 1, 2005, is approximately $11 million.  Estimating the tax liability that would arise if these earnings were repatriated is not practicable at this time.
During the year ended December 31, 2014, we recorded a decrease to our liability for unrecognized tax benefits of approximately $16 million.  This decrease is primarily due to actual cash repatriations during the current year that offset the liability established in prior years for deemed repatriations  and settlements of tax audits in various foreign and domestic jurisdictions.  In accordance with ASC 740, we recognize interest and penalties related to unrecognized tax benefits as a component of income tax expense.
The beginning and ending amount of unrecognized tax benefits reconciles as follows:
(In millions)		2014			2013			2012
Balance at January 1		$	44		$	41		$	46
Gross (decreases) increases for tax positions taken during current year		2			(1		)	—
Gross increases for tax positions taken during a prior period		2			1			3
Gross decreases for tax positions taken during a prior period		(19		)	—			(1		)
Decreases from the expiration of the statute of limitations		—			—			—
Settlements / payments		(2		)	—			(10		)
Foreign currency impact		1			3			3
Balance at December 31		$	28		$	44		$	41
We recognized no net interest expense in 2014 related to unrecognized tax benefits within tax expense in our Consolidated Statements of Operations and interest expense of $1 million in 2013 and 2012.  We also recognized, in our Consolidated Balance Sheets at December 31, 2014 and 2013, a total amount of $10 million and $14 million of interest, respectively, related to unrecognized tax benefits.  We file income tax returns in the U.S., various U.S. states and certain foreign jurisdictions.  The Internal Revenue Service has completed our federal examination through tax years ending December 31, 2012.  The are no tax years currently under examination by the Internal Revenue Service.
Foreign and United States jurisdictions have statutes of limitations generally ranging from 3 to 5 years.  We have a number of state, local and foreign examinations currently in process.  Major foreign exams in process include Germany, Canada, France and Italy.
We believe it is reasonably possible that our unrecognized tax benefits may decrease by approximately $2 million within the next year.  This reduction may occur due to the statute of limitations expirations or conclusion of examinations by tax authorities.  We further expect that the amount of unrecognized tax benefits will continue to change as a result of ongoing operations, the outcomes of audits, and the expiration of the statute of limitations.  This change is not expected to have a significant impact on our results of operations or financial condition.

CAPITAL_STOCK_AND_EARNINGS_LOS

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE	12 Months Ended
	Dec. 31, 2014
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
	10)  CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
	Capital Stock
	Common  Shares
	We are authorized to issue 500 million shares of $0.01 par value common stock.  There were 100.5 million shares issued, of which 28.8 million were held in treasury at December 31, 2014 and there were 100.5 million shares issued, of which 4.0 million were held in treasury at December 31, 2013.  We are authorized to issue 0.3 million shares of $0.01 par value preferred stock, none of which are outstanding.
	Treasury Shares
	In November 2013, the Board authorized an increase in our share repurchase program to $291 million and extended the program through November 9, 2014.  In May 2014, the Board authorized a further increase in the share repurchase program by $100 million, up to $391 million when combined with the November 2013 authorization.  During 2014, we purchased 12.1 million shares for $287 million under this share repurchase program.  We purchased 17.9 million shares for $382 million since inception under this repurchase program.  The remaining authorization of $9 million expired unpurchased in November 2014.
	In October 2014, the Board approved a new share repurchase authorization of up to $500 million conditioned upon the sale of the Agrochemical Manufacturing business.  The new share repurchase authorization will expire on December 1, 2015.  In October 2014, we announced the commencement of modified Dutch auction tender offer to purchase for cash shares of our common stock (the “Tender Offer”).  In December 2014, we completed the Tender Offer and purchased 12.5 million shares of our common stock at a purchase price of $24.20 per share, for an aggregate cost of $302 million, excluding fees and expenses.  In December 2014, we purchased an additional 1.2 million shares for $28 million under this program through open market purchases
	For the full year 2014, we repurchased a total of 25.8 million shares of our common stock under our share repurchase programs at a cost of $618 million of which $170 million from the October 2014 Authorization remains at December 31, 2014.
	The shares are expected to be repurchased from time to time through open market purchases.  Our share repurchase programs do not obligate us to repurchase any particular amount of common stock, may be modified or suspended at any time at the Board’s discretion.  The manner, price, number and timing of such repurchases, if any, will be subject to a variety of factors, including market conditions and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”).  We release the value of treasury shares at the weighted average price per share when shares are issued from treasury.
	Earnings (Loss) per Common Share
	The computation of basic earnings (loss) per common share is based on the weighted average number of common shares outstanding.  The computation of diluted earnings (loss) per common share is based on the weighted average number of common and common share equivalents outstanding.  For the year ended December 31, 2013, the computation of diluted earnings (loss) per share equals the basic earnings (loss) per common share calculation since common stock equivalents were antidilutive due to losses from continuing operations.  Common stock equivalents amounted to 1.3 million for the year ended December 31, 2013.
	The following is a reconciliation of the shares used in the computation of earnings (loss) per share:
		Year ended
	(In millions)	2014	2013	2012
	Weighted average shares outstanding - Basic	90.2	97.7	98.2
	Dilutive effect of common share equivalents	1.3	—	0.6
	Weighted average shares outstanding - Diluted	91.5	97.7	98.8

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE LOSS	12 Months Ended
	Dec. 31, 2014
ACCUMULATED OTHER COMPREHENSIVE LOSS.
ACCUMULATED OTHER COMPREHENSIVE LOSS
	11)  ACCUMULATED OTHER COMPREHENSIVE LOSS
	The components of accumulated other comprehensive loss (“AOCL”), net of tax at December 31, 2014 and 2013, are as follows:
	(in millions)	Foreign			Unrecognized			Unrealized			Total
		Currency			Pension and			loss on
		Translation			Other Post-			available for
		Adjustments			Retirement			sale securities
					Benefit Costs
	As of December 31, 2013	$	(13	)	$	(267	)	$	—		$	(280	)
	Other comprehensive (loss) income before reclassifications	(70		)	(70		)	(5		)	(145		)
	Amounts reclassified from AOCL	(3		)	31			—			28
	Net current period other comprehensive loss	(73		)	(39		)	(5		)	(117		)
	As of December 31, 2014	$	(86	)	$	(306	)	$	(5	)	$	(397	)
	The following table summarizes the reclassifications from AOCL to the Consolidated Statement of Operations for the period ending December 31, 2014 and 2013:
		Amount Reclassified from AOCL						Affected line item in the
								consolidated statement of
	(in millions)	2014			2013			operations
	Foreign currency translation items:
	Liquidation of consolidated entities	$	—		$	13		Other income, net
	Gain on sale of business (b)	3			—			Gain on sale of business
	Sale of discontinued operations (c)	—			38			Loss on sale of discontinued operations, net of tax
	Net of tax	3			51
	Defined benefit pension plan items:
	Amortization of prior-service costs (a)	5			5			Primarily SG&A
	Amortization of actuarial losses (a)	(18		)	(21		)	Primarily SG&A
	Settlement loss (a)	(21		)	—			Primarily SG&A
	Sale of discontinued operations (c)	—			(127		)	Loss on sale of discontinued operations, net of tax
	Total before tax	(34		)	(143		)
	Tax on continuing operations	3			1			Income Tax Benefit
	Tax on discontinued operations	—			15			Loss on sale of discontinued operations, net of tax
	Total tax	3			16
	Net of tax	(31		)	(127		)
	Total reclassifications	$	(28	)	$	(76	)
	(a) These items are included in the computation of net periodic benefit pension cost (see Note 13 - Pension and Other Post-Retirement Plans for additional information).
	(b) Sale of the Chemtura AgroSolutions business (see Note 2 - Divestitures and Acquisitions)
	(c) Sale of the Antioxidant and Consumer Products businesses (see Note 2 - Divestitures and Acquisitions)

STOCK_INCENTIVE_PLANS

STOCK INCENTIVE PLANS	12 Months Ended
	Dec. 31, 2014
STOCK INCENTIVE PLANS
STOCK INCENTIVE PLANS
	12)  STOCK INCENTIVE PLANS
	We utilize various employee stock-based compensation plans.  Awards under these plans are granted to eligible officers, management employees and non-employee directors.  Awards may be made in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock and/or restricted stock units (“RSUs”).  Under the plans, we issue additional shares of common stock upon the exercise of stock options or the vesting of RSUs.  Stock issuances can be from treasury shares or newly issued shares.
	Description of the Plans
	In 2010, we adopted the Chemtura Corporation 2010 Long-Term Incentive Plan (the “2010 LTIP”) .  The 2010 LTIP provides for grants of nonqualified stock options (“NQOs”), incentive stock options (“ISOs”), stock appreciation rights, dividend equivalent rights, stock units, bonus stock, performance awards, share awards, restricted stock, time-based RSUs and performance-based RSUs.  The 2010 LTIP provides for the issuance of a maximum of 11 million shares.  Stock options may be granted under the 2010 LTIP at prices equal to the fair market value of the underlying common shares on the date of the grant.  All outstanding stock options will expire not more than ten years from the date of the grant.
	During the years ended December 31, 2014 and 2013, we had 4.6 million and 4.9 million shares available for grant, respectively.
	Total stock-based compensation expense, including amounts for RSUs and stock options, was $14 million, $14 million and $24 million for 2014, 2013 and 2012, respectively.
	In 2014, stock-based compensation expense of $13 million, $1 million was reported in SG&A and COGS respectively.  In 2013, stock-based compensation expense of $12 million, $1 million and $1 million was reported in SG&A, COGS and earnings from discontinued operations, net of tax, respectively.  In 2012, stock-based compensation expense of $19 million, $3 million, and $2 million was reported in SG&A, COGS and loss from discontinued operations, net of tax, respectively.
	Approximately 23%, 23% and 24% of the stock-based compensation expense was allocated to our operating segments in 2014, 2013 and 2012, respectively.  All other stock-based compensation expense was included in our Corporate segment.
	Stock Options
	The compensation committee of the Board of Directors (the “Compensation Committee”) did not grant any stock options during the year ended December 31, 2014.
	In March 2013, the Compensation Committee approved the grant of 0.4 million NQOs under the 2013 long-term incentive awards (the “2013 Awards”).  These options vest ratably over a three-year period.
	In March 2012, the Compensation Committee approved the grant of 0.8 million NQOs under the 2012 long-term incentive awards (the “2012 Awards”).  These options vest ratably over a three-year period.
	We use the Black-Scholes option-pricing model to determine the fair value of NQOs.  We have elected to recognize compensation cost for NQOs equally over the requisite service period for each separately vesting tranche, as if multiple awards were granted.  Using this method, the weighted average fair value of stock options granted during the years ended December 31, 2013 and 2012 was $9.92 and $8.15, respectively.  The Black-Scholes option-pricing model requires the use of various assumptions.
	The following table presents the weighted average assumptions used:
		Years Ended December 31,
		2013		2012
	Dividend yield	0.0	%	0.0	%
	Expected volatility	51.0	%	56.7	%
	Risk-free interest rate	1.0	%	1.2	%
	Expected life (in years)	6		6
	The weighted average expected life of six years for the 2013 and 2012 grants reflects the simplified method, which defines the expected life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.  We continue to use the simplified method because there is insufficient data to develop a justifiable expected term.  Expected volatility for the 2013 and 2012 awards of NQOs is based primarily on a combination of the historical volatility prior to our entering into Chapter 11 and historical volatility since emergence from Chapter 11.
	A summary of our stock option activities for 2014 is summarized as follows:
							Weighted		Aggregate
							Average		Intrinsic
							Remaining
		Price Per Share			Shares		Contractual		Value
		Average			(in millions)		Life		(in millions)
	Outstanding at 12/31/13	16.46			2.8		7.4		32
	Exercised	16.01			(0.6	)			5
	Lapsed	18.07			—
	Outstanding at 12/31/14	$	16.56		2.2		6.5		18
	Exercisable at 12/31/14	$	16.16		1.8		6.2		$	15
	The intrinsic value of the exercised options was $5 million, $4 million and $1 million for 2014, 2013 and 2012, respectively.
	Total remaining unrecognized compensation cost associated with unvested stock options at December 31, 2014 was $1 million, which will be recognized over the weighted average period of approximately 1 year.
	Restricted Stock Awards
	In March 2014, the Compensation Committee approved the grant of 0.4 million time-based RSUs under the 2014 long-term incentive awards (the “2014 Awards”).  These RSUs vest ratably over a three-year period.
	In March 2014, the Compensation Committee approved the grant of 0.2 million performance shares under the 2014 Awards.  The share grant is subject to a performance multiplier of up to 2 times the targeted award.  The performance measurement period is the three calendar year period ending December 31, 2016, the performance share metric used will be our relative total shareholder return against the companies comprising the Dow Jones Chemical Index.  The performance shares will be settled as soon as practicable after the performance period but no later than March 15, 2017.  We used the Monte-Carlo simulation model to determine the fair value of the performance shares.  Using this method, the average per share fair value of these awards was $26.98.
	In March 2013, the Compensation Committee approved the grant of 0.2 million time-based RSUs under the 2013 Awards.  These RSUs vest ratably over a three-year period.
	In March 2013, the Compensation Committee approved the grant of 0.2 million performance shares under the 2013 Awards.  The share grant is subject to a performance multiplier of up to 2 times the targeted award.  The performance measurement period is the three calendar year period ending December 31, 2015, the performance share metric used will be our relative total shareholder return against the companies comprising the Russell 3000 Index.  The performance shares will be settled as soon as practicable after the performance period but no later than March 15, 2016.  We used the Monte-Carlo simulation model to determine the fair value of the performance shares.  Using this method, the average per share fair value of these awards was $27.27.
	In March 2012, the Compensation Committee approved the grant of 0.6 million time-based RSUs under the 2012 Awards.  These RSUs vest ratably over a three-year period.
	In March 2012, the Compensation Committee approved the grant of 0.3 million performance shares under the 2012 Awards.  The share grant is subject to a performance multiplier of up to 2 times the targeted award.  The performance measurement period is the three calendar year period ending December 31, 2014, the performance share metric used will be our relative total shareholder return against the companies comprising the Russell 3000 Index.  The performance shares were settled in Januray 2015.  We used the Monte-Carlo simulation model to determine the fair value of the performance shares.  Using this method, the average per share fair value of these awards was $25.38.
	RSUs award activity for 2014 is as follows:
		Shares		Weighted			Aggregate
		(in millions)		Average			Fair Value
				Grant Date			(in millions)
				Fair Value
	Unvested RSU awards, December 31, 2013	1		20.53			30
	Cancelled	(0.1	)	23.47
	Granted	0.6		25.56
	Vested	(0.4	)	18.32			8
	Unvested RSU awards, December 31, 2014	1.1		$	23.81		$	28
	The weighted average grant date fair value of restricted units granted was $25.56, $23.18 and $17.72 for 2014, 2013 and 2012, respectively.  The fair value of restricted share units at time of vesting was $8 million, $8 million and $17 million for 2014, 2013 and 2012, respectively.
	Total remaining unrecognized compensation expense associated with unvested RSUs at December 31, 2014 was $10 million, which will be recognized over the weighted average period of approximately 2 years.
	Tax Benefits of Stock-Based Compensation Plans
	ASC 718 Stock Compensation requires the benefits of tax deductions in excess of grant-date fair value be presented in the cash flows from financing section of our Consolidated Statements of Cash Flows. We recognized a cash tax benefit in the amount of $5 million associated with shares exercised during the year ended December 31, 2014.  We did not obtain any cash tax benefit associated with shares exercised during the year ended December 31, 2013 as we utilized net operating losses.  Cash proceeds received from option exercises during 2014, 2013 and 2012 was $10 million, $8 million and $5 million, respectively.

PENSION_AND_OTHER_POSTRETIREME

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS	12 Months Ended
	Dec. 31, 2014
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS
	13)  PENSION AND OTHER POST-RETIREMENT PLANS
	We have several defined benefit and defined contribution pension plans covering substantially all of our domestic employees and certain international employees.  Benefits under the defined benefit plans are primarily based on the employees’ years of service and compensation during employment.  Effective January 1, 2006, we eliminated future earnings benefits to participants of our domestic defined benefit plans for non-bargained employees.  All active non-bargained employees would subsequently earn benefits under defined contribution plans for all service incurred on or after January 1, 2006.  Our funding policy for the defined benefit plans is based on contributions at the minimum annual amounts required by law plus such amounts as we may deem appropriate.  Contributions for the defined contribution plans are determined as a percentage of the covered employee’s salary.  Plan assets consist of publicly traded securities and mutual funds and investments in commingled funds administered by independent investment advisors.
	International employees are covered by various pension benefit arrangements, some of which are considered to be defined benefit plans for financial reporting purposes.  Assets of these plans are comprised primarily of equity investments and fixed-income investments.  Benefits under these plans are primarily based upon levels of compensation.  Funding policies are based on legal requirements, tax considerations and local practices.
	We also provide health and life insurance benefits for substantially all of our active domestic employees and certain retired and international employees.  These plans are generally not prefunded and are paid by us as incurred.
	In September 2014, we offered vested pension plan participants in our U.S. qualified pension plan who are no longer employed at the Company a limited-time opportunity to take their pension benefits as a one-time single lump sum or an immediate annuity.  Announcement letters were mailed on September 12, 2014.  The window for participants to make the election was from September 22, 2014 until October 31, 2014.  Based on the elections received, we reduced our projected benefit obligation and plan assets by $52 million which resulted in a settlement charge in the fourth quarter of 2014 of $21 million.
	In May 2011, one of our UK subsidiaries entered into definitive agreements with the trustees of the Great Lakes U.K. Limited Pension Plan (“the UK Pension Plan”) over the terms of a “recovery plan” which provided for a series of additional cash contributions to be made to reduce the underfunding over time.  The agreements provided, among other things, for our UK subsidiary to make cash contributions of £60 million (approximately $96 million) between 2011 and 2014.  The final contribution of £8 million ($12 million) was made in the first quarter of 2014.  The agreements also provided for the granting of both a security interest and a guarantee to support certain of the liabilities under the UK Pension Plan.
	There was also an evaluation being undertaken as to whether additional benefit obligations exist in connection with the equalization of certain benefits under the UK Pension Plan that occurred in the early 1990s.  Based on the results of the evaluation in 2011, $8 million of expense was recorded in the fourth quarter of 2011, which was subject to adjustment as further information was gathered as part of the evaluation.  Additional information was gathered and evaluated during the second quarter of 2013 and resulted in a reduction of the estimated liability from that originally estimated.  Accordingly we recorded $2 million of income to SG&A in the second quarter of 2013.  During the third quarter of 2014, we obtained a recovery from third parties that reduced our estimated net liability by a further $4 million which was released to SG&A.  When we reach agreement with the trustees of the UK Pension Plan as to what additional benefit obligations exist, our UK subsidiary will be required to make additional cash contributions to the UK Pension Plan.
	Benefit Obligations
			Defined Benefit Pension Plans
			Qualified						International and						Post-Retirement
			Domestic Plans						Non-Qualified Plans						Health Care Plans
	(In millions)		2014			2013			2014			2013			2014			2013
	Change in projected benefit obligation:
	Projected benefit obligation at beginning of year		$	623		$	1,040		$	519		$	499		$	96		$	124
	Service cost		—			—			2			3			—			—
	Interest cost		28			30			21			19			4			4
	Plan participants’ contributions		—			—			—			1			—			—
	Actuarial (gains) losses (a)		99			(69		)	64			11			20			(20		)
	Benefits paid		(46		)	(51		)	(20		)	(19		)	(11		)	(10		)
	Business divestitures (b)		—			(327		)	—			—			—			—
	Settlements		(52		)	—			(3		)	(6		)	—			—
	Foreign currency exchange rate changes (c)		—			—			(41		)	11			(1		)	(2		)
	Projected benefit obligation at end of year		$	652		$	623		$	542		$	519		$	108		$	96
	Accumulated benefit obligation at end of year		$	651		$	622		$	541		$	506
	Weighted-average year-end assumptions used to determine benefit obligations:
	Discount rate		3.8		%	4.6		%	3.28		%	4.18		%	3.7		%	4.35		%
	Rate of compensation increase		3		%	3		%	2.41		%	2.85		%	N/A			N/A
	Health care cost trend rate														6.16		%	6.27		%
		(a)		The losses for 2014 primarily related to the utilization of the recently revised mortality tables and decreases in discount rates.
		(b)		Business divestitures includes the transfer of $315 million of projected benefit obligations with the sale of our Antioxidants business in April 2013 and $12 million with the sale of our Consumer Products business in December 2013.
		(c)		The significant foreign currency decrease in 2014 is due to decreases in Euro and British Pound exchange rates from December 2013 to December 2014.
	A 6.16% weighted-average rate of increase in the health care cost trend rate was assumed for the accumulated post-retirement benefit obligation as of December 31, 2014.  The rate was assumed to decrease gradually to a weighted average rate of 5.0% over approximately the next 5 to 7 years.  Assumed health care cost trend rates have a significant effect on the post-retirement benefit obligation reported for the health care plans.  A one percentage point increase in assumed health care cost trend rates would increase the accumulated post-retirement benefit obligation by $5 million for health care benefits as of December 31, 2014.  A one percentage point decrease in assumed health care cost trend rates would decrease the accumulated post-retirement benefit obligation by $4 million for health care benefits as of December 31, 2014.
	Plan Assets
			Defined Benefit Pension Plans
			Qualified						International and						Post-Retirement
			Domestic Plans						Non-Qualified Plans						Health Care Plans
	(In millions)		2014			2013			2014			2013			2014			2013
	Change in plan assets:
	Fair value of plan assets at beginning of year		$	595		$	814		$	408		$	370		$	—		$	—
	Actual return on plan assets		59			51			75			30			—			—
	Employer contributions		14			20			24			27			11			10
	Plan participants’ contributions		—			—			—			1			—			—
	Benefits paid		(46		)	(51		)	(20		)	(19		)	(11		)	(10		)
	Business divestitures (a)		—			(239		)	—			—			—			—
	Settlements		(52		)	—			(3		)	(6		)	—			—
	Foreign currency exchange rate changes (b)		—			—			(29		)	5			—			—
	Fair value of plan assets at end of year		$	570		$	595		$	455		$	408		$	—		$	—
		(a)		Business divestitures includes the transfer of $233 million of plan assets with the sale of our Antioxidants business in April 2013 and $6 million of plan assets with the sale of our Consumer Products business in December 2013.
		(b)		The significant foreign currency decrease in 2014 is due to decreases in Euro and British Pound exchange rates from December 2013 to December 2014.
	Our pension plan assets are managed by outside investment managers.  For our U.S. qualified pension plans, the Employee Investment Committee (“EIC”) appointed SEI Investments Management Corporation (“SEI”) as an investment manager effective February 1, 2012.  The assets of the plans were transitioned from previous investment managers to SEI at the end of March 2012.  SEI has assisted the EIC in developing a suitable asset allocation, selecting appropriate investment managers, monitoring and evaluating the performance of such managers.  For our Canadian non-qualified pension plans, the EIC appointed Northern Trust as the investment manager effective January 2013 and transitioned the plan assets from the previous investment managers in February 2013.  For our UK pension plans, the EIC appointed Mercer Limited as the investment manager effective in July and August 2013 and transitioned the plan assets from previous investment managers in August and November 2013.  Assets are monitored regularly to ensure they are within the range of parameters as set forth by the EIC.  Our investment strategy with respect to pension assets is to achieve the expected rate of return within an acceptable or appropriate level of risk.  Our investment strategy is designed to promote diversification, to moderate volatility and to attempt to balance the expected return with risk levels.  The target allocations for qualified domestic plans are 32% equity securities, 58% fixed income securities and 10% to all other types of investments.  The weighted average target allocations for international pension plans are 33% equity securities, 53% fixed income securities and 14% to all other types of investments.
	The fair values of our defined benefit pension plan assets at December 31, 2014 and 2013, by asset category are as follows:
			Fair Value Measurements at December 31, 2014
			Defined Benefit Pension Plans
			Qualified Domestic Plans												International and Non-Qualified Plans
	(In millions)		Total			Quoted Prices			Significant			Significant			Total			Quoted Prices			Significant			Significant
						in Active			Observable			Unobservable						in Active			Observable			Unobservable
						Markets for			Inputs			Inputs						Markets for			Inputs			Inputs
						Identical			(Level 2)			(Level 3)						Identical			(Level 2)			(Level 3)
						Assets												Assets
						(Level 1)												(Level 1)
	Equity securities:
	Pooled equity (a)		$	164		$	164		$	—		$	—		$	152		$	8		$	144		$	—
	Fixed income securities:
U.S. government bonds (b)		72			—			72			—			—			—			—			—
International government bonds (b)		—			—			—			—			20			—			20			—
Pooled fixed income funds (c)		258			258			—			—			268			—			265			3
Alternative collective funds (d)		75			—			—			75			—			—			—			—
Other instruments (e)		1			1			—			—			14			—			—			14
Cash & cash equivalents		—			—			—			—			1			1			—			—
		$	570		$	423		$	72		$	75		$	455		$	9		$	429		$	17
		Fair Value Measurements at December 31, 2013
		Defined Benefit Pension Plans
		Qualified Domestic Plans												International and Non-Qualified Plans
(in millions)		Total			Quoted			Significant			Significant			Total			Quoted			Significant			Significant
					Prices in			Observable			Unobservable						Prices in			Observable			Unobservable
					Active			Inputs			Inputs						Active			Inputs			Inputs
					Markets for			(Level 2)			(Level 3)						Markets for			(Level 2)			(Level 3)
					Identical												Identical
					Assets												Assets
					(Level 1)												(Level 1)
Equity securities:
Pooled equity (a)		$	141		$	141		$	—		$	—		$	146		$	12		$	134		$	—
Fixed income securities:
U.S. government bonds (b)		71			—			71			—			—			—			—			—
International government bonds (b)		—			—			—			—			2			—			2			—
Pooled fixed income funds (c)		287			287			—			—			247			—			243			4
Alternative collective funds (d)		91			—			—			91			—			—			—			—
Other instruments (e)		1			1			—			—			11			—			—			11
Cash & cash equivalents		4			4			—			—			2			2			—			—
		$	595		$	433		$	71		$	91		$	408		$	14		$	379		$	15
	(a)		Pooled equity funds include mutual and collective funds that invest primarily in marketable equity securities of various sized companies in a diverse set of industries in various regions of the world.  Shares of publicly traded mutual funds are valued at the closing price reported on the U.S. and international exchanges where the underlying securities are actively traded.  Units of collective funds are valued at the per unit value determined by the fund manager, which is based on market price of the underlying securities.  The increase in the value of pooled equity funds of our domestic plans is primarily due to shifting assets from pooled fixed income funds in 2014.
	(b)		U.S. and international government bonds include U.S. treasury, municipal and agency obligations and international government debt.  Such instruments are valued at quoted market prices for those instruments or on institutional bid valuations.
	(c)		Pooled fixed income funds are fixed income funds that invest primarily in corporate and government bonds.  Such instruments are valued using securities in active markets and observable data or broker or dealer quotations.  The decrease in the value of pooled fixed income funds of our domestic plans is primarily due to shifting assets into pooled equity funds in 2014.
	(d)		Alternative collective funds include funds that invest mainly in asset backed securities, real estate funds, hedge funds and other alternative investments.  The underlying funds are valued based on the net asset values of the investments as determined by the respective individual fund administrators on a daily, weekly or monthly basis depending on the fund.  Such valuations are reviewed by the portfolio managers who determine the value of collective funds based on these inputs.  Certain of these funds have lock up periods and all of them have notification periods.  Due to the process used to value these funds and the restricted trading, we have categorized these funds as level 3.  The disbursements are primarily related to the lump sum payout made to certain participants in our U.S. qualified pension plan.
	(e)		Other instruments include primarily annuities and real estate funds instruments for which there are significant unobservable inputs and therefore have been classified as level 3.
Below is the rollforward of the activity in the pension plan assets classified as Level 3 above:
		Alternative			Other Instruments (e)			Total Level 3
		Collective Funds (d)						Investments
Balance at December 31, 2013		$	91		$	15		$	106
Purchases		—			4			4
Realized gains		2			—			2
Unrealized gains		6			(2		)	4
Disbursements		(24		)	—			(24		)
Balance at December 31, 2014		$	75		$	17		$	92
Funded Status
The funded status at the end of the year, and the related amounts recognized on the Consolidated Balance Sheet, are as follows:
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified Plans						Health Care Plans
(In millions)		2014			2013			2014			2013			2014			2013
Funded status, end of year:
Fair value of plan assets		$	570		$	595		$	455		$	408		$	—		$	—
Benefit obligations		652			623			542			519			108			96
Net amount recognized		$	(82	)	$	(28	)	$	(87	)	$	(111	)	$	(108	)	$	(96	)
Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
Noncurrent assets		$	—		$	—		$	57		$	30		$	—		$	—
Current liability		—			—			(7		)	(9		)	(9		)	(9		)
Noncurrent liability		(82		)	(28		)	(137		)	(132		)	(99		)	(87		)
Net amount recognized		$	(82	)	$	(28	)	$	(87	)	$	(111	)	$	(108	)	$	(96	)
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial loss/(gain)		$	269		$	219		$	130		$	120		$	49		$	31
Prior service cost/(credit)		—			—			—			—			(35		)	(40		)
		$	269		$	219		$	130		$	120		$	14		$	(9	)
As of December 31, 2014 and 2013, the current liability positions are included in accrued expenses, the noncurrent assets are included in other assets, and the noncurrent liability positions are shown as pension and post-retirement health care liabilities in our Consolidated Balance Sheets.
The estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in 2015 are as follows:
(In millions)		Qualified			International			Post-
		Domestic			and Non-			Retirement
		Plans			Qualified			Health Care
					Plans			Plans
Actuarial loss		$	14		$	6		$	3
Prior service credit		—			—			(5		)
Total amortization cost (credit)		$	14		$	6		$	(2	)
Our funding assumptions for our domestic pension plans assume no significant change with regards to demographics, legislation, plan provisions, or actuarial assumptions or methods to determine the estimated funding requirements.  We contributed approximately $49 million and $57 million to our pension and post retirement plans in 2014 and 2013, respectively.  The 2014 contribution includes $12 million for one of our UK pension plans as required by the “recovery plan” agreed to with the trustees of that plan and a $14 million discretionary contribution to one of our domestic qualified plans.  The 2013 contribution included $12 million for one of our UK pension plans as required by the “recovery plan” agreed to with the trustees of that plan and a $10 million discretionary contribution to one of our domestic qualified plans.
The projected benefit obligation and fair value of plan assets for pension and post-retirement plans with a projected benefit obligation in excess of plan assets at December 31, 2014 and 2013 were as follows:
(In millions)		2014			2013
Projected benefit obligation in excess of plan assets at end of year:
Projected benefit obligation		$	919		$	876
Fair value of plan assets		584			612
The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension and post-retirement plans with an accumulated benefit obligation in excess of plan assets at December 31, 2014 and 2013 were as follows:
(In millions)		2014			2013
Accumulated benefit obligation in excess of plan assets at end of year:
Projected benefit obligation		$	798		$	778
Accumulated benefit obligation		797			777
Fair value of plan assets		572			611
Expected Cash Flows
Information about the expected cash flows for the domestic qualified defined benefit plans, international and non-qualified defined benefit plans and post-retirement health care plans are as follows:
		Defined Benefit Pension Plans
		Qualified			International			Post-
		Domestic			and			Retirement
					Non-Qualified			Health Care
(in millions)		Plans			Plans			Plans
Expected Employer Contributions: (a)
2015		$	—		$	3		$	9
Expected Benefit Payments (b):
2015		46			21			9
2016		46			21			9
2017		45			22			8
2018		45			25			8
2019		44			24			8
2020-2024		207			130			33
	(a)		The expected employer contributions reflect the minimum required by law or contractual obligation. We may elect to make additional discretionary contributions as deemed appropriate consistent with past practice.
	(b)		The expected benefit payments are based on the same assumptions used to measure our benefit obligation at the end of the year and include benefits attributable to estimated future employee service.
Net Periodic Cost
		Defined Benefit Pension Plans
		Qualified									International and									Post-Retirement
		Domestic Plans (a)									Non-Qualified Plans									Health Care Plans
(In millions)		2014			2013			2012			2014			2013			2012			2014			2013			2012
Components of net periodic benefit cost (credit):
Service cost		$	—		$	—		$	1		$	2		$	3		$	3		$	—		$	—		$	1
Interest cost		28			30			43			21			20			21			4			4			5
Expected return on plan assets		(41		)	(45		)	(54		)	(26		)	(23		)	(22		)	—			—			—
Amortization of prior service cost		—			—			—			—			—			—			(5		)	(5		)	(6		)
Recognized actuarial losses		11			14			14			4			5			2			3			2			3
Curtailment loss recognized		—			—			—			—			1			—			—			—			—
Settlement loss recognized (b)		21			32			—			—			—			—			—			—			—
Net periodic benefit cost		$	19		$	31		$	4		$	1		$	6		$	4		$	2		$	1		$	3
	(a)		The net periodic benefit cost for the years ended December 31, 2013 and 2012 include pension expense related to the earnings (loss) from discontinued operations of $1 million and $2 million, respectively.
	(b)		The settlement loss recognized in 2014 of $21 million relates to the lump sum payout made to certain participants in our U.S. qualified pension plan (included in SG&A). The settlement loss recognized in 2013 includes a loss of $40 million related to the divestiture of our Antioxidants business in April 2013 (included in loss on sale of discontinued operations), partly offset by a $2 million gain related to the divestiture of our Consumer Products business (included in loss on sale of discontinued operations) and a $6 million gain related to an adjustment for a legacy pension plan ($2 million included in SG&A and $4 million in loss from discontinued operations).
Weighted-average assumptions used to determine net cost:
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified Plans						Health Care Plans
		2014		2013		2012		2014		2013		2012		2014		2013		2012
Discount rate		4.60	%	3.80	%	4.60	%	4.20	%	3.89	%	4.64	%	4.45	%	3.71	%	4.15	%
Expected return on plan assets		7.50	%	7.50	%	7.50	%	6.68	%	6.53	%	6.71	%
Rate of compensation increase		3.00	%	3.00	%	4.00	%	2.85	%	2.77	%	3.22	%
The expected return on pension plan assets is based on our investment strategy, historical experience, and our expectations for long term rates of return.  We determine the long-term rate of return assumptions for the domestic and international pension plans based on its investment allocation between various asset classes.  The expected rate of return on plan assets is derived by applying the expected returns on various asset classes to our target asset allocation.  The expected returns are based on the expected performance of the various asset classes and are further supported by historical investment returns.  We utilized a weighted average expected long-term rate of 7.50% on all domestic assets and a weighted average rate of 6.68% for the international plan assets for the year ended December 31, 2014.
Assumed health care cost trend rates have a significant effect on the service and interest cost components reported for the health care plans.  A one percentage point increase or decrease in assumed health care cost trend rates increases or decreases the service and interest cost components of net periodic post-retirement health care benefit cost by less than $1 million for 2014.
Our cost of the defined contribution plans was $11 million for 2014, 2013 and 2012.
We participate in a multi-employer pension plan that provides defined benefits to certain employees covered under a collective bargaining agreement.  The risks of participating in a multi-employer plan differ from those of a single employer plan.  The net pension cost of a multi-employer plan is equal to the annual contribution determined in accordance with the provisions of the collective bargaining agreement.  Contributions that we make to the plan are not segregated and may be used to fund benefits to employees of other participating employers.  The future cost of the plan is dependent on a number of factors, including the funded status of the plan and the ability of other participating companies to meet ongoing funding obligations.  If one employer stops contributing to the plan the unfunded obligation of the plan may have to be assumed by the remaining participating employers.
Our contributions to the plan for 2014 and prior years have been insignificant.  However, due to the pending withdrawal of certain employers from the plan, there is uncertainty regarding the impact on our future contributions.

FINANCIAL_INSTRUMENTS_AND_FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
	14)  FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
	Financial Instruments
	The carrying amounts for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities, approximate their fair value because of the short-term maturities of these instruments.  The fair value of debt is based primarily on quoted market values.
	The following table presents the carrying amounts and estimated fair values of material financial instruments used by us in the normal course of our business:
	Fair Value Measurements
	We apply provisions of ASC 820 with respect to our financial assets and liabilities that are measured at fair value within the financial statements on a recurring basis.  ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions.  The fair value hierarchy specified by ASC 820 is as follows:
		·	Level 1 — Quoted prices in active markets for identical assets and liabilities.
		·	Level 2 — Quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market date.
		·	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	Level 1 fair value measurements in 2014 and 2013 included securities purchased in connection with the deferral of compensation, our match and investment earnings related to the supplemental savings plan.  These securities are considered our general assets until distributed to the participant and are included in other assets in our Consolidated Balance Sheets.  A corresponding liability is included in other liabilities at December 31, 2014 and 2013 in our Consolidated Balance Sheets.  Quoted market prices were used to determine fair values of these Level 1 investments which are held in a trust with a third-party brokerage firm.  The fair value of the asset and corresponding liability was $3 million at December 31, 2014 and 2013.
	For the year ended December 31, 2014, there were no transfers into or out of Level 1 and Level 2.
	Level 3 fair value measurements are utilized in our impairment reviews of Goodwill (see Note 6 — Goodwill and Intangible Assets).
	During the second quarter of 2013, we obtained an investment in non-public preferred equity securities with a face value of $9 million.  We have estimated the fair value to be $4 million, utilizing Level 3 measurements, where the fair value estimate is determined internally based on business and market sector fundamentals.  We have reported the fair value of this investment in Other Non-Current Assets and reported the difference between the face value and fair value at the date received in loss on sale of discontinued operations in 2013.
	In connection with the sale of our Chemtura AgroSolutions business we obtained 2 million shares of Platform common stock which carried a restriction period of six months from the date of sale.  The stock is traded publicly on the New York Stock Exchange (“NYSE”).  As of December 31, 2014, we have valued the stock based upon the Platform closing price on December 31, 2014 adjusted for the value of the restriction.  The valuation of these securities is based upon Level 2 valuation techniques which utilized historical volatility of the Platform stock.  These marketable securities are deemed available-for-sale and as such changes in the valuation between periods is included in AOCL (see Note 2 — Divestitures and Acquisitions).
	Level 1, 2 and 3 fair value measurements are utilized for defined benefit plan assets, depending on their nature, in determining the funded status of our pension and post-retirement benefit plan liabilities on an annual basis at December 31 (see Note 13 — Pension and Other Post-Retirement Plans).

LEGAL_PROCEEDINGS_AND_CONTINGE

LEGAL PROCEEDINGS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
LEGAL PROCEEDINGS AND CONTINGENCIES
LEGAL PROCEEDINGS AND CONTINGENCIES
	15)  LEGAL PROCEEDINGS AND CONTINGENCIES
	We are involved in claims, litigation, administrative proceedings and investigations of various types in a number of jurisdictions.  A number of such matters involve, or may involve, claims for a material amount of damages and relate to or allege, among other things, environmental liabilities, including clean-up costs associated with hazardous waste disposal sites, natural resource damages, property damage and personal injury.
	Emergence from Chapter 11
	On March 18, 2009 (the “Petition Date”) Chemtura and 26 of our U.S. affiliates (collectively the “U.S. Debtors” or the “Debtors” when used in relation to matters before August 8, 2010) filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code (“Chapter 11”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”).
	On August 8, 2010, our Canadian subsidiary, Chemtura Canada Co/Cie (“Chemtura Canada”), filed a voluntary petition for relief under Chapter 11.  The U.S. Debtors along with Chemtura Canada after it filed for Chapter 11 (collectively the “Debtors”) requested the Bankruptcy Court to enter an order jointly administering Chemtura Canada’s Chapter 11 case with the previously filed Chapter 11 cases and appoint Chemtura Canada as the “foreign representative” for the purposes of the Canadian Case.  Such orders were granted on August 9, 2010.
	On November 3, 2010, the Bankruptcy Court entered an order confirming the Debtors’ plan of reorganization (the “Plan”).  On November 10, 2010 (the “Effective Date”), the Debtors substantially consummated their reorganization through a series of transactions contemplated by the Plan and the Plan became effective.
	As of March 31, 2014, the Bankruptcy Court had entered orders granting final decrees closing all of the Debtors’ Chapter 11 cases.
	Litigation and Claims
	Environmental Liabilities
	As part of the Chapter 11 cases, under the Plan, the Debtors retained responsibility for environmental cleanup liabilities relating to currently owned or operated sites (i.e. sites that were part of the Debtors’ estates) and, with certain exceptions, discharged or settled liabilities relating to formerly owned or operated sites (i.e., sites that were no longer part of the Debtors’ estates) and third-party sites (i.e., sites that were never part of the Debtors’ estates).
	We are involved in environmental matters of various types in a number of jurisdictions.  A number of such matters involve claims for material amounts of damages and relate to or allege environmental liabilities, including clean-up costs associated with hazardous waste disposal sites and natural resource damages.
	The Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (“CERCLA”), and comparable state statutes impose strict liability upon various classes of persons with respect to the costs associated with the investigation and remediation of waste disposal sites.  Such persons are typically referred to as “Potentially Responsible Parties” or PRPs.  Chemtura and several of our subsidiaries have been identified by federal, state or local governmental agencies or by other PRPs, as a PRP at various locations in the United States.  Because in certain circumstances these laws have been construed to authorize the imposition of joint and several liability, the Environmental Protection Agency (“EPA”) and comparable state agencies could seek to recover all costs involving a waste disposal site from any one of the PRPs for such site, including Chemtura, despite the involvement of other PRPs.  In many cases, we are one of a large number of PRPs with respect to a site.  In a few instances, we are the sole or one of only a handful of PRPs performing investigation and remediation.  Where other financially responsible PRPs are involved, we expect that any ultimate liability resulting from such matters will be apportioned between us and such other parties.  In addition, we are involved with environmental remediation and compliance activities at some of our current and former sites in the United States and abroad.
	Each quarter, we evaluate and review estimates for future remediation and other costs to determine appropriate environmental reserve amounts.  For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments toward the remediation plan will occur.  At sites where we expect to incur ongoing operation and maintenance expenditures, we accrue on an undiscounted basis for a period of generally 10 years those costs which we believe are probable and estimable.
	The total amount accrued for environmental liabilities as of December 31, 2014 and December 31, 2013, was $76 million and $93 million, respectively.  At December 31, 2014 and December 31, 2013, $17 million and $18 million, respectively, of these environmental liabilities were reflected as accrued expenses and $59 million and $75 million, respectively, were reflected as other liabilities in our Consolidated Balance Sheets.  We estimate that ongoing environmental liabilities could range up to $87 million at December 31, 2014.  Our accruals for environmental liabilities include estimates for determinable clean-up costs.  We recorded a pre-tax charge of $6 million in 2014, $29 million in 2013, and $7 million in 2012, to increase our environmental liabilities and made payments of $18 million in 2014, $15 million in 2013 and $12 million in 2012.  At certain sites, we have contractual agreements with certain other parties to share remediation costs.  As of December 31, 2014, no receivables are outstanding related to these agreements.  At a number of these sites, the extent of contamination has not yet been fully investigated or the final scope of remediation is not yet determinable.  We intend to assert all meritorious legal defenses and will pursue other equitable factors that are available with respect to these matters.  However, the final cost of clean-up at these sites could exceed our present estimates, and could have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations or cash flows.  Our estimates for environmental remediation liabilities may change in the future should additional sites be identified, further remediation measures be required or undertaken, current laws and regulations be modified or additional environmental laws and regulations be enacted, and as negotiations with respect to certain sites.
	Other
	We are routinely subject to other civil claims, litigation and arbitration, and regulatory investigations, arising in the ordinary course of our business, as well as in respect of our divested businesses.  Some of these claims and litigations relate to product liability claims, including claims related to our current and historic products and asbestos-related claims concerning premises and historic products of our corporate affiliates and predecessors.
	Guarantees
	In addition to the letters of credit of $15 million and $14 million outstanding at December 31, 2014 and 2013, we have guarantees that have been provided to various financial institutions.  At December 31, 2014 and 2013, we had $10 million and $12 million in guarantees.  The letters of credit and guarantees were primarily related to liabilities for insurance obligations, environmental obligations, banking and credit facilities, vendor deposits and European value added tax (“VAT”) obligations.
	We have applied the disclosure provisions of ASC Topic 460, Guarantees (“ASC 460”), to our agreements that contain guarantee or indemnification clauses.  We are a party to an agreement pursuant to which we may be obligated to indemnify a third party with respect to certain loan obligations of a joint venture company in which we had an equity interest.  These obligations arose to provide initial financing for a joint venture start-up, fund an acquisition and/or provide project capital.  Such obligations mature through May 2016.  In the event that any of the joint venture companies were to default on these loan obligations, we would indemnify the other party up to its proportionate share of the obligation based upon its ownership interest in the joint venture.  At December 31, 2014, the maximum potential future principal and interest payments due under these guarantees were $1 million.  At December 31, 2013, the maximum potential future principal and interest payments due under these guarantees were $2 million.  In accordance with ASC 460, we have accrued less than $1 million in reserves, which represents the fair value of these guarantees at December 31, 2014 and 2013.  The reserve has been included in long-term liabilities on our Consolidated Balance Sheet at December 31, 2014 and 2013 with an offset to other assets.
	In addition, we have financing agreements with banks in Brazil for certain customers under which we receive funds from the banks at invoice date, and in turn, the customer agrees to pay the banks on the due date.  These customers are primarily related to the Chemtura AgroSolutions business.  In anticipation of the sale of the Chemtura AgroSolutions business, the utilization of these facilities was reduced, and one of the financing agreements was terminated, with a resultant increase in accounts receivable balances in Brazil.  We provide a full recourse guarantee to the banks in the event of customer non-payment.
	In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation, claims or environmental matters relating to our past performance.  For any losses that we believe are probable and estimable, we have accrued for such amounts in our Consolidated Balance Sheets.

BUSINESS_SEGMENTS

BUSINESS SEGMENTS	12 Months Ended
	Dec. 31, 2014
BUSINESS SEGMENTS
BUSINESS SEGMENTS
	16)  BUSINESS SEGMENTS
	We evaluate a segment’s performance based on several factors, of which the primary factor is operating income (loss).  In computing operating income (loss) by segment, the following items have not been deducted: (1) general corporate expense; (2) amortization; (3) facility closures, severance and related costs; and (4) gain (loss) on sale of business.  Pursuant to ASC Topic 280, Segment Reporting (“ASC 280”), these items have been excluded from our presentation of segment operating income (loss) because they are not reported to the chief operating decision maker for purposes of allocating resources among reporting segments or assessing segment performance.
	Industrial Performance Products
	Industrial Performance Products are engineered solutions for our customers’ specialty chemical needs.  Industrial Performance Products include petroleum additives that provide detergency, friction modification and corrosion protection in automotive lubricants, greases, refrigeration and turbine lubricants as well as synthetic lubricant base-stocks and greases; castable urethane prepolymers engineered to provide superior abrasion resistance and durability in many industrial and recreational applications; and polyurethane dispersions and urethane prepolymers used in various types of coatings such as clear floor finishes, high-gloss paints and textiles treatments.  These products are sold directly to manufacturers and through distribution channels.
	Industrial Engineered Products
	Industrial Engineered Products are chemical additives designed to improve the performance of polymers in their end-use applications.  Industrial Engineered Products include brominated performance products, flame retardants, fumigants and organometallics.  The products are sold across the entire value chain ranging from direct sales to monomer producers, polymer manufacturers, compounders and fabricators, manufacturers of electronic components, fine chemical manufacturers, utilities, pharmaceutical manufacturers and oilfield service companies to industry distributors.
	Agrochemical Manufacturing (formerly Chemtura AgroSolutions)
	In November 2014, we completed the sale of the Chemtura AgroSolutions business to Platform.  Under the terms of the SAPA, we will retain most of the property, plant and equipment used to manufacture products of the Chemtura AgroSolutions business and will continue to manufacture products for Platform under several supply agreements with minimum terms of between two and four years.  In alignment with the change in the nature of operations we changed the name of this segment to Agrochemical Manufacturing.
	The supply agreements with Platform are designed to recover the cash costs incurred to manufacture the products under the agreement.  Because of this, the supply agreements are considered below-market contracts for their full term and we have recorded an obligation, on a discounted basis, which represents the loss of profit on these products over the terms of the supply agreements, including contractual obligations to continue to supply for a period of up to 2 years after the termination of the contracts.  The recognition of this obligation, along with the accretion of the obligation to its undiscounted value, will be recorded as net sales on a straight-line basis over the term of each supply agreement based on our estimate of the timing of shipments.  Although the recognition of this obligation will be recorded as net sales to the Agrochemical Manufacturing Segment over this period, this recognition will not generate cash flows during the term of the supply agreements.
	Prior to the sale, Chemtura AgroSolutions developed, supplied and registered and sold agricultural chemicals formulated for specific crops in various geographic regions for the purpose of enhancing quality and improving yields. The business was focused on specific target markets in six major product lines: seed treatments, fungicides, miticides, insecticides, growth regulators and herbicides, which were mainly sold to distributors and retailers in the agricultural sector.
	Corporate and Other Charges
	Corporate includes costs and expenses that are of a general corporate nature or managed on a corporate basis.  These costs (net of allocations to the business segments) primarily represent corporate stewardship and administration activities together with costs associated with legacy activities and intangible asset amortization.  Functional costs are allocated between the business segments and general corporate expense.  Certain functional and other expenses that are managed company-wide that were allocated to the Antioxidant and Consumer Products businesses do not transfer directly under the sale agreements.  As such, in historic periods these costs are shown as part of continuing operations in the corporate segment and not included under earnings (loss) from discontinued operations, net of tax.  These costs approximate $20 million and $26 million for 2013 and 2012, respectively.  Additionally, our Corporate segment excludes $8 million and $14 million for 2013 and 2012, respectively, of amortization expense related directly to our Antioxidant and Consumer Product business which has been included in earnings (loss) from discontinued operations, net of tax in our Consolidated Statement of Operations.  Facility closures, severance and related costs are primarily for severance costs related to our cost savings initiatives.  The gain on sale of business relates to the sale of our Chemtura AgroSolutions business in 2014.
	Corporate assets are principally cash and cash equivalents, intangible assets (including goodwill) and other assets (including deferred tax assets) maintained for general corporate purposes.
	Discontinued Operations
	Consumer Products
	In December 2013, we completed the sale of our investment in legal entities dedicated to the Consumer Products business.  As a result, earnings and direct costs associated with Consumer Products business prior to the date of sale have been presented as earnings (loss) from discontinued operations, net of tax in our Consolidated Statements of Operations.
	Antioxidant Business
	In April 2013, we completed the sale of our Antioxidant business.  As a result earnings and direct costs associated with the Antioxidant business prior to the date of sale have been presented as earnings (loss) from discontinued operations, net of tax. The Antioxidant business was formerly included in the Industrial Performance Product segment.
	A summary of business data for our reportable segments for the years 2014, 2013 and 2012 is as follows:
	Information by Business Segment
	(In millions)
		2014			2013			2012
	Net Sales
	Petroleum additives	$	687		$	689		$	600
	Urethanes	300			290			291
	Industrial Performance Products	987			979			891
	Bromine based & related products	641			639			730
	Organometallics	159			164			166
	Industrial Engineered Products	800			803			896
	Agrochemical Manufacturing	403			449			409
	Net Sales	$	2,190		$	2,231		$	2,196
		2014			2013			2012
	Operating Income
	Industrial Performance Products	$	106		$	109		$	102
	Industrial Engineered Products	16			55			140
	Agrochemical Manufacturing	86			88			65
	Segment Operating Income	208			252			307
	General corporate expense	(80		)	(97		)	(101		)
	Amortization	(13		)	(15		)	(16		)
	Facility closures, severance and related costs	(25		)	(42		)	(11		)
	Gain on sale of business	529			—			—
	Total Operating Income	$	619		$	98		$	179
		2014			2013			2012
	Depreciation and Amortization
	Industrial Performance Products	$	34		$	28		$	25
	Industrial Engineered Products	44			43			43
	Agrochemical Manufacturing	8			12			13
		86			83			81
	Corporate	16			18			19
	Total continuing operations	102			101			100
	Discontinued operations	—			22			39
		$	102		$	123		$	139
		2014			2013			2012
	Segment Assets
	Industrial Performance Products	$	642		$	591		$	514
	Industrial Engineered Products	696			743			693
	Agrochemical Manufacturing	87			285			319
		1,425			1,619			1,526
	Discontinued operations	—			—			654
	Corporate	1,242			1,085			850
		$	2,667		$	2,704		$	3,030
		2014			2013			2012
	Capital Expenditures
Industrial Performance Products	$	54		$	73		$	52
Industrial Engineered Products	51			73			69
Agrochemical Manufacturing	6			7			5
	111			153			126
Corporate	2			6			10
Total continuing operations	113			159			136
Discontinued operations	—			11			13
	$	113		$	170		$	149
Information by Geographic Area
(In millions)
	2014			2013			2012
Net sales (based on location of customer)
United States	$	888		$	944		$	878
Canada	48			42			39
Latin America	174			194			159
Europe/Africa	639			624			676
Asia/Pacific	441			427			444
	$	2,190		$	2,231		$	2,196
	2014			2013			2012
Property, Plant and Equipment
United States	$	338		$	336		$	341
Canada	54			61			69
Latin America	10			13			13
Europe/Africa	181			216			187
Asia/Pacific	121			91			35
	$	704		$	717		$	645

GUARANTOR_CONDENSED_CONSOLIDAT

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA	12 Months Ended
	Dec. 31, 2014
GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA
GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA
	17)  GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA
	Our obligations under the 2021 Senior Notes are fully and unconditionally guaranteed on a senior unsecured basis, jointly and severally, by each current and future domestic restricted subsidiary, other than excluded subsidiaries that guarantee any indebtedness of Chemtura or our restricted subsidiaries.  Our subsidiaries that do not guarantee the 2021 Senior Notes are referred to as the “Non-Guarantor Subsidiaries.”  The Guarantor Condensed Consolidating Financial Data presented below presents the statements of operations, statements of comprehensive income, balance sheets and statements of cash flow data for: (i) Chemtura Corporation (the “Parent Company”), the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries on a consolidated basis (which is derived from Chemtura historical reported financial information); (ii) the Parent Company, alone (accounting for our Guarantor Subsidiaries and the Non-Guarantor Subsidiaries on an equity basis under which the investments are recorded by each entity owning a portion of another entity at cost, adjusted for the applicable share of the subsidiary’s cumulative results of operations, capital contributions and distributions, and other equity changes); (iii) the Guarantor Subsidiaries alone; and (iv) the Non-Guarantor Subsidiaries alone.
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2014
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net sales	$	2,190		$	(1,878	)	$	1,346		$	437		$	2,285
	Cost of goods sold	1,682			(1,878		)	1,112			370			2,078
	Selling, general and administrative	255			—			150			16			89
	Depreciation and amortization	102			—			25			32			45
	Research and development	36			—			14			6			16
	Facility closures, severance and related costs	25			—			3			2			20
	Gain on sale of business	(529		)	—			(399		)	—			(130		)
	Operating income	619			—			441			11			167
	Interest expense	(45		)	—			(50		)	—			5
	Loss on early extinguishment of debt	(7		)	—			(7		)	—			—
	Other income (expense), net	12			—			(11		)	2			21
	Equity in net earnings of subsidiaries	—			(145		)	145			—			—
	Earnings from continuing operations before income taxes	579			(145		)	518			13			193
	Income tax benefit (expense)	192			—			244			(4		)	(48		)
	Earnings from continuing operations	771			(145		)	762			9			145
	Earnings from discontinued operations, net of tax	1			—			1			—			—
	Loss on sale of discontinued operations, net of tax	(9		)	—			—			(8		)	(1		)
	Net earnings attributable to Chemtura	$	763		$	(145	)	$	763		$	1		$	144
	Condensed Consolidating Statement of Comprehensive Income (Loss)
	As of December 31, 2014
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net earnings	$	763		$	(145	)	$	763		$	1		$	144
	Other comprehensive income (loss), net of tax:
	Foreign currency translation adjustments	(73		)	—			45			—			(118		)
	Unrecognized pension and other post-retirement benefit costs	(39		)	—			(32		)	—			(7		)
	Unrealized loss on available for sale securities	(5		)	—			(5		)	—			—
	Comprehensive income (loss)	$	646		$	(145	)	$	771		$	1		$	19
	Condensed Consolidating Balance Sheet
	As of December 31, 2014
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	ASSETS
	Current assets	$	1,216		$	—		$	539		$	113		$	564
	Intercompany receivables	—			(6,937		)	3,094			2,752			1,091
	Investment in subsidiaries	—			(4,923		)	822			1,134			2,967
	Property, plant and equipment	704			—			116			222			366
	Goodwill	172			—			93			3			76
	Other assets	575			—			448			36			91
	Total assets	$	2,667		$	(11,860	)	$	5,112		$	4,260		$	5,155
	LIABILITIES AND EQUITY
	Current liabilities	$	405		$	—		$	155		$	44		$	206
	Intercompany payables	—			(6,937		)	2,971			3,031			935
	Long-term debt	556			—			541			—			15
	Other long-term liabilities	652			—			391			83			178
	Total liabilities	1,613			(6,937		)	4,058			3,158			1,334
	Total equity	1,054			(4,923		)	1,054			1,102			3,821
	Total liabilities and equity	$	2,667		$	(11,860	)	$	5,112		$	4,260		$	5,155
	Condensed Consolidating Statement of Cash Flows
	Year ended December 31, 2014
	(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	763		$	(145	)	$	763		$	1		$	144
Adjustments to reconcile net earnings to net cash (used in) provided by operations:
Loss on sale of discontinued operations	9			—			—			8			1
Gain on sale of business	(529		)	—			(399		)	—			(130		)
Agrochemical Manufacturing supply agreements	(6		)	—			(5		)	—			(1		)
Loss on early extinguishment of debt	7			—			7			—			—
Depreciation and amortization	102			—			25			32			45
Stock-based compensation expense	14			—			14			—			—
Deferred tax (benefit) expense	(274		)	—			(278		)	4			—
Excess tax benefit from share-based payment arrangements	(5		)	—			(5		)	—			—
Changes in assets and liabilities, net	(159		)	145			(213		)	(27		)	(64		)
Net cash (used in) provided by operations	(78		)	—			(91		)	18			(5		)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net	984			—			964			15			5
Payments for acquisitions, net of cash acquired	—			—			—			—			—
Capital expenditures	(113		)	—			(18		)	(33		)	(62		)
Net cash provided by (used in) investing activities	871			—			946			(18		)	(57		)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt	19			—			—			—			19
Payments on long term debt, includes premium on tendering of notes	(350		)	—			(342		)	—			(8		)
Payments on short term borrowings, net	(1		)	—			—			—			(1		)
Common shares acquired	(618		)	—			(618		)	—			—
Proceeds from the exercise of stock options	10			—			10			—			—
Excess tax benefit from share-based payment arrangements	5			—			5			—			—
Net cash (used in) provided by financing activities	(935		)	—			(945		)	—			10
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents	(15		)	—			—			—			(15		)
Change in cash and cash equivalents	(157		)	—			(90		)	—			(67		)
Cash and cash equivalents at beginning of year	549			—			$	317		$	—		$	232
Cash and cash equivalents at end of year	$	392		$	—		$	227		$	—		$	165
Condensed Consolidating Statement of Operations
Year ended December 31, 2013
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
Net sales	$	2,231		$	(1,813	)	$	1,443		$	449		$	2,152
Cost of goods sold	1,721			(1,813		)	1,235			389			1,910
Selling, general and administrative	229			—			109			15			105
Depreciation and amortization	101			—			29			35			37
Research and development	40			—			15			8			17
Facility closures, severance and related costs	42			—			21			1			20
Operating income	98			—			34			1			63
Interest expense	(60		)	—			(69		)	—			9
Loss on early extinguishment of debt	(50		)	—			(50		)	—			—
Other income (expense), net	8			—			(21		)	—			29
Equity in net earnings of subsidiaries	—			(85		)	85			—			—
(Loss) earnings from continuing operations before income taxes	(4		)	(85		)	(21		)	1			101
Income tax expense	(18		)	—			—			—			(18		)
(Loss) earnings from continuing operations	(22		)	(85		)	(21		)	1			83
Earnings (loss) from discontinued operations, net of tax	25			—			(3		)	23			5
(Loss) gain on sale of discontinued operations, net of tax	(180		)	—			(153		)	14			(41		)
Net earnings (loss)	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
Condensed Consolidating Statement of Comprehensive (Loss) Income
As of December 31, 2013
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(60		)	—			(18		)	2			(44		)
Unrecognized pension and other post-retirement benefit costs	208			—			202			—			6
Comprehensive (loss) income	$	(29	)	$	(85	)	$	7		$	40		$	9
Condensed Consolidating Balance Sheet
As of December 31, 2013
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
ASSETS
Current assets	$	1,525		$	—		$	571		$	121		$	833
Intercompany receivables	—			(7,671		)	2,681			2,349			2,641
Investment in subsidiaries	—			(7,277		)	1,530			1,135			4,612
Property, plant and equipment	717			—			121			215			381
Goodwill	179			—			93			3			83
Other assets	283			—			137			44			102
Total assets	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
LIABILITIES AND EQUITY
Current liabilities	$	484		$	—		$	244		$	39		$	201
Intercompany payables	—			(7,671		)	2,944			2,583			2,144
Long-term debt	781			—			764			—			17
Other long-term liabilities	440			—			182			54			204
Total liabilities	1,705			(7,671		)	4,134			2,676			2,566
Total equity	999			(7,277		)	999			1,191			6,086
Total liabilities and equity	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
Condensed Consolidating Statement of Cash Flows
Year ended December 31, 2013
(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:
Loss (gain) on sale of discontinued operations	180			—			153			(14		)	41
Impairment charges	7			—			—			7			—
Reclass of translation adjustment from liquidated entities	(13		)	—			—			—			(13		)
Loss on early extinguishment of debt	50			—			50			—			—
Depreciation and amortization	123			—			33			45			45
Stock-based compensation expense	14			—			14			—			—
Changes in assets and liabilities, net	(105		)	85			(84		)	(27		)	(79		)
Net cash provided by (used in) operations	79			—			(11		)	49			41
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from divestments, net	357			—			255			(2		)	104
Payments for acquisitions, net of cash acquired	(3		)	—			—			—			(3		)
Capital expenditures	(170		)	—			(20		)	(47		)	(103		)
Net cash provided by (used in) investing activities	184			—			235			(49		)	(2		)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt	481			—			457			—			24
Payments on long term debt, includes premium on tendering of notes	(502		)	—			(499		)	—			(3		)
Payments on short term borrowings, net	(1		)	—			—			—			(1		)
Payments for debt issuance costs	(12		)	—			(12		)	—			—
Common shares acquired	(54		)	—			(54		)	—			—
Proceeds from exercise of stock options	8			—			8			—			—
Net cash (used in) provided by financing activities	(80		)	—			(100		)	—			20
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents	1			—			—			—			1
Change in cash and cash equivalents	184			—			124			—			60
Cash and cash equivalents at beginning of year	365			—			193			—			172
Cash and cash equivalents at end of year	$	549		$	—		$	317		$	—		$	232
Condensed Consolidating Statement of Operations
Year ended December 31, 2012
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
Net sales	$	2,196		$	(1,623	)	$	1,477		$	454		$	1,888
Cost of goods sold	1,615			(1,623		)	1,192			383			1,663
Selling, general and administrative	246			—			121			17			108
Depreciation and amortization	100			—			27			44			29
Research and development	41			—			16			7			18
Facility closures, severance and related costs	11			—			8			—			3
Equity loss	4			—			—			—			4
Operating income	179			—			113			3			63
Interest expense	(64		)	—			(69		)	2			3
Loss on early extinguishment of debt	(1		)	—			(1		)	—			—
Other income (expense), net	15			—			(22		)	—			37
Equity in net earnings of subsidiaries	—			(81		)	81			—			—
Earnings from continuing operations before income taxes	129			(81		)	102			5			103
Income tax expense	(26		)	—			—			—			(26		)
Earnings from continuing operations	103			(81		)	102			5			77
(Loss) earnings from discontinued operations, net of tax	(3		)	—			(1		)	28			(30		)
Net earnings	100			(81		)	101			33			47
Less: net loss attributable to non-controlling interests	1			—			—			—			1
Net earnings attributable to Chemtura	$	101		$	(81	)	$	101		$	33		$	48
Condensed Consolidating Statement of Comprehensive Income
As of December 31, 2012
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
Net earnings	$	100		$	(81	)	$	101		$	33		$	47
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(6		)	—			(11		)	1			4
Unrecognized pension and other post-retirement benefit costs	(76		)	—			(44		)	—			(32		)
Comprehensive income	18			(81		)	46			34			19
Comprehensive loss attributable to non-controlling interests	1			—			—			—			1
Comprehensive income attributable to Chemtura	$	19		$	(81	)	$	46		$	34		$	20
Condensed Consolidating Statement of Cash Flows
Year ended December 31, 2012
(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	100		$	(81	)	$	101		$	33		$	47
Adjustments to reconcile net earnings to net cash provided by operations:
Impairment charges	47			—			12			—			35
Reclass of translation adjustment from liquidation of entities	(21		)	—			—			—			(21		)
Loss on early extinguishment of debt	1			—			1			—			—
Depreciation and amortization	139			—			36			51			52
Stock-based compensation expense	24			—			24			—			—
Other non-cash transactions	3			—			2			—			1
Changes in assets and liabilities, net	(75		)	81			(106		)	(37		)	(13		)
Net cash provided by operations	218			—			70			47			101
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net	9			—			—			—			9
Capital expenditures	(149		)	—			(21		)	(47		)	(81		)
Net cash used in investing activities	(140		)	—			(21		)	(47		)	(72		)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt	125			—			125			—			—
Payments on other short term borrowings, net	(3		)	—			—			—			(3		)
Payments for debt issuance and refinancing costs	(2		)	—			(1		)	—			(1		)
Common shares acquired	(20		)	—			(20		)	—			—
Proceeds from exercise of stock options	5			—			5			—			—
Net cash provided by (used in) financing activities	105			—			109			—			(4		)
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents	2			—			—			—			2
Change in cash and cash equivalents	185			—			158			—			27
Cash and cash equivalents at beginning of year	180			—			35			—			145
Cash and cash equivalents at end of year	$	365		$	—		$	193		$	—		$	172

SUMMARIZED_UNAUDITED_QUARTERLY

SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA	12 Months Ended
	Dec. 31, 2014
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
	18)  SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
	(In millions, except per share data)		2014
			First			Second			Third			Fourth
	Net sales		$	556		$	609		$	558		$	467
	Gross profit		$	120		$	158		$	134		$	96
	Earnings from continuing operations, net of tax		$	10	(a)	$	43	(b)	$	15	(c)	$	703	(d)
	Earnings from discontinued operations, net of tax		1			—			—			—
	Loss on sale of discontinued operations, net of tax		(5		)	(4		)	—			—
	Net earnings		$	6		$	39		$	15		$	703
	BASIC PER SHARE (i):
	Earnings from continuing operations, net of tax		$	0.1		$	0.46		$	0.17		$	8.57
	Earnings from discontinued operations, net of tax		0.01			—			—			—
	Loss on sale of discontinued operations, net of tax		(0.05		)	(0.04		)	—			—
	Net earnings		$	0.06		$	0.42		$	0.17		$	8.57
	DILUTED PER SHARE (i):
	Earnings from continuing operations, net of tax		$	0.1		$	0.46		$	0.17		$	8.44
	Earnings from discontinued operations, net of tax		0.01			—			—			—
	Loss on sale of discontinued operations, net of tax		(0.05		)	(0.04		)	—			—
	Net earnings		$	0.06		$	0.42		$	0.17		$	8.44
	Basic weighted-average shares outstanding		96.3			93.2			89.4			82
	Diluted weighted-average shares outstanding		97.8			94.4			90.7			83.3
			2013
			First			Second			Third			Fourth
	Net sales		$	528		$	590		$	569		$	544
	Gross profit		$	110		$	146		$	121		$	133
	(Loss) earnings from continuing operations, net of tax		$	(18	)(e)	$	27	(f)	$	(44	)(g)	$	13	(h)
	(Loss) earnings from discontinued operations, net of tax		(5		)	26			7			(3		)
	Loss on sale of discontinued operations, net of tax		—			(146		)	(3		)	(31		)
	Net loss		$	(23	)	$	(93	)	$	(40	)	$	(21	)
	BASIC PER SHARE (i):
	(Loss) earnings from continuing operations, net of tax		$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05		)	0.26			0.07			(0.03		)
	Loss on sale of discontinued operations, net of tax		—			(1.48		)	(0.03		)	(0.32		)
	Net loss		$	(0.23	)	$	(0.95	)	$	(0.41	)	$	(0.22	)
	DILUTED PER SHARE (i):
	(Loss) earnings from continuing operations, net of tax		$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05		)	0.26			0.07			(0.03		)
	Loss on sale of discontinued operations, net of tax		—			(1.46		)	(0.03		)	(0.32		)
	Net loss		$	(0.23	)	$	(0.93	)	$	(0.41	)	$	(0.22	)
	Basic weighted-average shares outstanding		98.2			98.6			97.5			96.6
	Diluted weighted-average shares outstanding		98.2			99.7			97.5			98.1
		(a)		The earnings from continuing operations for the first quarter of 2014 included pre-tax charges for facility closures, severance and related costs of $2 million.
		(b)		The earnings from continuing operations for the second quarter of 2014 included pre-tax charges for facility closures, severance and related costs of $4 million.
		(c)		The earnings from continuing operations for the third quarter of 2014 included pre-tax charges for accelerated depreciation of property, plant and equipment of $4 million.
		(d)		The earnings from continuing operations for the fourth quarter of 2014 included the pre-tax gain on sale of the Agrochemical Manufacturing business of $529 million and pre-tax charges for facility closures, severance and related costs of $19 million and loss on early extinguishment of debt of $7 million.
		(e)		The loss from continuing operations for the first quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $14 million.
		(f)		The earnings from continuing operations for the second quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $11 million.
		(g)		The loss from continuing operations for the third quarter of 2013 included pre-tax charges for loss on early extinguishment of debt of $50 million and facility closures, severance and related costs of $3 million.
		(h)		The earnings from continuing operations for the fourth quarter of 2013 included a pre-tax charges for facility closures, severance and related costs of $14 million.
		(i)		The sum of the earnings (loss) per common share for the four quarters may not equal the total earnings (loss) per common share for the full year due to quarterly changes in the average number of shares outstanding.

NATURE_OF_OPERATIONS_AND_SUMMA1

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
	Basis of Presentation
	The accompanying Consolidated Financial Statements include the accounts of Chemtura and our wholly-owned and majority-owned subsidiaries that we control.  Other affiliates in which we have a 20% to 50% ownership interest or a non-controlling majority interest are accounted for in accordance with the equity method.  Other investments in which we have less than 20% ownership are recorded at cost.  All significant intercompany balances and transactions have been eliminated in consolidation.
	Our Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from these estimates.
	Certain prior year amounts have been reclassified to conform to the current year’s presentation.  These changes did not have a material impact on previously reported results of operations, cash flows or financial position.
Revenue Recognition
	Revenue Recognition
	Substantially all of our revenues are derived from the sale of products.  Revenue is recognized when risk of loss and title to the product is transferred to the customer.  Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities with the collected taxes recorded as current liabilities until remitted to the respective governmental authorities.  Our products are sold subject to various shipping terms.  Our terms of delivery are included on our sales invoices and order confirmation documents.
	We record the revenue and costs associated with our supply agreements for our Agrochemical Manufacturing segment on a gross basis.  Additionally, included in revenue for this segment is the recognition of the below market contract obligation associated with these supply agreements, on a straight-line basis based on our estimate of the timing of shipments.
Customer Rebates
	Customer Rebates
	We accrue for the estimated cost of customer rebates as a reduction of sales.  Customer rebates are primarily based on customers achieving defined sales targets over a specified period of time.  We estimate the cost of these rebates based on the likelihood of the rebate being achieved and recognize the cost as a deduction from sales when such sales are recognized.
	Rebate programs are monitored on a regular basis and adjusted as required.  Customer rebates are included as a reduction to accounts receivable on our Consolidated Balance Sheet.  Activity in customer rebate accounts is a follows:
	(In millions)		2014			2013			2012
	Balance, January 1		$	10		$	14		$	14
	Charged to costs and expenses		37			36			8
	Payments to customers		(40		)	(40		)	(8		)
	Other(1)		(5		)	—			—
	Balance, December 31		$	2		$	10		$	14
		-1		Relates to the sale of Chemtura AgroSolutions in November 2014.
Operating Costs and Expenses
	Operating Costs and Expenses
	Cost of goods sold (“COGS”) includes all costs incurred in manufacturing goods, including raw materials, direct manufacturing costs and manufacturing overhead.  COGS also includes warehousing, distribution, engineering, purchasing, customer service, environmental, health and safety functions, and shipping and handling costs for outbound product shipments.  Selling, general and administrative (“SG&A”) expenses include costs and expenses related to the following functions and activities: selling, advertising, legal, provision for doubtful accounts, corporate facilities and corporate administration.  SG&A also includes accounting, information technology, finance and human resources, excluding direct support in manufacturing operations, which is included as COGS.  Research and development (“R&D”) expenses include basic and applied research and development activities of a technical and non-routine nature.  R&D costs are expensed as incurred.  COGS, SG&A and R&D expenses exclude depreciation and amortization expenses which are presented on a separate line in our Consolidated Statements of Operations.
Other Income (Expense), Net
	Other Income (Expense), Net
	Other income (expense), net includes:
	(In millions)		2014			2013			2012
	Foreign exchange gain (loss)		$	10		$	(7	)	$	(6	)
	Interest income		3			3			5
	Release of cumulative foreign currency translation adjustments from liquidation of entities		—			13			21
	Reorganization items, net		(1		)	(1		)	(5		)
			$	12		$	8		$	15
Allowance for doubtful accounts
	Allowance for Doubtful Accounts
	The allowance for doubtful accounts reflects a reserve representing our estimate of the amounts that may not be collectible.  In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserves, including historical data, experience, customer types, credit worthiness, and economic trends.  From time to time, we may adjust our assumptions for anticipated changes in any of these or other factors expected to affect collection.  Allowances for doubtful accounts are included as a reduction to accounts receivable in our Consolidated Balance Sheet.  Activity in allowance for doubtful accounts is a follows:
	(In millions)		2014			2013			2012
	Balance, January 1		$	11		$	11		$	15
	Charged to costs and expenses		8			2			2
	Write-offs		(3		)	(1		)	(6		)
	Other(1)		(14		)	(1		)	—
	Balance, December 31		$	2		$	11		$	11
		-1		Relates to the sale of Chemtura AgroSolutions in November 2014.
Inventory Valuation
	Inventory Valuation
	Inventories are valued at the lower of cost or market.  Cost is determined using the first-in, first-out (“FIFO”) method.
Property, Plant and Equipment
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation.  Depreciation expense is principally computed on the straight-line method using the following ranges of asset lives: land improvements - 3 to 20 years; buildings and improvements - 2 to 40 years; machinery and equipment - 2 to 25 years; information systems and equipment - 2 to 10 years; and furniture, fixtures and other - 1 to 10 years.  See Note 5 — Property, Plant and Equipment for further information.
	Renewals and improvements that significantly extend the useful lives of the assets are capitalized.  Capitalized leased assets and leasehold improvements are depreciated over the shorter of their useful lives or the remaining lease term.  Expenditures for maintenance and repairs are charged to expense as incurred.
Intangible Assets
	Intangible Assets
	Patents, trademarks and other intangibles assets are being amortized principally on a straight-line basis using the following ranges for their estimated useful lives: patents - 10 to 20 years; trademarks - 30 to 40 years; customer relationships - 15 to 30 years; production rights - 10 years; and other intangibles - 5 to 50 years.  See Note 6 — Goodwill and Intangible Assets for further information.
Marketable Securities
	Marketable Securities
	We apply the provision of ASC Topic 360 - Investments - Debt and Equity Securities (“ASC 320”), in evaluating and accounting for marketable securities.  Our primary marketable security is 2 million shares of Platform Specialty Products Corporation (“Platform”) common stock of which was acquired as part of the sale of our Chemtura AgroSolutions business in 2014.  The stock is restricted from trading for a period of six months from the date of sale.  We have deemed these securities to be considered available-for-sale.  The valuation of these securities is based upon Level 2 valuation techniques.  As of December 31, 2014. the value of the shares of $45 million was included in Other Current Assets on our Consolidated Balance Sheet.  Changes in the valuation of these securities is included in Accumulated Other Comprehensive Loss (“AOCL”) on our Consolidated Balance Sheet.
Asset Retirement Obligation
	Asset Retirement Obligation
	We apply the provisions of ASC Topic 410, Asset Retirements and Environmental Obligations (“ASC 410”), which requires us to make estimates regarding future events in order to record a liability for asset retirement obligations in the period in which a legal obligation is created.  Such liabilities are recorded at fair value, with an offsetting increase to the carrying value of the related long-lived assets.  The fair value is estimated by discounting projected cash flows over the estimated life of the assets using our credit adjusted risk-free rate applicable at the time the obligation is initially recorded.  In future periods, the liability is accreted to its present value and the capitalized cost is depreciated over the useful life of the related asset.  We also adjust the liability for changes resulting from revisions to the timing of future cash flows or the amount of the original estimate.  Upon retirement of the long-lived asset, we either settle the obligation for its recorded amount or incur a gain or loss.
	Our asset retirement obligations are primarily the result of legal obligations for the removal of leasehold improvements and restoration of premises to their original condition upon termination of leases; legal obligations to close brine supply, brine disposal, waste disposal and hazardous waste injection wells and the related pipelines at the end of their useful lives; and decommissioning and decontamination obligations that are legally required to be fulfilled upon closure of our manufacturing facilities.
	During 2014 and 2013, accretion expense recorded to COGS was $3 million.  At December 31, 2014, $3 million of the asset retirement obligation balance was included in accrued expenses and $13 million was included in other liabilities in our Consolidated Balance Sheet.  At December 31, 2013, $3 million of the asset retirement obligation balance was included in accrued expenses and $13 million was included in other liabilities in our Consolidated Balance Sheet.
Recoverability of Long-Lived Assets and Goodwill
	Recoverability of Long-Lived Assets and Goodwill
	We evaluate the recoverability of the carrying value of long-lived assets, excluding goodwill, whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Under such circumstances, we assess whether the projected undiscounted cash flows of our long-lived assets are sufficient to recover the existing unamortized cost of our long-lived assets.  If the undiscounted projected cash flows are not sufficient, we calculate the impairment amount by discounting the projected cash flows using our weighted-average cost of capital.  The amount of the impairment is written off against earnings in the period in which the impairment is determined.
	We have elected to perform our annual goodwill impairment procedures for all of our reporting units in accordance with ASC Subtopic 350-20, Intangibles — Goodwill and Other - Goodwill (“ASC 350-20”) as of July 31, or sooner, if events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below the carrying value.  We estimate the fair value of our reporting units utilizing income and market approaches through the application of discounted cash flow and market comparable methods (Level 3 inputs as described in Note 14 — Financial Instruments and Fair Value Measurements).  The assessment is required to be performed in two steps: step one to test for a potential impairment of goodwill and, if a potential impairment is identified, step two to measure the impairment loss through a full fair valuation of the assets and liabilities of the reporting unit utilizing the acquisition method of accounting.  We concluded that no goodwill impairment existed in any of our reporting units based on our reviews in 2014 and 2013.
Income Taxes
	Income Taxes
	We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities using enacted rates. The effect of a change in tax rates on deferred tax assets is recognized in income in the period that includes the enactment date.
	We recognize the financial statement effects of an uncertain income tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We accrue for other tax contingencies when it is probable that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated.
	Provision is made for taxes on undistributed earnings of foreign subsidiaries and related companies to the extent that such earnings are not deemed to be indefinitely reinvested.
	Valuation allowances are established when we determine that it is more likely than not that the results of future operations will not generate sufficient taxable income to realize our deferred tax assets. We consider the scheduled reversal of deferred tax assets and liabilities, projected future taxable income, and tax planning strategies in making this assessment. Thus, changes in future results of operations could result in adjustments to our valuation allowances.
Environmental Liabilities
	Environmental Liabilities
	Each quarter, we evaluate and review our estimates for future remediation, operation and management costs directly related to environmental remediation, to determine appropriate environmental reserve amounts.  For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments to implement the remediation plan will occur. In regards to remediation costs, we accrue on an undiscounted basis, for a period of generally no more than 10 years, those costs which are probable and estimable.  At sites where we expect to incur ongoing operations and maintenance expenditures, we accrue on an undiscounted basis, for a period of generally no more than 10 years, those costs which are probable and estimable.
Below-Market Obligation
	Below-Market Obligation
	Contemporaneously with the sale of our Chemtura AgroSolutions business we entered into supply agreements with Platform to manufacture products of that business.  The supply agreements were designed to recover the cash costs incurred to manufacture the products under the agreements and do not include reimbursement for depreciation and amortization of property, plant and equipment we have retained to perform under these supply agreements.  As such, we have determined that the supply agreements with Platform are below-market. To determine the undiscounted value of this obligation we utilized a Level 3 fair value technique.  Our fair value calculation was based upon taking the reduction in selling prices on a before and after basis factoring in the the favorable cost benefit of reduced SG&A, R&D and distribution expense.  Historical volumes under the supply agreements are anticipated to represent the requirements of Platform on a going forward basis.  We did not consider depreciation or amortization as these amounts are not reimbursable under the terms of the supply agreements.  We applied a growth factor to each year to represent inflation over the terms of the supply agreements.  We discounted the calculated loss of profits for those products over the period of the supply agreements by applying our internal weighted average cost of capital to determine the amount of the initial obligation.
	Accretion of the obligation to its undiscounted fair value and the recognition of the below market contract obligation is taken to net sales on a straight-line basis over the estimated 6 year life of the supply agreements based on the estimated timing of shipments on an annual basis.
Litigation and Contingencies
	Litigation and Contingencies
	In accordance with guidance now codified under ASC Topic 450, Contingencies and ASC Topic 460, Guarantees, we record in our Consolidated Financial Statements amounts representing our probable and estimable liability for claims, litigation and guarantees.  As information about current or future litigation or other contingencies becomes available, management assesses whether such information warrants the recording of additional expenses relating to those contingencies.  See Note 15 - Legal Proceedings and Contingencies for further information.
Stock-Based Compensation
	Stock-Based Compensation
	We recognize compensation expense for stock-based awards issued over the requisite service period for each separately vesting tranche, as if multiple awards were granted.  Stock-based compensation expense is measured at the date of grant, based on the fair value of the award.  We used the Monte-Carlo simulation model to determine the fair value of performance shares.  We used the Black-Scholes option-pricing model to determine the fair value of nonqualified stock options.  See Note 12 - Stock Incentive Plans for further information.
Translation of Foreign Currencies
	Translation of Foreign Currencies
	Balance sheet accounts denominated in foreign currencies are translated at the current rate of exchange as of the balance sheet date, while revenues and expenses are translated at average rates of exchange during the periods presented.  The cumulative foreign currency adjustments resulting from such translation are included in accumulated other comprehensive loss. Upon complete or substantial liquidation of any of our subsidiaries, the value of the cumulative translation adjustment of such subsidiaries prior to their liquidation is reported in net earnings.
Derivatives and Hedging
	Derivatives and Hedging
	Our activities expose our earnings, cash flows and financial condition to a variety of market risks, including the effects of changes in foreign currency exchange rates, interest rates and energy prices.  We maintain a risk management strategy that may utilize derivative instruments to mitigate risk against foreign currency movements and to manage energy price volatility.  We do not enter into derivative instruments for trading or speculative purposes.
	We have exposure to changes in foreign currency exchange rates resulting from transactions entered into by us and our foreign subsidiaries in currencies other than their functional currency (primarily trade payables and receivables).  We are also exposed to currency risk on intercompany transactions (including intercompany loans).  We manage these currency risks on a consolidated basis, which allows us to net our exposure.
	There were no outstanding derivatives at December 31, 2014.
Cash Flows
	Cash Flows
	Cash and cash equivalents include bank term deposits with original maturities of three months or less.
	In March 2009, Chemtura and 26 of our affiliates filed for relief under Chapter 11 of Title 11 of the United States Code (“Chapter 11”) the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”).  In November 2010, the Bankruptcy Court entered an order confirming our plan of reorganization (the “Plan”).  In 2012, we settled approximately $5 million in cash relating to our Chapter 11 cases.  The $5 million paid in 2012, was paid from restricted cash.  Additionally, in 2012 we issued approximately $26 million of common stock for the settlement of liabilities in accordance with the Plan.
	Cash payments included interest payments of $46 million in 2014, $57 million in 2013 and $58 million in 2012.  Cash payments also included income tax payments, net of refunds of $68 million in 2014, $21 million in 2013 and $45 million in 2012.

NATURE_OF_OPERATIONS_AND_SUMMA2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule for customer rebates
	(In millions)		2014			2013			2012
	Balance, January 1		$	10		$	14		$	14
	Charged to costs and expenses		37			36			8
	Payments to customers		(40		)	(40		)	(8		)
	Other(1)		(5		)	—			—
	Balance, December 31		$	2		$	10		$	14
		-1		Relates to the sale of Chemtura AgroSolutions in November 2014.
Schedule of other income (expense), net
	(In millions)		2014			2013			2012
	Foreign exchange gain (loss)		$	10		$	(7	)	$	(6	)
	Interest income		3			3			5
	Release of cumulative foreign currency translation adjustments from liquidation of entities		—			13			21
	Reorganization items, net		(1		)	(1		)	(5		)
			$	12		$	8		$	15
Schedule of Allowances for doubtful accounts
	(In millions)		2014			2013			2012
	Balance, January 1		$	11		$	11		$	15
	Charged to costs and expenses		8			2			2
	Write-offs		(3		)	(1		)	(6		)
	Other(1)		(14		)	(1		)	—
	Balance, December 31		$	2		$	11		$	11
		-1		Relates to the sale of Chemtura AgroSolutions in November 2014.

DIVESTITURES_ACQUISITIONS_AND_

DIVESTITURES ACQUISITIONS AND ACQUISITIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Divestitures and Acquisitions
Schedule of Earnings from discontinued operations
			Year Ended
	(In millions)		2014			2014			2014			2013			2013			2013			2012			2012			2012
			Consumer			Antioxidant			Total			Consumer			Antioxidant			Total			Consumer			Antioxidant			Total
	Net sales		$	—		$	—		$	—		$	408		$	123		$	531		$	433		$	387		$	820
	Earnings (loss) from discontinued operations:
	Pre-tax earnings (loss)		$	1		$	—		$	1		$	24		$	4		$	28		$	33		$	(45	)	$	(12	)
	Income tax (expense) benefit		—			—			—			(3		)	—			(3		)	(2		)	11			9
	Earnings (loss), net of taxes		1			—			1			21			4			25			31			(34		)	(3		)
	Net loss attributable to non-controlling interests		—			—			—			—			—			—			—			1			1
	Earnings (loss), net of taxes - attributable to Chemtura		$	1		$	—		$	1		$	21		$	4		$	25		$	31		$	(33	)	$	(2	)
	Loss on sale of discontinued operations:
	Pre-tax loss		$	(8	)	$	(1	)	$	(9	)	$	(24	)	$	(164	)	$	(188	)
	Income tax (expense) benefit (a)		—			—			—			(1		)	9			8
	Net loss		$	(8	)	$	(1	)	$	(9	)	$	(25	)	$	(155	)	$	(180	)
Schedule of functional and other expenses allocated to businesses that will not transfer directly under the sale agreements, and which is shown as part of continuing operations in the corporate segment
	(In millions)		2013			2012
	Antioxidant		$	6		$	13
	Consumer Products		14			13
	Amortization expense (a)		(8		)	(14		)
	Net increase in Corporate Segment		$	12		$	12
	(a) Our Corporate segment included amortization expense which related directly to the Antioxidant and Consumer Products businesses which is now included in earnings (loss) from discontinued operations, net of tax.
Chemtura AgroSolutions
Divestitures and Acquisitions
Summary of the assets and liabilities sold or settled and the assets and liabilities of discontinued operations
	(In millions)		December 31, 2014			November 3, 2014			December 31, 2013
	Cash and cash equivalents		$	—		$	7		$	—
	Accounts receivable, net		3			158			128
	Inventories, net		1			94			71
	Other current assets		—			8			7
	Property, plant and equipment		—			11			8
	Intangible assets, net		—			32			28
	Other assets		2			3			3
	Assets		6			313			245
	Accounts payable		—			21			24
	Accrued expenses		9			30			13
	Income taxes payable		—			4			1
	Liabilities		9			55			38
	Net Assets		$	(3	)	$	258		$	207
Schedule of reconciliation of adjusted cash proceeds to pre-tax gain/loss on sale
	(In millions)		2014
	Cash consideration		$	950
	Pre-closing working capital and other adjustments		28
	Cash proceeds		978
	Platform Stock (1)		51
	Less direct items:
	Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effect		258
	Below market supply contract		230
	Transaction costs and other (2)		21
	Post-closing adjustments, obligations and other, net		(6		)
	Less non-cash items:
	Release of AOCL - cumulative translation adjustment		(3		)
	Pre-tax gain on sale of Chemtura AgroSolutions		$	529
	(1) Represents 2 million shares of PSP common stock at $26.00 per share discounted for the value of a restriction to sell of $1 million.
	(2) Transaction costs include success fees to a financial adviser, legal fees and other direct costs incurred to sell the business since October 1, 2014.
Consumer Products Business Divestiture
Divestitures and Acquisitions
Summary of the assets and liabilities sold or settled and the assets and liabilities of discontinued operations
	(In millions)		December 31, 2013
	Cash and cash equivalents		$	13
	Accounts receivable, net		55
	Inventories, net		64
	Current domestic tax assets reversed upon sale		7
	Other current assets, includes foreign deferred tax assets		8
	Property, plant and equipment		63
	Intangible assets, net		195
	Other assets		5
	Assets		410
	Accounts payable		16
	Accrued expenses		14
	Income taxes payable		—
	Pension and post-retirement health care liabilities		6
	Domestic tax liabilities reversed upon sale		44
	Other liabilities, includes foreign deferred tax liabilities		32
	Liabilities		112
	Net Assets		$	298
Schedule of reconciliation of adjusted cash proceeds to pre-tax gain/loss on sale
	(In millions)		2014			2013
	Cash consideration					$	300
	Working capital and other adjustments		$	(3	)	(36		)
	Cash proceeds					264
	Less direct items:
	Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effect					335
	Transaction costs and other (1)		5			10
	Post-closing adjustments, obligations and other, net					(18		)
	Less non-cash items:
	Release of AOCL - pension					5
	Release of AOCL - cumulative translation adjustment					(44		)
	Pre-tax loss on sale of discontinued operations		$	(8	)	$	(24	)
		-1		Transaction costs include legal fees and other direct costs incurred to sell the business since October 1, 2013
Antioxidant Business Divestiture
Divestitures and Acquisitions
Summary of the assets and liabilities sold or settled and the assets and liabilities of discontinued operations
	(In millions)		April 30, 2013
	Cash and cash equivalents		$	2
	Accounts and trade receivable, net		70
	Inventories, net		76
	Other current assets		2
	Property, plant and equipment		48
	Intangible assets, net		14
	Other assets		32
	Assets		244
	Accounts payable		39
	Accrued expenses		2
	Income taxes payable		—
	Pension and post-retirement health care liabilities		81
	Other liabilities		11
	Liabilities		133
	Net Assets		$	111
Schedule of reconciliation of adjusted cash proceeds to pre-tax gain/loss on sale
	(In millions)		2014			2013
	Cash consideration					$	97
	Working capital and other adjustments					(10		)
	Post-closing adjustments		$	(1	)	(2		)
	Cash proceeds					85
	Preferred stock					9
	Less direct items:
	Net assets sold or settled					111
	Transaction costs and other (1)					5
	Post-closing obligations and other, net					8
	Fair value of supply agreements					13
	Less non-cash items:
	Release of AOCL - pension					122
	Release of AOCL - cumulative translation adjustment					6
	Release of non-controlling interest					(7		)
	Pre-tax loss on sale of discontinued operations		$	(1	)	$	(164	)
		-1		Transaction costs include legal fees and other direct costs incurred to sell the business since April 1, 2013.

RESTRUCTURING_AND_ASSET_IMPAIR1

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2014
RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES
Summary of changes in liabilities established for restructuring programs
	(In millions)	Severance and			Other Facility			Total
		Related Costs			Closure Costs
	Balance at January 1, 2012	$	1		$	—		$	1
	Facility closure, severance and related costs
	Continuing operations	6			5			11
	Discontinued operations	6			—			6
	Cash payments	(5		)	(5		)	(10		)
	Balance at December 31, 2012	8			—			8
	Facility closure, severance and related costs:
	Continuing operations	27			15			42
	Discontinued operations	—			1			1
	Cash payments	(19		)	(14		)	(33		)
	Reclassifications	(2		)	—			(2		)
	Balance at December 31, 2013	14			2			16
	Facility closure, severance and related costs:
	Continuing operations	22			3			25
	Cash payments	(15		)	(5		)	(20		)
	Balance at December 31, 2014	$	21		—			$	21

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2014
INVENTORIES
Components of inventories
	(In millions)	2014		2013
	Finished goods	$	200	$	223
	Work in process	35		35
	Raw materials and supplies	94		88
		$	329	$	346

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
PROPERTY, PLANT AND EQUIPMENT
Schedule of property, plant and equipment
	(In millions)	2014		2013
	Land and improvements	$	71	$	74
	Buildings and improvements	209		212
	Machinery and equipment	1,248		1,225
	Information systems and equipment	167		171
	Furniture, fixtures and other	22		24
	Construction in progress	82		94
		1,799		1,800
	Less: accumulated depreciation	1,095		1,083
		$	704	$	717

GOODWILL_AND_INTANGIBLE_ASSETS1

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
GOODWILL AND INTANGIBLE ASSETS
Schedule of goodwill by reportable segment
	(In millions)	Gross Goodwill			Accumulated			Net Goodwill
					Impairments
	Balance at December 31, 2012	$	267		$	(90	)	$	177
	Foreign currency translation	2			—			2
	Balance at December 31, 2013	269			(90		)	179
	Foreign currency translation	(7		)	—			(7		)
	Balance at December 31, 2014	$	262		$	(90	)	$	172
Schedule of intangible assets (excluding goodwill)
		2014									2013
	(In millions)	Gross			Accumulated			Net			Gross		Accumulated			Net
		Value			Amortization			Intangibles			Value		Amortization			Intangibles
	Patents	$	26		$	(17	)	$	9		$	33	$	(21	)	$	12
	Trademarks	44			(13		)	31			45		(12		)	33
	Customer relationships	41			(20		)	21			42		(18		)	24
	Production rights	45			(41		)	4			45		(36		)	9
	Other	72			(38		)	34			74		(38		)	36
	Total	$	228		$	(129	)	$	99		$	239	$	(125	)	$	114

DEBT_Tables

DEBT (Tables)	12 Months Ended
	Dec. 31, 2014
DEBT
Schedule of debt
		2014					2013
	(In millions)	Carrying			Fair Value		Carrying			Fair Value
		Value					Value
	5.75% Senior Notes due 2021, with an effective interest rate of 5.93% in 2014 and 5.83% in 2013	$	450		$	439	$	450		$	456
	7.875% Senior Notes due 2018, net of unamortized discount of $1 million in 2013 with an effective interest rate of 8.90% in 2013	—			—		100			108
	Term Loan due 2016, net of unamortized discount of less than $1 million in 2014 and $2 million 2013 with an effective interest rate of 3.78% in 2014 and 5.39% in 2013	82			82		316			320
	Other borrowings	42			42		32			32
	Total Debt	574			$	563	898			$	916
	Less: Other short-term borrowings	(18		)			(7		)
	Less: Current portion of Term Loan	—					(110		)
	Total Long-Term Debt	$	556				$	781

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
INCOME TAXES
Schedule of (loss) earnings from continuing operations before income taxes and the income tax expense (benefit)
	(In millions)	2014			2013			2012
	Pre-tax Earnings (Loss) from Continuing Operations:
	Domestic	$	388		$	(105	)	$	26
	Foreign	191			101			103
		$	579		$	(4	)	$	129
	Income Tax Expense (Benefit)
	Domestic
	Current	$	34		$	—		$	—
	Deferred	(274		)	(1		)	—
		(240		)	(1		)	—
	Foreign
	Current	48			17			23
	Deferred	—			2			3
		48			19			26
	Total
	Current	82			17			23
	Deferred	(274		)	1			3
		$	(192	)	$	18		$	26
Schedule of expense (benefit) for income taxes from continuing operations that differs from federal statutory rate
	(In millions)	2014			2013			2012
	Income tax (benefit) expense at the U.S. statutory rate	$	203		$	(1	)	$	45
	Foreign rate differential	(45		)	(17		)	(4		)
	Valuation allowances	(389		)	21			(25		)
	U.S. tax on foreign earnings	92			26			28
	Foreign withholding	40			—			—
	Nondeductible reorganizational expenses	—			—			1
	Nondeductible expenses, other	1			7			2
	Nondeductible stock compensation	1			1			1
	Depletion	(3		)	(3		)	(3		)
	Income tax credits	(85		)	(6		)	(18		)
	State income taxes, net of federal benefit	(12		)	—			—
	Taxes attributable to prior periods	(10		)	(11		)	(1		)
	Other, net	15			1			—
	Income tax (benefit) expense	$	(192	)	$	18		$	26
Schedule of components of the deferred tax assets and liabilities
	(In millions)	2014			2013
	Deferred tax assets:
	Pension and other post-retirement liabilities	$	83		$	61
	Net operating loss carryforwards	253			387
	Other accruals	3			15
	Below market contracts, net of discount	82			—
	Tax credit carryforwards	66			128
	Accruals for environmental remediation	23			29
	Intangibles	2			5
	Inventories and other	15			20
	Financial instruments	1			1
	Total deferred tax assets	528			646
	Valuation allowance	(127		)	(529		)
	Net deferred tax assets after valuation allowance	401			117
	Deferred tax liabilities:
	Unremitted foreign earnings of subsidiaries	(11		)	(36		)
	Property, plant and equipment	(63		)	(72		)
	Other	(13		)	(11		)
	Total deferred tax liabilities	(87		)	(119		)
	Net deferred tax asset (liability) after valuation allowance	$	314		$	(2	)
Schedule of net current and non-current deferred taxes from each tax jurisdiction
	(In millions)	2014			2013
	Net current deferred taxes
	Other current assets	$	34		$	10
	Other current liabilities	(8		)	(3		)
	Net non-current deferred taxes
	Other assets	313			25
	Other liabilities	(25		)	(34		)
Schedule of components of gross net operating loss
	(In millions)	2014			2013
	Federal NOL	$	591		$	974
	State NOL	$	929		$	1,034
	Foreign NOL	$	181		$	141
Schedule of reconciliation of beginning and ending amount of unrecognized tax benefits
	(In millions)	2014			2013			2012
	Balance at January 1	$	44		$	41		$	46
	Gross (decreases) increases for tax positions taken during current year	2			(1		)	—
	Gross increases for tax positions taken during a prior period	2			1			3
	Gross decreases for tax positions taken during a prior period	(19		)	—			(1		)
	Decreases from the expiration of the statute of limitations	—			—			—
	Settlements / payments	(2		)	—			(10		)
	Foreign currency impact	1			3			3
	Balance at December 31	$	28		$	44		$	41

CAPITAL_STOCK_AND_EARNINGS_LOS1

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE (Tables)	12 Months Ended
	Dec. 31, 2014
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
Schedule of reconciliation of the shares used in computation of earnings per share
		Year ended
	(In millions)	2014	2013	2012
	Weighted average shares outstanding - Basic	90.2	97.7	98.2
	Dilutive effect of common share equivalents	1.3	—	0.6
	Weighted average shares outstanding - Diluted	91.5	97.7	98.8

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	12 Months Ended
	Dec. 31, 2014
ACCUMULATED OTHER COMPREHENSIVE LOSS.
Schedule of components of accumulated other comprehensive loss ("AOCL"), net of tax
	(in millions)	Foreign			Unrecognized			Unrealized			Total
		Currency			Pension and			loss on
		Translation			Other Post-			available for
		Adjustments			Retirement			sale securities
					Benefit Costs
	As of December 31, 2013	$	(13	)	$	(267	)	$	—		$	(280	)
	Other comprehensive (loss) income before reclassifications	(70		)	(70		)	(5		)	(145		)
	Amounts reclassified from AOCL	(3		)	31			—			28
	Net current period other comprehensive loss	(73		)	(39		)	(5		)	(117		)
	As of December 31, 2014	$	(86	)	$	(306	)	$	(5	)	$	(397	)
Summary of reclassifications from AOCL to the Consolidated Statement of Operations
		Amount Reclassified from AOCL						Affected line item in the
								consolidated statement of
	(in millions)	2014			2013			operations
	Foreign currency translation items:
	Liquidation of consolidated entities	$	—		$	13		Other income, net
	Gain on sale of business (b)	3			—			Gain on sale of business
	Sale of discontinued operations (c)	—			38			Loss on sale of discontinued operations, net of tax
	Net of tax	3			51
	Defined benefit pension plan items:
	Amortization of prior-service costs (a)	5			5			Primarily SG&A
	Amortization of actuarial losses (a)	(18		)	(21		)	Primarily SG&A
	Settlement loss (a)	(21		)	—			Primarily SG&A
	Sale of discontinued operations (c)	—			(127		)	Loss on sale of discontinued operations, net of tax
	Total before tax	(34		)	(143		)
	Tax on continuing operations	3			1			Income Tax Benefit
	Tax on discontinued operations	—			15			Loss on sale of discontinued operations, net of tax
	Total tax	3			16
	Net of tax	(31		)	(127		)
	Total reclassifications	$	(28	)	$	(76	)
	(a)These items are included in the computation of net periodic benefit pension cost (see Note 13 - Pension and Other Post-Retirement Plans for additional information).
	(b) Sale of the Chemtura AgroSolutions business (see Note 2 - Divestitures and Acquisitions)
	(c) Sale of the Antioxidant and Consumer Products businesses (see Note 2 - Divestitures and Acquisitions)

STOCK_INCENTIVE_PLANS_Tables

STOCK INCENTIVE PLANS (Tables)	12 Months Ended
	Dec. 31, 2014
STOCK INCENTIVE PLANS
Schedule of weighted average assumptions
		Years Ended December 31,
		2013		2012
	Dividend yield	0.0	%	0.0	%
	Expected volatility	51.0	%	56.7	%
	Risk-free interest rate	1.0	%	1.2	%
	Expected life (in years)	6		6
Summary of stock option activities
							Weighted		Aggregate
							Average		Intrinsic
							Remaining
		Price Per Share			Shares		Contractual		Value
		Average			(in millions)		Life		(in millions)
	Outstanding at 12/31/13	16.46			2.8		7.4		32
	Exercised	16.01			(0.6	)			5
	Lapsed	18.07			—
	Outstanding at 12/31/14	$	16.56		2.2		6.5		18
	Exercisable at 12/31/14	$	16.16		1.8		6.2		$	15
Schedule of RSUs award activity
		Shares		Weighted			Aggregate
		(in millions)		Average			Fair Value
				Grant Date			(in millions)
				Fair Value
	Unvested RSU awards, December 31, 2013	1		20.53			30
	Cancelled	(0.1	)	23.47
	Granted	0.6		25.56
	Vested	(0.4	)	18.32			8
	Unvested RSU awards, December 31, 2014	1.1		$	23.81		$	28

PENSION_AND_OTHER_POSTRETIREME1

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2014
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS
Schedule of benefit obligation and weighted-average assumptions used
			Defined Benefit Pension Plans
			Qualified						International and						Post-Retirement
			Domestic Plans						Non-Qualified Plans						Health Care Plans
	(In millions)		2014			2013			2014			2013			2014			2013
	Change in projected benefit obligation:
	Projected benefit obligation at beginning of year		$	623		$	1,040		$	519		$	499		$	96		$	124
	Service cost		—			—			2			3			—			—
	Interest cost		28			30			21			19			4			4
	Plan participants’ contributions		—			—			—			1			—			—
	Actuarial (gains) losses (a)		99			(69		)	64			11			20			(20		)
	Benefits paid		(46		)	(51		)	(20		)	(19		)	(11		)	(10		)
	Business divestitures (b)		—			(327		)	—			—			—			—
	Settlements		(52		)	—			(3		)	(6		)	—			—
	Foreign currency exchange rate changes (c)		—			—			(41		)	11			(1		)	(2		)
	Projected benefit obligation at end of year		$	652		$	623		$	542		$	519		$	108		$	96
	Accumulated benefit obligation at end of year		$	651		$	622		$	541		$	506
	Weighted-average year-end assumptions used to determine benefit obligations:
	Discount rate		3.8		%	4.6		%	3.28		%	4.18		%	3.7		%	4.35		%
	Rate of compensation increase		3		%	3		%	2.41		%	2.85		%	N/A			N/A
	Health care cost trend rate														6.16		%	6.27		%
		(a)		The losses for 2014 primarily related to the utilization of the recently revised mortality tables and decreases in discount rates.
		(b)		Business divestitures includes the transfer of $315 million of projected benefit obligations with the sale of our Antioxidants business in April 2013 and $12 million with the sale of our Consumer Products business in December 2013.
		(c)		The significant foreign currency decrease in 2014 is due to decreases in Euro and British Pound exchange rates from December 2013 to December 2014.
Schedule of changes in fair value of plan assets
			Defined Benefit Pension Plans
			Qualified						International and						Post-Retirement
			Domestic Plans						Non-Qualified Plans						Health Care Plans
	(In millions)		2014			2013			2014			2013			2014			2013
	Change in plan assets:
	Fair value of plan assets at beginning of year		$	595		$	814		$	408		$	370		$	—		$	—
	Actual return on plan assets		59			51			75			30			—			—
	Employer contributions		14			20			24			27			11			10
	Plan participants’ contributions		—			—			—			1			—			—
	Benefits paid		(46		)	(51		)	(20		)	(19		)	(11		)	(10		)
	Business divestitures (a)		—			(239		)	—			—			—			—
	Settlements		(52		)	—			(3		)	(6		)	—			—
	Foreign currency exchange rate changes (b)		—			—			(29		)	5			—			—
	Fair value of plan assets at end of year		$	570		$	595		$	455		$	408		$	—		$	—
		(a)		Business divestitures includes the transfer of $233 million of plan assets with the sale of our Antioxidants business in April 2013 and $6 million of plan assets with the sale of our Consumer Products business in December 2013.
		(b)		The significant foreign currency decrease in 2014 is due to decreases in Euro and British Pound exchange rates from December 2013 to December 2014.
Schedule of fair values of defined benefit pension plan assets, by asset category
			Fair Value Measurements at December 31, 2014
			Defined Benefit Pension Plans
			Qualified Domestic Plans												International and Non-Qualified Plans
	(In millions)		Total			Quoted Prices			Significant			Significant			Total			Quoted Prices			Significant			Significant
						in Active			Observable			Unobservable						in Active			Observable			Unobservable
						Markets for			Inputs			Inputs						Markets for			Inputs			Inputs
						Identical			(Level 2)			(Level 3)						Identical			(Level 2)			(Level 3)
						Assets												Assets
						(Level 1)												(Level 1)
	Equity securities:
	Pooled equity (a)		$	164		$	164		$	—		$	—		$	152		$	8		$	144		$	—
	Fixed income securities:
	U.S. government bonds (b)		72			—			72			—			—			—			—			—
	International government bonds (b)		—			—			—			—			20			—			20			—
	Pooled fixed income funds (c)		258			258			—			—			268			—			265			3
	Alternative collective funds (d)		75			—			—			75			—			—			—			—
	Other instruments (e)		1			1			—			—			14			—			—			14
	Cash & cash equivalents		—			—			—			—			1			1			—			—
			$	570		$	423		$	72		$	75		$	455		$	9		$	429		$	17
			Fair Value Measurements at December 31, 2013
			Defined Benefit Pension Plans
			Qualified Domestic Plans												International and Non-Qualified Plans
	(in millions)		Total			Quoted			Significant			Significant			Total			Quoted			Significant			Significant
						Prices in			Observable			Unobservable						Prices in			Observable			Unobservable
						Active			Inputs			Inputs						Active			Inputs			Inputs
						Markets for			(Level 2)			(Level 3)						Markets for			(Level 2)			(Level 3)
						Identical												Identical
						Assets												Assets
						(Level 1)												(Level 1)
	Equity securities:
	Pooled equity (a)		$	141		$	141		$	—		$	—		$	146		$	12		$	134		$	—
	Fixed income securities:
	U.S. government bonds (b)		71			—			71			—			—			—			—			—
	International government bonds (b)		—			—			—			—			2			—			2			—
	Pooled fixed income funds (c)		287			287			—			—			247			—			243			4
	Alternative collective funds (d)		91			—			—			91			—			—			—			—
	Other instruments (e)		1			1			—			—			11			—			—			11
	Cash & cash equivalents		4			4			—			—			2			2			—			—
			$	595		$	433		$	71		$	91		$	408		$	14		$	379		$	15
		(a)		Pooled equity funds include mutual and collective funds that invest primarily in marketable equity securities of various sized companies in a diverse set of industries in various regions of the world.  Shares of publicly traded mutual funds are valued at the closing price reported on the U.S. and international exchanges where the underlying securities are actively traded.  Units of collective funds are valued at the per unit value determined by the fund manager, which is based on market price of the underlying securities.  The increase in the value of pooled equity funds of our domestic plans is primarily due to shifting assets from pooled fixed income funds in 2014.
		(b)		U.S. and international government bonds include U.S. treasury, municipal and agency obligations and international government debt.  Such instruments are valued at quoted market prices for those instruments or on institutional bid valuations.
		(c)		Pooled fixed income funds are fixed income funds that invest primarily in corporate and government bonds.  Such instruments are valued using securities in active markets and observable data or broker or dealer quotations.  The decrease in the value of pooled fixed income funds of our domestic plans is primarily due to shifting assets into pooled equity funds in 2014.
		(d)		Alternative collective funds include funds that invest mainly in asset backed securities, real estate funds, hedge funds and other alternative investments.  The underlying funds are valued based on the net asset values of the investments as determined by the respective individual fund administrators on a daily, weekly or monthly basis depending on the fund.  Such valuations are reviewed by the portfolio managers who determine the value of collective funds based on these inputs.  Certain of these funds have lock up periods and all of them have notification periods.  Due to the process used to value these funds and the restricted trading, we have categorized these funds as level 3.  The disbursements are primarily related to the lump sum payout made to certain participants in our U.S. qualified pension plan.
		(e)		Other instruments include primarily annuities and real estate funds instruments for which there are significant unobservable inputs and therefore have been classified as level 3.
Schedule of investments transferred into pooled equity and fixed income funds due to the change in asset management
			Alternative			Other Instruments (e)			Total Level 3
			Collective Funds (d)						Investments
	Balance at December 31, 2013		$	91		$	15		$	106
	Purchases		—			4			4
	Realized gains		2			—			2
	Unrealized gains		6			(2		)	4
	Disbursements		(24		)	—			(24		)
	Balance at December 31, 2014		$	75		$	17		$	92
Schedule of funded status and related amounts recognized on statement of financial condition
			Defined Benefit Pension Plans
			Qualified						International and						Post-Retirement
			Domestic Plans						Non-Qualified Plans						Health Care Plans
	(In millions)		2014			2013			2014			2013			2014			2013
	Funded status, end of year:
	Fair value of plan assets		$	570		$	595		$	455		$	408		$	—		$	—
	Benefit obligations		652			623			542			519			108			96
	Net amount recognized		$	(82	)	$	(28	)	$	(87	)	$	(111	)	$	(108	)	$	(96	)
	Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
	Noncurrent assets		$	—		$	—		$	57		$	30		$	—		$	—
	Current liability		—			—			(7		)	(9		)	(9		)	(9		)
	Noncurrent liability		(82		)	(28		)	(137		)	(132		)	(99		)	(87		)
	Net amount recognized		$	(82	)	$	(28	)	$	(87	)	$	(111	)	$	(108	)	$	(96	)
	Amounts recognized in accumulated other comprehensive loss consist of:
	Net actuarial loss/(gain)		$	269		$	219		$	130		$	120		$	49		$	31
	Prior service cost/(credit)		—			—			—			—			(35		)	(40		)
			$	269		$	219		$	130		$	120		$	14		$	(9	)
Schedule of estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year
	(In millions)		Qualified			International			Post-
			Domestic			and Non-			Retirement
			Plans			Qualified			Health Care
						Plans			Plans
	Actuarial loss		$	14		$	6		$	3
	Prior service credit		—			—			(5		)
	Total amortization cost (credit)		$	14		$	6		$	(2	)
Schedule of projected benefit obligation in excess of plan assets
	(In millions)		2014			2013
	Projected benefit obligation in excess of plan assets at end of year:
	Projected benefit obligation		$	919		$	876
	Fair value of plan assets		584			612
Schedule of accumulated benefit obligation in excess of plan assets
	(In millions)		2014			2013
	Accumulated benefit obligation in excess of plan assets at end of year:
	Projected benefit obligation		$	798		$	778
	Accumulated benefit obligation		797			777
	Fair value of plan assets		572			611
Schedule of expected employer contributions and expected benefit payments
			Defined Benefit Pension Plans
			Qualified			International			Post-
			Domestic			and			Retirement
						Non-Qualified			Health Care
	(in millions)		Plans			Plans			Plans
	Expected Employer Contributions: (a)
	2015		$	—		$	3		$	9
	Expected Benefit Payments (b):
	2015		46			21			9
	2016		46			21			9
	2017		45			22			8
	2018		45			25			8
	2019		44			24			8
	2020-2024		207			130			33
		(a)		The expected employer contributions reflect the minimum required by law or contractual obligation. We may elect to make additional discretionary contributions as deemed appropriate consistent with past practice.
		(b)		The expected benefit payments are based on the same assumptions used to measure our benefit obligation at the end of the year and include benefits attributable to estimated future employee service.
Schedule of components of net periodic benefit cost (credit) and weighted-average assumptions used to determine net cost
			Defined Benefit Pension Plans
			Qualified									International and									Post-Retirement
			Domestic Plans (a)									Non-Qualified Plans									Health Care Plans
	(In millions)		2014			2013			2012			2014			2013			2012			2014			2013			2012
	Components of net periodic benefit cost (credit):
	Service cost		$	—		$	—		$	1		$	2		$	3		$	3		$	—		$	—		$	1
	Interest cost		28			30			43			21			20			21			4			4			5
	Expected return on plan assets		(41		)	(45		)	(54		)	(26		)	(23		)	(22		)	—			—			—
	Amortization of prior service cost		—			—			—			—			—			—			(5		)	(5		)	(6		)
	Recognized actuarial losses		11			14			14			4			5			2			3			2			3
	Curtailment loss recognized		—			—			—			—			1			—			—			—			—
	Settlement loss recognized (b)		21			32			—			—			—			—			—			—			—
	Net periodic benefit cost		$	19		$	31		$	4		$	1		$	6		$	4		$	2		$	1		$	3
		(a)		The net periodic benefit cost for the years ended December 31, 2013 and 2012 include pension expense related to the earnings (loss) from discontinued operations of $1 million and $2 million, respectively.
		(b)		The settlement loss recognized in 2014 of $21 million relates to the lump sum payout made to certain participants in our U.S. qualified pension plan (included in SG&A). The settlement loss recognized in 2013 includes a loss of $40 million related to the divestiture of our Antioxidants business in April 2013 (included in loss on sale of discontinued operations), partly offset by a $2 million gain related to the divestiture of our Consumer Products business (included in loss on sale of discontinued operations) and a $6 million gain related to an adjustment for a legacy pension plan ($2 million included in SG&A and $4 million in loss from discontinued operations).
	Weighted-average assumptions used to determine net cost:
			Defined Benefit Pension Plans
			Qualified						International and						Post-Retirement
			Domestic Plans						Non-Qualified Plans						Health Care Plans
			2014		2013		2012		2014		2013		2012		2014		2013		2012
	Discount rate		4.60	%	3.80	%	4.60	%	4.20	%	3.89	%	4.64	%	4.45	%	3.71	%	4.15	%
	Expected return on plan assets		7.50	%	7.50	%	7.50	%	6.68	%	6.53	%	6.71	%
	Rate of compensation increase		3.00	%	3.00	%	4.00	%	2.85	%	2.77	%	3.22	%

BUSINESS_SEGMENTS_Tables

BUSINESS SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
BUSINESS SEGMENTS
Summary of revenue and operating profit for reportable segments
	(In millions)
		2014			2013			2012
	Net Sales
	Petroleum additives	$	687		$	689		$	600
	Urethanes	300			290			291
	Industrial Performance Products	987			979			891
	Bromine based & related products	641			639			730
	Organometallics	159			164			166
	Industrial Engineered Products	800			803			896
	Agrochemical Manufacturing	403			449			409
	Net Sales	$	2,190		$	2,231		$	2,196
		2014			2013			2012
	Operating Income
	Industrial Performance Products	$	106		$	109		$	102
	Industrial Engineered Products	16			55			140
	Agrochemical Manufacturing	86			88			65
	Segment Operating Income	208			252			307
	General corporate expense	(80		)	(97		)	(101		)
	Amortization	(13		)	(15		)	(16		)
	Facility closures, severance and related costs	(25		)	(42		)	(11		)
	Gain on sale of business	529			—			—
	Total Operating Income	$	619		$	98		$	179
		2014			2013			2012
	Depreciation and Amortization
	Industrial Performance Products	$	34		$	28		$	25
	Industrial Engineered Products	44			43			43
	Agrochemical Manufacturing	8			12			13
		86			83			81
	Corporate	16			18			19
	Total continuing operations	102			101			100
	Discontinued operations	—			22			39
		$	102		$	123		$	139
		2014			2013			2012
	Segment Assets
	Industrial Performance Products	$	642		$	591		$	514
	Industrial Engineered Products	696			743			693
	Agrochemical Manufacturing	87			285			319
		1,425			1,619			1,526
	Discontinued operations	—			—			654
	Corporate	1,242			1,085			850
		$	2,667		$	2,704		$	3,030
		2014			2013			2012
	Capital Expenditures
	Industrial Performance Products	$	54		$	73		$	52
	Industrial Engineered Products	51			73			69
	Agrochemical Manufacturing	6			7			5
		111			153			126
	Corporate	2			6			10
	Total continuing operations	113			159			136
	Discontinued operations	—			11			13
		$	113		$	170		$	149
Schedule of information by geographic area
	(In millions)
		2014			2013			2012
	Net sales (based on location of customer)
	United States	$	888		$	944		$	878
	Canada	48			42			39
	Latin America	174			194			159
	Europe/Africa	639			624			676
	Asia/Pacific	441			427			444
		$	2,190		$	2,231		$	2,196
		2014			2013			2012
	Property, Plant and Equipment
	United States	$	338		$	336		$	341
	Canada	54			61			69
	Latin America	10			13			13
	Europe/Africa	181			216			187
	Asia/Pacific	121			91			35
		$	704		$	717		$	645

GUARANTOR_CONDENSED_CONSOLIDAT1

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Tables)	12 Months Ended
	Dec. 31, 2014
GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA
Schedule of condensed consolidating statement of operations
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2014
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net sales	$	2,190		$	(1,878	)	$	1,346		$	437		$	2,285
	Cost of goods sold	1,682			(1,878		)	1,112			370			2,078
	Selling, general and administrative	255			—			150			16			89
	Depreciation and amortization	102			—			25			32			45
	Research and development	36			—			14			6			16
	Facility closures, severance and related costs	25			—			3			2			20
	Gain on sale of business	(529		)	—			(399		)	—			(130		)
	Operating income	619			—			441			11			167
	Interest expense	(45		)	—			(50		)	—			5
	Loss on early extinguishment of debt	(7		)	—			(7		)	—			—
	Other income (expense), net	12			—			(11		)	2			21
	Equity in net earnings of subsidiaries	—			(145		)	145			—			—
	Earnings from continuing operations before income taxes	579			(145		)	518			13			193
	Income tax benefit (expense)	192			—			244			(4		)	(48		)
	Earnings from continuing operations	771			(145		)	762			9			145
	Earnings from discontinued operations, net of tax	1			—			1			—			—
	Loss on sale of discontinued operations, net of tax	(9		)	—			—			(8		)	(1		)
	Net earnings attributable to Chemtura	$	763		$	(145	)	$	763		$	1		$	144
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net sales	$	2,231		$	(1,813	)	$	1,443		$	449		$	2,152
	Cost of goods sold	1,721			(1,813		)	1,235			389			1,910
	Selling, general and administrative	229			—			109			15			105
	Depreciation and amortization	101			—			29			35			37
	Research and development	40			—			15			8			17
	Facility closures, severance and related costs	42			—			21			1			20
	Operating income	98			—			34			1			63
	Interest expense	(60		)	—			(69		)	—			9
	Loss on early extinguishment of debt	(50		)	—			(50		)	—			—
	Other income (expense), net	8			—			(21		)	—			29
	Equity in net earnings of subsidiaries	—			(85		)	85			—			—
	(Loss) earnings from continuing operations before income taxes	(4		)	(85		)	(21		)	1			101
	Income tax expense	(18		)	—			—			—			(18		)
	(Loss) earnings from continuing operations	(22		)	(85		)	(21		)	1			83
	Earnings (loss) from discontinued operations, net of tax	25			—			(3		)	23			5
	(Loss) gain on sale of discontinued operations, net of tax	(180		)	—			(153		)	14			(41		)
	Net earnings (loss)	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2012
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net sales	$	2,196		$	(1,623	)	$	1,477		$	454		$	1,888
	Cost of goods sold	1,615			(1,623		)	1,192			383			1,663
	Selling, general and administrative	246			—			121			17			108
	Depreciation and amortization	100			—			27			44			29
	Research and development	41			—			16			7			18
	Facility closures, severance and related costs	11			—			8			—			3
	Equity loss	4			—			—			—			4
	Operating income	179			—			113			3			63
	Interest expense	(64		)	—			(69		)	2			3
	Loss on early extinguishment of debt	(1		)	—			(1		)	—			—
Other income (expense), net	15			—			(22		)	—			37
Equity in net earnings of subsidiaries	—			(81		)	81			—			—
Earnings from continuing operations before income taxes	129			(81		)	102			5			103
Income tax expense	(26		)	—			—			—			(26		)
Earnings from continuing operations	103			(81		)	102			5			77
(Loss) earnings from discontinued operations, net of tax	(3		)	—			(1		)	28			(30		)
Net earnings	100			(81		)	101			33			47
Less: net loss attributable to non-controlling interests	1			—			—			—			1
Net earnings attributable to Chemtura	$	101		$	(81	)	$	101		$	33		$	48
Schedule of condensed consolidating statement of comprehensive income
	Condensed Consolidating Statement of Comprehensive Income (Loss)
	As of December 31, 2014
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net earnings	$	763		$	(145	)	$	763		$	1		$	144
	Other comprehensive income (loss), net of tax:
	Foreign currency translation adjustments	(73		)	—			45			—			(118		)
	Unrecognized pension and other post-retirement benefit costs	(39		)	—			(32		)	—			(7		)
	Unrealized loss on available for sale securities	(5		)	—			(5		)	—			—
	Comprehensive income (loss)	$	646		$	(145	)	$	771		$	1		$	19
	Condensed Consolidating Statement of Comprehensive (Loss) Income
	As of December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Other comprehensive (loss) income, net of tax:
	Foreign currency translation adjustments	(60		)	—			(18		)	2			(44		)
	Unrecognized pension and other post-retirement benefit costs	208			—			202			—			6
	Comprehensive (loss) income	$	(29	)	$	(85	)	$	7		$	40		$	9
	Condensed Consolidating Statement of Comprehensive Income
	As of December 31, 2012
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	Net earnings	$	100		$	(81	)	$	101		$	33		$	47
	Other comprehensive (loss) income, net of tax:
	Foreign currency translation adjustments	(6		)	—			(11		)	1			4
	Unrecognized pension and other post-retirement benefit costs	(76		)	—			(44		)	—			(32		)
	Comprehensive income	18			(81		)	46			34			19
	Comprehensive loss attributable to non-controlling interests	1			—			—			—			1
	Comprehensive income attributable to Chemtura	$	19		$	(81	)	$	46		$	34		$	20
Schedule of condensed consolidating balance sheet	[ T
	Condensed Consolidating Balance Sheet
	As of December 31, 2014
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	ASSETS
	Current assets	$	1,216		$	—		$	539		$	113		$	564
	Intercompany receivables	—			(6,937		)	3,094			2,752			1,091
	Investment in subsidiaries	—			(4,923		)	822			1,134			2,967
	Property, plant and equipment	704			—			116			222			366
	Goodwill	172			—			93			3			76
	Other assets	575			—			448			36			91
	Total assets	$	2,667		$	(11,860	)	$	5,112		$	4,260		$	5,155
	LIABILITIES AND EQUITY
	Current liabilities	$	405		$	—		$	155		$	44		$	206
	Intercompany payables	—			(6,937		)	2,971			3,031			935
	Long-term debt	556			—			541			—			15
	Other long-term liabilities	652			—			391			83			178
	Total liabilities	1,613			(6,937		)	4,058			3,158			1,334
	Total equity	1,054			(4,923		)	1,054			1,102			3,821
	Total liabilities and equity	$	2,667		$	(11,860	)	$	5,112		$	4,260		$	5,155
	Condensed Consolidating Balance Sheet
	As of December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	ASSETS
	Current assets	$	1,525		$	—		$	571		$	121		$	833
	Intercompany receivables	—			(7,671		)	2,681			2,349			2,641
	Investment in subsidiaries	—			(7,277		)	1,530			1,135			4,612
	Property, plant and equipment	717			—			121			215			381
	Goodwill	179			—			93			3			83
	Other assets	283			—			137			44			102
	Total assets	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
	LIABILITIES AND EQUITY
	Current liabilities	$	484		$	—		$	244		$	39		$	201
	Intercompany payables	—			(7,671		)	2,944			2,583			2,144
	Long-term debt	781			—			764			—			17
	Other long-term liabilities	440			—			182			54			204
	Total liabilities	1,705			(7,671		)	4,134			2,676			2,566
	Total equity	999			(7,277		)	999			1,191			6,086
	Total liabilities and equity	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
Schedule of condensed consolidating statement of cash flows
	Condensed Consolidating Statement of Cash Flows
	Year ended December 31, 2014
	(In millions)
	Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	CASH FLOWS FROM OPERATING ACTIVITIES
	Net earnings	$	763		$	(145	)	$	763		$	1		$	144
	Adjustments to reconcile net earnings to net cash (used in) provided by operations:
	Loss on sale of discontinued operations	9			—			—			8			1
	Gain on sale of business	(529		)	—			(399		)	—			(130		)
	Agrochemical Manufacturing supply agreements	(6		)	—			(5		)	—			(1		)
	Loss on early extinguishment of debt	7			—			7			—			—
	Depreciation and amortization	102			—			25			32			45
	Stock-based compensation expense	14			—			14			—			—
	Deferred tax (benefit) expense	(274		)	—			(278		)	4			—
	Excess tax benefit from share-based payment arrangements	(5		)	—			(5		)	—			—
	Changes in assets and liabilities, net	(159		)	145			(213		)	(27		)	(64		)
	Net cash (used in) provided by operations	(78		)	—			(91		)	18			(5		)
	CASH FLOWS FROM INVESTING ACTIVITIES
	Proceeds from divestments, net	984			—			964			15			5
	Payments for acquisitions, net of cash acquired	—			—			—			—			—
	Capital expenditures	(113		)	—			(18		)	(33		)	(62		)
	Net cash provided by (used in) investing activities	871			—			946			(18		)	(57		)
	CASH FLOWS FROM FINANCING ACTIVITIES
	Proceeds from issuance of long term debt	19			—			—			—			19
	Payments on long term debt, includes premium on tendering of notes	(350		)	—			(342		)	—			(8		)
	Payments on short term borrowings, net	(1		)	—			—			—			(1		)
	Common shares acquired	(618		)	—			(618		)	—			—
	Proceeds from the exercise of stock options	10			—			10			—			—
	Excess tax benefit from share-based payment arrangements	5			—			5			—			—
	Net cash (used in) provided by financing activities	(935		)	—			(945		)	—			10
	CASH AND CASH EQUIVALENTS
	Effect of exchange rates on cash and cash equivalents	(15		)	—			—			—			(15		)
	Change in cash and cash equivalents	(157		)	—			(90		)	—			(67		)
	Cash and cash equivalents at beginning of year	549			—			$	317		$	—		$	232
	Cash and cash equivalents at end of year	$	392		$	—		$	227		$	—		$	165
	Condensed Consolidating Statement of Cash Flows
	Year ended December 31, 2013
	(In millions)
	Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-
								Company			Subsidiaries			Guarantor
														Subsidiaries
	CASH FLOWS FROM OPERATING ACTIVITIES
	Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:
	Loss (gain) on sale of discontinued operations	180			—			153			(14		)	41
	Impairment charges	7			—			—			7			—
	Reclass of translation adjustment from liquidated entities	(13		)	—			—			—			(13		)
	Loss on early extinguishment of debt	50			—			50			—			—
	Depreciation and amortization	123			—			33			45			45
	Stock-based compensation expense	14			—			14			—			—
	Changes in assets and liabilities, net	(105		)	85			(84		)	(27		)	(79		)
	Net cash provided by (used in) operations	79			—			(11		)	49			41
	CASH FLOWS FROM INVESTING ACTIVITIES
	Net proceeds from divestments, net	357			—			255			(2		)	104
	Payments for acquisitions, net of cash acquired	(3		)	—			—			—			(3		)
	Capital expenditures	(170		)	—			(20		)	(47		)	(103		)
	Net cash provided by (used in) investing activities	184			—			235			(49		)	(2		)
	CASH FLOWS FROM FINANCING ACTIVITIES
	Proceeds from issuance of long term debt	481			—			457			—			24
	Payments on long term debt, includes premium on tendering of notes	(502		)	—			(499		)	—			(3		)
	Payments on short term borrowings, net	(1		)	—			—			—			(1		)
Payments for debt issuance costs	(12		)	—			(12		)	—			—
Common shares acquired	(54		)	—			(54		)	—			—
Proceeds from exercise of stock options	8			—			8			—			—
Net cash (used in) provided by financing activities	(80		)	—			(100		)	—			20
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents	1			—			—			—			1
Change in cash and cash equivalents	184			—			124			—			60
Cash and cash equivalents at beginning of year	365			—			193			—			172
Cash and cash equivalents at end of year	$	549		$	—		$	317		$	—		$	232
Condensed Consolidating Statement of Cash Flows
Year ended December 31, 2012
(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-
							Company			Subsidiaries			Guarantor
													Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	100		$	(81	)	$	101		$	33		$	47
Adjustments to reconcile net earnings to net cash provided by operations:
Impairment charges	47			—			12			—			35
Reclass of translation adjustment from liquidation of entities	(21		)	—			—			—			(21		)
Loss on early extinguishment of debt	1			—			1			—			—
Depreciation and amortization	139			—			36			51			52
Stock-based compensation expense	24			—			24			—			—
Other non-cash transactions	3			—			2			—			1
Changes in assets and liabilities, net	(75		)	81			(106		)	(37		)	(13		)
Net cash provided by operations	218			—			70			47			101
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net	9			—			—			—			9
Capital expenditures	(149		)	—			(21		)	(47		)	(81		)
Net cash used in investing activities	(140		)	—			(21		)	(47		)	(72		)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt	125			—			125			—			—
Payments on other short term borrowings, net	(3		)	—			—			—			(3		)
Payments for debt issuance and refinancing costs	(2		)	—			(1		)	—			(1		)
Common shares acquired	(20		)	—			(20		)	—			—
Proceeds from exercise of stock options	5			—			5			—			—
Net cash provided by (used in) financing activities	105			—			109			—			(4		)
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents	2			—			—			—			2
Change in cash and cash equivalents	185			—			158			—			27
Cash and cash equivalents at beginning of year	180			—			35			—			145
Cash and cash equivalents at end of year	$	365		$	—		$	193		$	—		$	172

SUMMARIZED_UNAUDITED_QUARTERLY1

SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA (Tables)	12 Months Ended
	Dec. 31, 2014
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
Schedule of summarized unaudited quarterly financial data
	(In millions, except per share data)		2014
			First			Second			Third			Fourth
	Net sales		$	556		$	609		$	558		$	467
	Gross profit		$	120		$	158		$	134		$	96
	Earnings from continuing operations, net of tax		$	10	(a)	$	43	(b)	$	15	(c)	$	703	(d)
	Earnings from discontinued operations, net of tax		1			—			—			—
	Loss on sale of discontinued operations, net of tax		(5		)	(4		)	—			—
	Net earnings		$	6		$	39		$	15		$	703
	BASIC PER SHARE (i):
	Earnings from continuing operations, net of tax		$	0.1		$	0.46		$	0.17		$	8.57
	Earnings from discontinued operations, net of tax		0.01			—			—			—
	Loss on sale of discontinued operations, net of tax		(0.05		)	(0.04		)	—			—
	Net earnings		$	0.06		$	0.42		$	0.17		$	8.57
	DILUTED PER SHARE (i):
	Earnings from continuing operations, net of tax		$	0.1		$	0.46		$	0.17		$	8.44
	Earnings from discontinued operations, net of tax		0.01			—			—			—
	Loss on sale of discontinued operations, net of tax		(0.05		)	(0.04		)	—			—
	Net earnings		$	0.06		$	0.42		$	0.17		$	8.44
	Basic weighted-average shares outstanding		96.3			93.2			89.4			82
	Diluted weighted-average shares outstanding		97.8			94.4			90.7			83.3
			2013
			First			Second			Third			Fourth
	Net sales		$	528		$	590		$	569		$	544
	Gross profit		$	110		$	146		$	121		$	133
	(Loss) earnings from continuing operations, net of tax		$	(18	)(e)	$	27	(f)	$	(44	)(g)	$	13	(h)
	(Loss) earnings from discontinued operations, net of tax		(5		)	26			7			(3		)
	Loss on sale of discontinued operations, net of tax		—			(146		)	(3		)	(31		)
	Net loss		$	(23	)	$	(93	)	$	(40	)	$	(21	)
	BASIC PER SHARE (i):
	(Loss) earnings from continuing operations, net of tax		$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05		)	0.26			0.07			(0.03		)
	Loss on sale of discontinued operations, net of tax		—			(1.48		)	(0.03		)	(0.32		)
	Net loss		$	(0.23	)	$	(0.95	)	$	(0.41	)	$	(0.22	)
	DILUTED PER SHARE (i):
	(Loss) earnings from continuing operations, net of tax		$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05		)	0.26			0.07			(0.03		)
	Loss on sale of discontinued operations, net of tax		—			(1.46		)	(0.03		)	(0.32		)
	Net loss		$	(0.23	)	$	(0.93	)	$	(0.41	)	$	(0.22	)
	Basic weighted-average shares outstanding		98.2			98.6			97.5			96.6
	Diluted weighted-average shares outstanding		98.2			99.7			97.5			98.1
		(a)		The earnings from continuing operations for the first quarter of 2014 included pre-tax charges for facility closures, severance and related costs of $2 million.
		(b)		The earnings from continuing operations for the second quarter of 2014 included pre-tax charges for facility closures, severance and related costs of $4 million.
		(c)		The earnings from continuing operations for the third quarter of 2014 included pre-tax charges for accelerated depreciation of property, plant and equipment of $4 million.
		(d)		The earnings from continuing operations for the fourth quarter of 2014 included the pre-tax gain on sale of the Agrochemical Manufacturing business of $529 million and pre-tax charges for facility closures, severance and related costs of $19 million and loss on early extinguishment of debt of $7 million.
		(e)		The loss from continuing operations for the first quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $14 million.
		(f)		The earnings from continuing operations for the second quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $11 million.
		(g)		The loss from continuing operations for the third quarter of 2013 included pre-tax charges for loss on early extinguishment of debt of $50 million and facility closures, severance and related costs of $3 million.
		(h)		The earnings from continuing operations for the fourth quarter of 2013 included a pre-tax charges for facility closures, severance and related costs of $14 million.
		(i)		The sum of the earnings (loss) per common share for the four quarters may not equal the total earnings (loss) per common share for the full year due to quarterly changes in the average number of shares outstanding.

NATURE_OF_OPERATIONS_AND_SUMMA3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Other Expense, Net
Foreign exchange loss	$10	($7)	($6)
Interest income	3	3	5
Release of cumulative foreign currency translation adjustments from liquidation of entities		13	21
Reorganization items, net	-1	-1	-5
Other income (expense), net	12	8	15
Allowance for Promotions [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, January 1	10	14	14
Charged to costs and expenses	37	36	8
Payments to customers and writeoffs	-40	-40	-8
Other	-5
Balance, December 31	2	10	14
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, January 1	11	11	15
Charged to costs and expenses	8	2	2
Payments to customers and writeoffs	-3	-1	-6
Other	-14	-1
Balance, December 31	$2	$11	$11
Minimum
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of Countries in which Entity Operates	80
Maximum
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Ownership interest in other affiliates to be accounted for at cost (as a percent)	20.00%

NATURE_OF_OPERATIONS_AND_SUMMA4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2014
Land improvements | Minimum
Property, plant and equipment
Asset lives	3 years
Land improvements | Maximum
Property, plant and equipment
Asset lives	20 years
Buildings and improvements | Minimum
Property, plant and equipment
Asset lives	2 years
Buildings and improvements | Maximum
Property, plant and equipment
Asset lives	40 years
Machinery and equipment | Minimum
Property, plant and equipment
Asset lives	2 years
Machinery and equipment | Maximum
Property, plant and equipment
Asset lives	25 years
Information systems equipment | Minimum
Property, plant and equipment
Asset lives	2 years
Information systems equipment | Maximum
Property, plant and equipment
Asset lives	10 years
Furniture, fixtures and other | Minimum
Property, plant and equipment
Asset lives	1 year
Furniture, fixtures and other | Maximum
Property, plant and equipment
Asset lives	10 years

NATURE_OF_OPERATIONS_AND_SUMMA5

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	12 Months Ended
	Dec. 31, 2014
Patents | Minimum
Intangible assets (excluding goodwill)
Estimated useful lives	10 years
Patents | Maximum
Intangible assets (excluding goodwill)
Estimated useful lives	20 years
Trademarks | Minimum
Intangible assets (excluding goodwill)
Estimated useful lives	30 years
Trademarks | Maximum
Intangible assets (excluding goodwill)
Estimated useful lives	40 years
Customer relationships | Minimum
Intangible assets (excluding goodwill)
Estimated useful lives	15 years
Customer relationships | Maximum
Intangible assets (excluding goodwill)
Estimated useful lives	30 years
Production rights
Intangible assets (excluding goodwill)
Estimated useful lives	10 years
Other | Minimum
Intangible assets (excluding goodwill)
Estimated useful lives	5 years
Other | Maximum
Intangible assets (excluding goodwill)
Estimated useful lives	50 years

NATURE_OF_OPERATIONS_AND_SUMMA6

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Mar. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2009
								item
Marketable Securities
Primary marketable security					$2
Marketable securities held as other current assets					45
Period stock is restricted from trading					6 months
Term of supply contract					6 years
Asset Retirement Obligation
Accretion expense					3	3
Asset retirement obligations included in accrued expenses					3	3
Asset retirement obligations included in other liabilities					13	13
Recoverability of Long-Lived Assets and Goodwill
Goodwill impairment charge	0	0	0	0
Stock-Based Compensation
Stock-based compensation expense					14	14	24
Outstanding derivatives					0
Cash Flows
Maximum term of original maturity to classify bank term deposits as cash equivalents					3 months
Number of Affiliates								26
Cash paid for settlement of liabilities subject to compromise							5
Value of common stock issued for settlement of liabilities subject to compromise							26
Interest paid					46	57	58
Income taxes (net of refunds)					$68	$21	$45
Environmental
Environmental Liabilities
Period for accrual of probable and reasonable remediation costs on an undiscounted basis					10 years

DIVESTITURES_AND_ACQUISITIONS_

DIVESTITURES AND ACQUISITIONS (Details) (USD $)	3 Months Ended						12 Months Ended		1 Months Ended				0 Months Ended
Share data in Millions, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2014	Mar. 31, 2014	Apr. 30, 2013	Dec. 31, 2013	Nov. 03, 2014
Additional disclosures, divestitures
Pre-tax gain (loss)							($9,000,000)	($188,000,000)
After-tax loss on sale of business		4,000,000	5,000,000	31,000,000	3,000,000	146,000,000	9,000,000	180,000,000
Shares of common stock received as consideration	2						2
Term of supply contract							6 years
Extension term of supply contract after termination							2 years
Accrued expenses	170,000,000			176,000,000			170,000,000	176,000,000				176,000,000
Other liabilities	124,000,000			160,000,000			124,000,000	160,000,000				160,000,000
Gain on sale of business	529,000,000						529,000,000
Assets and liabilities held for sale
Assets	6,000,000			245,000,000			6,000,000	245,000,000				245,000,000
Liabilities	9,000,000			38,000,000			9,000,000	38,000,000				38,000,000
Consumer Products Business Divestiture
Acquisitions/Divestitures
Cash consideration on sale of business				300,000,000				300,000,000				300,000,000
Additional disclosures, divestitures
Pre-tax gain (loss)							-8,000,000	-24,000,000
After-tax loss on sale of business							8,000,000	25,000,000
Non-cash charges								39,000,000
Assets and liabilities held for sale
Cash and cash equivalents				13,000,000				13,000,000				13,000,000
Accounts receivable, net				55,000,000				55,000,000				55,000,000
Inventories, net				64,000,000				64,000,000				64,000,000
Current domestic tax assets reversed upon sale				7,000,000				7,000,000				7,000,000
Other current assets				8,000,000				8,000,000				8,000,000
Property, plant and equipment				63,000,000				63,000,000				63,000,000
Intangible assets, net				195,000,000				195,000,000				195,000,000
Other assets				5,000,000				5,000,000				5,000,000
Assets				410,000,000				410,000,000				410,000,000
Accounts payable				16,000,000				16,000,000				16,000,000
Accrued expenses				14,000,000				14,000,000				14,000,000
Pension and post-retirement health care liabilities				6,000,000				6,000,000				6,000,000
Domestic tax liabilities reversed upon sale				44,000,000				44,000,000				44,000,000
Other liabilities, includes foreign deferred tax liabilities				32,000,000				32,000,000				32,000,000
Liabilities				112,000,000				112,000,000				112,000,000
Net Assets				298,000,000				298,000,000				298,000,000
Advance payment for final adjustments										9,000,000
Remaining payment received									5,000,000
Antioxidant Business Divestiture
Acquisitions/Divestitures
Ownership interest in a joint venture (as a percent)											49.00%
Cash consideration on sale of business											97,000,000
Assumption of pension, environmental and other liabilities											91,000,000
Cash consideration paid as part of adjustment								2,000,000
Final payment received for remaining working capital adjustments			4,000,000							4,000,000
Additional disclosures, divestitures
Pre-tax gain (loss)							-1,000,000	-164,000,000
After-tax loss on sale of business							1,000,000	155,000,000
Non-cash charges								121,000,000
Assets and liabilities held for sale
Cash and cash equivalents											2,000,000
Accounts receivable, net											70,000,000
Inventories, net											76,000,000
Other current assets											2,000,000
Property, plant and equipment											48,000,000
Intangible assets, net											14,000,000
Other assets											32,000,000
Assets											244,000,000
Accounts payable											39,000,000
Accrued expenses											2,000,000
Pension and post-retirement health care liabilities											81,000,000
Other liabilities, includes foreign deferred tax liabilities											11,000,000
Liabilities											133,000,000
Net Assets											111,000,000
Antioxidant Business Divestiture | Minimum
Additional disclosures, divestitures
Series A Preferred Stock dividend rate (as a percent)											7.00%
Term of supply contract											2 years
Antioxidant Business Divestiture | Maximum
Additional disclosures, divestitures
Series A Preferred Stock dividend rate (as a percent)											11.00%
Term of supply contract											5 years
Chemtura AgroSolutions
Acquisitions/Divestitures
Cash consideration on sale of business	950,000,000						950,000,000
Additional disclosures, divestitures
Gain on sale of business							529,000,000
Assets and liabilities held for sale
Cash and cash equivalents													7,000,000
Accounts receivable, net	3,000,000			128,000,000			3,000,000	128,000,000				128,000,000	158,000,000
Inventories, net	1,000,000			71,000,000			1,000,000	71,000,000				71,000,000	94,000,000
Other current assets				7,000,000				7,000,000				7,000,000	8,000,000
Property, plant and equipment				8,000,000				8,000,000				8,000,000	11,000,000
Intangible assets, net				28,000,000				28,000,000				28,000,000	32,000,000
Other assets	2,000,000			3,000,000			2,000,000	3,000,000				3,000,000	3,000,000
Assets	6,000,000			245,000,000			6,000,000	245,000,000				245,000,000	313,000,000
Accounts payable				24,000,000				24,000,000				24,000,000	21,000,000
Accrued expenses	9,000,000			13,000,000			9,000,000	13,000,000				13,000,000	30,000,000
Income taxes payable				1,000,000				1,000,000				1,000,000	4,000,000
Liabilities	9,000,000			38,000,000			9,000,000	38,000,000				38,000,000	55,000,000
Net Assets	-3,000,000			207,000,000			-3,000,000	207,000,000				207,000,000	258,000,000
Chemtura AgroSolutions | Minimum
Additional disclosures, divestitures
Term of transition service agreements							6 months
Chemtura AgroSolutions | Maximum
Additional disclosures, divestitures
Term of transition service agreements							1 year
SK and Addivant | Antioxidant Business Divestiture
Acquisitions/Divestitures
Cash consideration on sale of business				97,000,000				97,000,000				97,000,000
Preferred stock received as consideration											9,000,000
Additional disclosures, divestitures
Shares of Series A Preferred Stock received as consideration											9.2
Face value of Series A Preferred Stock received as part of the consideration											9,000,000
Pre-tax gain (loss)							-1,000,000	-164,000,000
KIK Custom Products Inc. (KIK) | Consumer Products Business Divestiture
Acquisitions/Divestitures
Cash consideration on sale of business				300,000,000				300,000,000				300,000,000
Assumption of pension, environmental and other liabilities				8,000,000				8,000,000				8,000,000
Period for determining working capital based on average against which it would be measured								12 months
Additional disclosures, divestitures
Option exercisable period from the closing date under the terms of supply contract								6 months
Impairment charge related to property, plant and equipment held for sale								7,000,000				7,000,000
Platform | Chemtura AgroSolutions
Acquisitions/Divestitures
Period for determining working capital based on average against which it would be measured													12 months
Cash consideration on sale of business													950,000,000
Consideration on sale of business													1,000,000,000
Additional disclosures, divestitures
Non-cash charges							3,000,000
Shares of common stock received as consideration													2
Deferred gain													230,000,000
Extension term of supply contract after termination													2 years
Deferred income and accretion liability													345,000,000
Remaining deferred gain	223,000,000						223,000,000
Accrued expenses	38,000,000						38,000,000
Other liabilities	185,000,000						185,000,000
Ownership interest in Certis Europe B V not transferred due to pending approval	15.00%						15.00%
Gain on sale of business							$529,000,000
Platform | Chemtura AgroSolutions | Minimum
Additional disclosures, divestitures
Term of supply contract													2 years
Platform | Chemtura AgroSolutions | Maximum
Additional disclosures, divestitures
Term of supply contract													4 years

DIVESTITURES_AND_ACQUISITIONS_1

DIVESTITURES AND ACQUISITIONS (Details 2)	3 Months Ended							12 Months Ended						0 Months Ended	12 Months Ended		0 Months Ended		12 Months Ended				12 Months Ended						12 Months Ended											1 Months Ended	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	15-May-13	15-May-13	Dec. 31, 2013	Dec. 31, 2012	Nov. 28, 2011	Nov. 28, 2011	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2014	Apr. 30, 2012	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	ISEM	ISEM	Daystar	Daystar	Corporate	Corporate	Tetrabrom Technologies Ltd.	Tetrabrom Technologies Ltd.	Consumer Products Business Divestiture	Consumer Products Business Divestiture	Consumer Products Business Divestiture	Consumer Products Business Divestiture	Consumer Products Business Divestiture	Consumer Products Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant Business Divestiture	Antioxidant and Consumer Product businesses	Antioxidant and Consumer Product businesses	Antioxidant and Consumer Product businesses	Antioxidant and Consumer Product businesses	Chemtura AgroSolutions	Chemtura AgroSolutions	Forward contract	Forward contract	Forward contract	Forward contract
											USD ($)	EUR (€)	USD ($)	UP Chemical	USD ($)	USD ($)		USD ($)	USD ($)	USD ($)	USD ($)	KIK Custom Products Inc. (KIK)	Corporate	Corporate	USD ($)	USD ($)	USD ($)	USD ($)	Forecast	SK and Addivant	SK and Addivant	Corporate	Corporate	Corporate	Corporate	Corporate	Corporate	USD ($)	Platform	Tetrabrom Technologies Ltd.	Tetrabrom Technologies Ltd.	Tetrabrom Technologies Ltd.	Tetrabrom Technologies Ltd.
											item			USD ($)								USD ($)	USD ($)	USD ($)					USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	Continuing operations	Continuing operations		USD ($)	USD ($)	item	Maximum	Maximum
																																				USD ($)	USD ($)			facility		USD ($)	USD ($)
																																								installment
Earnings from discontinued operations
Net sales									$531	$820										$408	$433					$123	$387
Pre-tax earnings from discontinued operations								1	28	-12									1	24	33					4	-45
Income tax expense									-3	9										-3	-2						11
Earnings from discontinued operations, net of taxes								1	25	-3									1	21	31					4	-34
Net earnings attributable to non-controlling interests										1																	1
Earnings (loss) net of taxes - attributable to Chemtura			1	-3	7	26	-5	1	25	-2									1	21	31					4	-33
Loss on sale of discontinued operations:
Pre-tax gain (loss)								-9	-188										-8	-24					-1	-164				-1	-164
Income tax benefit									8											-1						9
Net loss		-4	-5	-31	-3	-146		-9	-180										-8	-25					-1	-155
Functional and other expenses allocated to businesses that will not transfer directly under the sale agreements
Functional and other expenses																							14	13								6	13
Amortization expense								-13	-15	-16																								-8	-14
Net increase								80	97	101					12	12																				20	26
Sales price of investment																		38
Period for receiving proceeds from sale of an investment interest in annual installments																	3 years
Pre-tax gain on sale of business	529							529																														529	529
Number of forward contracts purchased to reduce the risk of currency exposure																																								2
Notional amount of option and forward contracts purchased to reduce the risk of currency exposure																																								25
Annual installments																																								2
Percentage ownership interest sold																	50.00%																							50.00%
Number of contracts expired																																									1
Gain (loss) due to change in fair market value of foreign exchange forward contracts																																										1	1
Reconciliation of cash proceeds to pre-tax loss on sale
Cash consideration																				300		300						97			97
Working capital and other adjustments																			-3	-36											-10							-28
Post-closing adjustments																														-1	-2
Cash proceeds								984	357	9										264											85							978
Platform Stock																																						52
Preferred stock																															9
Less direct items:
Net assets sold or settled, excluding tax liabilities reversed upon sale and included in tax effect																				335											111							258
Below market supply contract																																						231
Transaction costs and other																			5	10											5							21
Post-closing adjustments, obligations and other, net																				18											-8							-5
Fair value of supply agreements																													13		13
Less non-cash items:
Release of AOCL - pension																				5											122
Release of AOCL - cumulative translation adjustment																				-44											6							-3
Release of non-controlling interest																															-7
Pre-tax loss on sale of discontinued operations								-9	-188										-8	-24					-1	-164				-1	-164
Pre-tax gain on sale of business	529							529																														529	529
Acquisitions/Divestitures
Number of transactions by joint venture											2	2
Number of product lines sold by joint venture											2	2
Amount of sale of product lines by joint venture											51	38
Remaining interest purchased (as a percent)													50.00%
Purchase price for remaining interest													3
Amount of loan reimbursed														$3

RESTRUCTURING_AND_ASSET_IMPAIR2

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES (Details) (USD $)	3 Months Ended	12 Months Ended		3 Months Ended	12 Months Ended	2 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2012	Dec. 31, 2014	Apr. 30, 2012	Nov. 30, 2014
Restructuring information
Accelerated depreciation of certain fixed assets	$4	$4	$1
Estimated cost of restructuring plan								37
Droitwich, UK facility
Restructuring information
Pre-tax charges for restructuring		7	44
Accelerated depreciation of certain fixed assets		5	1
Accelerated asset retirement obligations		1	1
Adrian, MI facility
Restructuring information
Pre-tax charges for restructuring				4
Accelerated asset retirement obligations				1
Adrian, MI facility | Minimum
Restructuring information
Estimated cost of restructuring plan				7
Adrian, MI facility | Maximum
Restructuring information
Estimated cost of restructuring plan				9
Industrial Performance Products | Italy
Restructuring information
Pre-tax charges for restructuring			1		33
Accelerated depreciation of certain fixed assets					4
Severance and Related Costs
Restructuring information
Pre-tax charges for restructuring						21
Severance and Related Costs | Droitwich, UK facility
Restructuring information
Pre-tax charges for restructuring		1	27
Severance and Related Costs | Adrian, MI facility
Restructuring information
Pre-tax charges for restructuring				3
Severance and Related Costs | Industrial Performance Products | Italy
Restructuring information
Pre-tax charge for severance to facility closures, severance and related costs					5
Severance and Related Costs | Corporate | Italy
Restructuring information
Pre-tax charge for severance to facility closures, severance and related costs					12
Other Facility Closure Costs | Droitwich, UK facility
Restructuring information
Pre-tax charges for restructuring			15
Other Facility Closure Costs | Industrial Performance Products | Italy
Restructuring information
Estimated cost of restructuring plan							40
Estimated non-cash cost of restructuring plan							6
Other Facility Closure Costs | Industrial Performance Products | Italy | Cost of goods sold
Restructuring information
Accelerated asset retirement obligations					2
Receivable write-off
Restructuring information
Write off of receivable					$10

RESTRUCTURING_AND_ASSET_IMPAIR3

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES (Details 2) (USD $)	0 Months Ended		1 Months Ended		3 Months Ended								12 Months Ended			1 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Mar. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs					($19)	($4)	($2)	($14)	($3)	($11)	($14)		($25)	($42)	($11)
Asset Impairment Review
Pre-tax charges for impairment												11		7	47
Impairment of property, plant and equipment, net												9
Impairment of intangible assets, net												2
Goodwill impairment charge	0	0	0	0
Consumer Products Business Divestiture | KIK Custom Products Inc. (KIK)
Asset Impairment Review
Impairment charge related to property, plant and equipment held for sale														7		7
Antioxidant Business Divestiture
Asset Impairment Review
Pre-tax charges for impairment									35
Impairment of property, plant and equipment, net									26
Impairment of intangible assets, net									9
Corporate Restructuring Programs
Changes in liabilities established for restructuring programs
Balance at beginning of period							16				8		16	8	1
Cash payments													-20	-33	-10
Reclassifications														-2
Balance at end of period					21			16				8	21	16	8	16
Corporate Restructuring Programs | Accrued expenses
Changes in liabilities established for restructuring programs
Balance at end of period								15						15		15
Corporate Restructuring Programs | Accounts payable
Changes in liabilities established for restructuring programs
Balance at end of period								1						1		1
Corporate Restructuring Programs | Continuing operations
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs													25	42	11
Corporate Restructuring Programs | Discontinued operations
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs														1	6
Severance and Related Costs | Corporate Restructuring Programs
Changes in liabilities established for restructuring programs
Balance at beginning of period							14				8		14	8	1
Cash payments													-15	-19	-5
Reclassifications														-2
Balance at end of period					21			14				8	21	14	8	14
Severance and Related Costs | Corporate Restructuring Programs | Continuing operations
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs													22	27	6
Severance and Related Costs | Corporate Restructuring Programs | Discontinued operations
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs															6
Other Facility Closure Costs | Corporate Restructuring Programs
Changes in liabilities established for restructuring programs
Balance at beginning of period							2						2
Cash payments													-5	-14	-5
Balance at end of period								2						2		2
Other Facility Closure Costs | Corporate Restructuring Programs | Continuing operations
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs													3	15	5
Other Facility Closure Costs | Corporate Restructuring Programs | Discontinued operations
Changes in liabilities established for restructuring programs
Facility closures, severance and related costs														$1

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
INVENTORIES
Finished goods	$200	$223
Work in process	35	35
Raw materials and supplies	94	88
Inventory, net	329	346
Inventory obsolescence reserves	$14	$19

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, plant and equipment
Property, plant and equipment, gross		$1,799	$1,800
Less: accumulated depreciation		1,095	1,083
Property, plant and equipment, net		704	717	645
Depreciation expense		87	82	80
Accelerated depreciation of certain fixed assets	4	4	1
Land and improvements
Property, plant and equipment
Property, plant and equipment, gross		71	74
Buildings and improvements
Property, plant and equipment
Property, plant and equipment, gross		209	212
Machinery and equipment
Property, plant and equipment
Property, plant and equipment, gross		1,248	1,225
Information systems equipment
Property, plant and equipment
Property, plant and equipment, gross		167	171
Furniture, fixtures and other
Property, plant and equipment
Property, plant and equipment, gross		22	24
Construction in progress
Property, plant and equipment
Property, plant and equipment, gross		$82	$94

GOODWILL_AND_INTANGIBLE_ASSETS2

GOODWILL AND INTANGIBLE ASSETS (Details) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Mar. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Goodwill by reportable segment
Net goodwill at the end of the period					$172	$179
Goodwill impairment charge	0	0	0	0
Industrial Performance Products
Goodwill by reportable segment
Goodwill at the beginning of the period					269	267
Accumulated impairments at the beginning of the period					-90	-90
Net goodwill at the beginning of the period					179	177
Foreign currency translation					-7	2
Goodwill at the end of the period					262	269
Accumulated impairments at the end of the period					-90	-90
Net goodwill at the end of the period					$172	$179

GOODWILL_AND_INTANGIBLE_ASSETS3

GOODWILL AND INTANGIBLE ASSETS (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Intangible assets (excluding goodwill)
Gross Cost	$228	$239
Accumulated Amortization	-129	-125
Net Intangibles	99	114
Amortization expense	15	19	20
Estimated amortization expense of intangible assets for the next five fiscal years
2015	12
2016	8
2017	8
2018	7
2019	7
Patents
Intangible assets (excluding goodwill)
Gross Cost	26	33
Accumulated Amortization	-17	-21
Net Intangibles	9	12
Trademarks
Intangible assets (excluding goodwill)
Gross Cost	44	45
Accumulated Amortization	-13	-12
Net Intangibles	31	33
Customer relationships
Intangible assets (excluding goodwill)
Gross Cost	41	42
Accumulated Amortization	-20	-18
Net Intangibles	21	24
Production rights
Intangible assets (excluding goodwill)
Gross Cost	45	45
Accumulated Amortization	-41	-36
Net Intangibles	4	9
Other
Intangible assets (excluding goodwill)
Gross Cost	72	74
Accumulated Amortization	-38	-38
Net Intangibles	$34	$36

DEBT_Details

DEBT (Details)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2014

Sep. 30, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Jul. 31, 2013

Aug. 31, 2010

Dec. 31, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Oct. 31, 2012

Nov. 30, 2014

Jan. 31, 2014

Aug. 31, 2010

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Aug. 31, 2013

Dec. 31, 2014

Nov. 30, 2010

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Jan. 31, 2015

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

ABL Facility

ABL Facility

ABL Facility

ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

US ABL Facility

US ABL Facility

Foreign ABL Facility

China Bank Facility

China Bank Facility

China Bank Facility

China Bank Facility

China Bank Facility

Promissory note

Other borrowings

Other borrowings

USD ($)

USD ($)

USD ($)

Redemption after July 15, 2016 prior to July 15, 2017

Redemption after July 15, 2017 prior to July 15, 2018

Redemption after July 15, 2019

Maximum

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redemption after September 1, 2014 prior to September 1, 2015

Redemption after September 1, 2015 prior to September 1, 2016

Redemption after September 1, 2016

Redemption prior to September 1, 2014

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Base Rate

Federal Funds rate

Primary rate

Eurodollar rate

Eurodollar rate

LIBOR

Minimum

Maximum

Maximum

Maximum

USD ($)

Minimum

Maximum

USD ($)

USD ($)

Base Rate

Eurodollar rate

Minimum

Minimum

Maximum

Maximum

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

CNY

USD ($)

Subsequent event

USD ($)

USD ($)

USD ($)

Interest option 1

Interest option 1

Interest option 1

Interest option 1

Interest option 2

Interest option 2

USD ($)

USD ($)

Interest option 2

Base Rate

Eurodollar rate

Base Rate

Eurodollar rate

USD ($)

DEBT

Debt and Capital Lease Obligations, Total

$574

$574

$898

$450

$450

$100

$82

$316

$42

$32

Total Debt, Fair value

563

563

916

439

456

108

82

320

42

32

Less: Other short-term borrowings

-18

-18

-7

Less: Current portion of Term Loan

-110

Total Long-term debt

556

556

781

Interest rate (as a percent)

5.75%

5.75%

7.88%

7.88%

5.29%

Aggregate principal amount

450

455

455

295

40

250

7

Amount redeemed

354

101

Charge for loss on early extinguishment of debt

7

-50

7

50

1

6

50

1

Charge for loss on early extinguishment of debt as difference between principal amount and tender offer consideration and consent payments

42

Write-off of unamortized discount

8

Proceeds from the offering of senior notes utilized for prepayment of principal of term loan

45

Cash on hand utilized for prepayment of principal of term loan

5

Prepayment of principal of debt

50

Term of debt

5 years

5 years

6 years

Issue price as a percentage of par value

7.88%

99.27%

Discount rate (as a percent)

1.00%

Option to increase the size of the facility

125

Term of credit facility

5 years

5 years

Percentage of principal amount at which the entity may redeem some or all of the notes

104.31%

102.88%

100.00%

101.44%

105.75%

101.00%

100.00%

Percentage of redeemable notes that can be redeemed from the proceeds of equity offerings

35.00%

Payments on secured debt

126

110

102

5

15

Maximum borrowing capacity

275

175

60

Maximum borrowing capacity for letter of credit sub-facility

125

125

Secured Leverage Ratio

2.5

Consolidated Interest Coverage Ratio

3

Margin over reference rate (as a percent)

1.75%

0.50%

1.00%

2.75%

0.50%

1.50%

1.00%

2.00%

Reference rate

Base Rate

Federal Funds rate

prime rate

Eurodollar Rate

Eurodollar Rate

reserve adjusted LIBOR

base rate

adjusted Eurocurrency Rate

Margin over alternate reference rate (as a percent)

0.75%

Fixed charge coverage ratio

1

1

Available Borrowings level that triggers applicability of fixed charge ratio covenant

25

18

Percentage of Aggregate Commitments that triggers applicability of fixed charge ratio covenant

10.00%

10.00%

Commitment period measurement

30 days

30 days

Outstanding borrowings

27

17

Outstanding letters of credit

15

15

14

14

15

Total undrawn availability

237

211

Tender premium

4

Unamortized discount

2

1

2

1

Effective interest rate (as a percent)

5.93%

5.83%

8.90%

3.78%

5.39%

Collateral - interest in domestic subsidiaries (as a percent)

100.00%

Collateral - interest in non-voting capital stock of foreign subsidiaries (as a percent)

100.00%

Collateral - interest in voting capital stock of foreign subsidiaries (as a percent)

65.00%

Trailing period used for calculation of fixed charge coverage ratio

12 months

Maturities

2015

18

18

2016

87

87

2017

11

11

2018

2

2

Thereafter

450

450

Drawdown of term loan

$125

LEASES_Details

LEASES (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
LEASES
Rental expenses under operating leases	$23	$23	$24
Minimum rental commitments, primarily for buildings, land and equipment under non-cancelable operating leases, net of sublease income
2015	8
2016	7
2017	6
2018	5
2019	4
2020 and thereafter	10
Aggregate minimum rental commitments	$40

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Pre-tax (Loss) Earnings from continuing Operations:
Domestic	$388	($105)	$26
Foreign	191	101	103
Total pre-tax (loss) earnings from continuing operations	579	-4	129
Domestic
Current	34
Deferred	-274	-1
Total domestic	-240	-1
Foreign
Current	48	17	23
Deferred		2	3
Total foreign	48	19	26
Total
Current	82	17	23
Deferred tax (benefit) expense	-274	1	3
Total income tax expense (benefit)	-192	18	26
Expense (benefit) for income taxes from continuing operations differing from federal statutory rate
Income tax (benefit) expense at the U.S. statutory rate	203	-1	45
Foreign rate differential	-45	-17	-4
Valuation allowances	-389	21	-25
U.S. tax on foreign earnings	92	26	28
Foreign withholding	40
Nondeductible reorganizational expenses			1
Nondeductible expenses, other	1	7	2
Nondeductible stock compensation	1	1	1
Depletion	-3	-3	-3
Income tax credits	-85	-6	-18
State income taxes, net of federal benefit	-12
Taxes attributable to prior periods	-10	-11	-1
Other, net	15	1
Income Tax Expense (Benefit)	-192	18	26
Deferred tax assets:
Pension and other post-retirement liabilities	83	61
Net operating loss carryforwards	253	387
Other accruals	3	15
Below market contracts, net of discount	82
Tax credit carryforwards	66	128
Accruals for environmental remediation	23	29
Intangibles	2	5
Inventories and other	15	20
Financial instruments	1	1
Total deferred tax assets	528	646
Valuation allowance	-127	-529
Net deferred tax assets after valuation allowance	401	117
Deferred tax liabilities:
Unremitted foreign earnings of subsidiaries	-11	-36
Property, plant and equipment	-63	-72
Other	-13	-11
Total deferred tax liabilities	-87	-119
Net deferred tax liability after valuation allowance	314	-2
Net current deferred taxes
Other current assets	34	10
Other current liabilities	-8	-3
Net non-current deferred taxes
Other assets	313	25
Other liabilities	($25)	($37)

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended		36 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation allowances
Amount of valuation allowances	$127	$529	$127		$529
Reduction in valuation allowance	402	99
Cumulative pretax income (loss) of U.S. operations			258	-105	-89
Cumulative adjusted three year domestic pretax income excluding divested businesses	38
Reduced U.S. operations interest expense compared to 2013	36
Reduced U.S. operations interest expense compared to 2012	2,012
U.S. Federal NOL carryforward period	20 years
Required U.S. Federal taxable income to realize all NOLs	725
NOL expiration period	16 years
Anticipated annual cost savings	26
Valuation allowance recorded in income tax (benefit) provision	-404	57
LIH deferred tax credits	23
Pre 2003 LIH deferred tax credits	10
Valuation allowance recorded in other comprehensive loss	2	42
Antioxidant Business Divestiture
Valuation allowances
Decrease in pension deferred asset and the associated valuation allowance due to sale of business		33
Chemtura AgroSolutions
Valuation allowances
Reduction in valuation allowance	141
U.S.
Valuation allowances
Amount of valuation allowances	102	506	102		506	605
Reduction in valuation allowance	406
Foreign
Valuation allowances
Amount of valuation allowances	25	23	25		23	23
Minimum
Valuation allowances
Expected foreign source income in U.S. operations	15
Maximum
Valuation allowances
Expected foreign source income in U.S. operations	$20

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
U.S.
Income taxes
NOL	$591	$974
U.S. | Earliest Tax Year [Member]
Income taxes
Cumulative NOL available for use in 2015	72
U.S. | Minimum | ax Years 2016 Through 2023 Member
Income taxes
NOL annual limitation	59
U.S. | Maximum | Latest Tax Year [Member]
Income taxes
NOL annual limitation	46
State
Income taxes
NOL	929	1,034
Foreign
Income taxes
NOL	$181	$141

INCOME_TAXES_Details_4

INCOME TAXES (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income taxes
Increase in deferred tax liability due to repatriation of undistributed earnings of foreign subsidiaries	$18
Net effect on tax expense as a result of increase in deferred tax liability due to repatriation of undistributed earnings of foreign subsidiaries		0
Undistributed earnings of foreign subsidiaries	747
U.S.
Income taxes
Tax credit carryforwards	63	125
State
Income taxes
Tax credit carryforwards	$3	$3

INCOME_TAXES_Details_5

INCOME TAXES (Details 5) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 01, 1999	Jul. 01, 2005
Income taxes
Increase (decrease) in liability for unrecognized tax benefits			$16
Reconciliation of beginning and ending amount of unrecognized tax benefits
Balance at the beginning of the period	44	41	46
Gross (decreases) increases for tax positions taken during current year	2	-1
Gross increases for tax positions taken during a prior period	2	1	3
Gross decreases for tax positions taken during a prior period	-19		-1
Settlements / payments	-2		-10
Foreign currency impact	1	3	3
Balance at the end of the period	28	44	41
Interest expense related to unrecognized tax benefits		1	1
Interest accrued related to unrecognized tax benefits	10	14
Potential decrease in unrecognized tax benefits within the next year	2
Minimum
Reconciliation of beginning and ending amount of unrecognized tax benefits
Statutes of limitations under foreign and United States jurisdictions	3 years
Maximum
Reconciliation of beginning and ending amount of unrecognized tax benefits
Statutes of limitations under foreign and United States jurisdictions	5 years
Subsidiaries of Witco
Income taxes
Basis difference of investments in the common stock of foreign subsidiaries				89
Subsidiaries of Great Lakes
Income taxes
Basis difference of investments in the common stock of foreign subsidiaries					$11

CAPITAL_STOCK_AND_EARNINGS_LOS2

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE (Details) (USD $)	1 Months Ended			3 Months Ended								12 Months Ended			20 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Nov. 30, 2014	31-May-14	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Oct. 31, 2014	Nov. 30, 2013
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
Shares authorized pursuant to Plan	500			500				500				500	500		500
Par value of common stock (in dollars per share)	$0.01			$0.01				$0.01				$0.01	$0.01		$0.01
Shares issued	100.5			100.5				100.5				100.5	100.5		100.5
Shares held in treasury	28.8			28.8				4				28.8	4		28.8
Authorized shares expired unpurchased		$9
Remaining value of common stock authorized to be repurchased	170			170								170			170
Preferred stock, shares authorized	0.3			0.3								0.3			0.3
Par value of preferred stock (in dollars per share)	$0.01			$0.01								$0.01			$0.01
Preferred stock, shares outstanding	0			0								0			0
Value of common stock authorized to be repurchased			391													500
Increase in value of common stock authorized to be repurchased			100
Number of shares repurchased	12.5											25.8			17.9
Value of shares repurchased	302											618			382
Number of shares repurchased through open market	1.2
Value of shares repurchased through open market	28
Value of shares repurchased (in dollars per share)	$24.20
Antidilutive securities excluded from the calculation of diluted earnings (loss) per share													1.3
Reconciliation of the shares used in the computation of earnings (loss) per share
Weighted average shares outstanding - Basic				82	89.4	93.2	96.3	96.6	97.5	98.6	98.2	90.2	97.7	98.2
Dilutive effect of common share equivalents												1.3		0.6
Weighted average shares outstanding - Diluted				83.3	90.7	94.4	97.8	98.1	97.5	99.7	98.2	91.5	97.7	98.8
Treasury Stock
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
Value of common stock authorized to be repurchased																	291
Number of shares repurchased												12.1
Value of shares repurchased												$287

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Changes in accumulated other comprehensive income (loss) by component
Balance at the beginning of the period	($280)
Other comprehensive income (loss) before reclassifications	-145
Amounts reclassified from AOCL	28
Net current period other comprehensive income	-117	148	-82
Balance at the end of the period	-397	-280
Foreign Currency Translation Adjustments
Changes in accumulated other comprehensive income (loss) by component
Balance at the beginning of the period	-13
Other comprehensive income (loss) before reclassifications	-70
Amounts reclassified from AOCL	-3
Net current period other comprehensive income	-73
Balance at the end of the period	-86
Defined benefit pension plan
Changes in accumulated other comprehensive income (loss) by component
Balance at the beginning of the period	-267
Other comprehensive income (loss) before reclassifications	-70
Amounts reclassified from AOCL	31
Net current period other comprehensive income	-39
Balance at the end of the period	-306
Unrealized loss on available for sale securities
Changes in accumulated other comprehensive income (loss) by component
Other comprehensive income (loss) before reclassifications	-5
Net current period other comprehensive income	-5
Balance at the end of the period	($5)

ACCUMULATED_OTHER_COMPREHENSIV3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 2) (USD $)	3 Months Ended						12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reclassifications out of AOCL to net earnings
Liquidation of consolidated entities								$13	$21
Gain on sale of business	529						529
Loss on sale of discontinued operations							-9	-188
Loss on sale of discontinued operations, net of tax		-4	-5	-31	-3	-146	-9	-180
Earnings (loss) from continuing operations before income taxes							579	-4	129
Tax on discontinued operations								8
Total tax							192	-18	-26
Net earnings (loss)							763	-177	100
Total reclassifications							-28
Amount Reclassified from AOCL
Reclassifications out of AOCL to net earnings
Settlement loss							-21
Foreign Currency Translation Adjustments
Reclassifications out of AOCL to net earnings
Total reclassifications							3
Foreign Currency Translation Adjustments | Amount Reclassified from AOCL
Reclassifications out of AOCL to net earnings
Liquidation of consolidated entities								13
Gain on sale of business							3
Loss on sale of discontinued operations								38
Net earnings (loss)							3	51
Defined benefit pension plan
Reclassifications out of AOCL to net earnings
Total reclassifications							-31
Defined benefit pension plan | Amount Reclassified from AOCL
Reclassifications out of AOCL to net earnings
Amortization of prior-service costs							5	5
Amortization of actuarial losses							-18	-21
Loss on sale of discontinued operations, net of tax								-127
Earnings (loss) from continuing operations before income taxes							-34	-143
Tax on continuing operations							3	1
Tax on discontinued operations								15
Total tax							3	16
Net earnings (loss)							-31	-127
Total reclassifications							($28)	($76)

STOCK_INCENTIVE_PLANS_Details

STOCK INCENTIVE PLANS (Details)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2010	Dec. 31, 2014	Dec. 31, 2013
Stock incentive plans
Number of shares available for grant		4.6	4.9
2010 LTIP
Stock incentive plans
Number of shares available for issuance	11
2010 LTIP | Maximum
Stock incentive plans
Expiration period	10 years

STOCK_INCENTIVE_PLANS_Details_

STOCK INCENTIVE PLANS (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
STOCK INCENTIVE PLANS
Stock-based compensation expense	$14	$14	$24
Percentage of stock-based compensation expense allocated to operating segments	23.00%	23.00%	24.00%
SG&A
STOCK INCENTIVE PLANS
Stock-based compensation expense	13	12	19
Cost of goods sold
STOCK INCENTIVE PLANS
Stock-based compensation expense	1	1	3
Earnings/loss from discontinued operations, net of tax
STOCK INCENTIVE PLANS
Stock-based compensation expense		$1	$2

STOCK_INCENTIVE_PLANS_Details_1

STOCK INCENTIVE PLANS (Details 3) (USD $)	12 Months Ended		1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Stock options
Stock incentive plans
Weighted average fair value of options granted (in dollars per share)	$9.92	$8.15
Weighted average assumptions
Dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	51.00%	56.70%
Risk-free interest rate (as a percent)	1.00%	1.20%
Expected life	6 years	6 years
2013 Awards | NQOs
Stock incentive plans
Grants approved (in shares)			0.4
Vesting period			3 years
2012 Awards | NQOs
Stock incentive plans
Grants approved (in shares)				0.8
Vesting period				3 years

STOCK_INCENTIVE_PLANS_Details_2

STOCK INCENTIVE PLANS (Details 4) (Stock options, USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Price Per Share
Outstanding at the beginning of the period, Average (in dollars per share)	$16.46
Outstanding at the end of the period, Average (in dollars per share)	$16.56	$16.46
Shares
Outstanding at the beginning of the year (in shares)	2.8
Exercised (in shares)	-0.6
Outstanding at the end of the year (in shares)	2.2	2.8
Exercisable
Shares	1.8
Aggregate Intrinsic Value
Outstanding	$18	$32
Exercised	5	4	1
Exercisable	15
Weighted Average Remaining Contractual Life
Outstanding	6 years 6 months	7 years 4 months 24 days
Exercisable	6 years 2 months 12 days
Unrecognized compensation expense
Remaining unrecognized compensation expense associated with unvested awards	$1
Weighted average period for recognition	1 year
Average
Price Per Share
Exercised (in dollars per share)	$16.01
Lapsed (in dollars per share)	$18.07
Exercisable
Price per share	$16.16

STOCK_INCENTIVE_PLANS_Details_3

STOCK INCENTIVE PLANS (Details 5) (USD $)	12 Months Ended			1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2012	Dec. 31, 2010
Tax Benefits of Stock-Based Compensation Plans
Cash tax benefit	$5
Proceeds from exercise of stock options	10	8	5
Restricted stock units
Stock incentive plans
Awards granted (in shares)	0.6
Shares
Unvested RSU awards at the beginning of the period (in shares)	1
Cancelled (in shares)	-0.1
Granted (in shares)	0.6
Vested (in shares)	-0.4
Unvested RSU awards at the end of the period (in shares)	1.1	1
Weighted Average Grant Date Fair Value
Unvested RSU awards at the beginning of the period (in dollars per share)	$20.53
Cancelled (in dollars per share)	$23.47
Granted (in dollars per share)	$25.56	$23.18	$17.72
Vested (in dollars per share)	$18.32
Unvested RSU awards at the end of the period (in dollars per share)	$23.81	$20.53
Aggregate Fair Values
Unvested RSU awards at the beginning of the period	30
Vested	8	8	17
Unvested RSU awards at the end of the period	28	30
Unrecognized compensation expense
Remaining unrecognized compensation expense associated with unvested awards	$10
Weighted average period for recognition	2 years
2010 LTIP
Stock incentive plans
Number of shares available for issuance							11
2013 Awards | Time-based RSU
Stock incentive plans
Grants approved (in shares)				0.2
Vesting period				3 years
2013 Awards | Performance-based RSU
Stock incentive plans
Grants approved (in shares)				0.2
Performance multiplier				2
Vesting period				3 years
Weighted average fair value of options granted (in dollars per share)				27.27
2014 Awards | Time-based RSU
Stock incentive plans
Grants approved (in shares)					0.4
Vesting period					3 years
2014 Awards | Performance-based RSU
Stock incentive plans
Grants approved (in shares)					0.2
Performance multiplier					2
Vesting period					3 years
Weighted average fair value of options granted (in dollars per share)					26.98
2012 Awards | Time-based RSU
Stock incentive plans
Grants approved (in shares)						0.6
Vesting period						3 years
2012 Awards | Performance-based RSU
Stock incentive plans
Grants approved (in shares)						0.3
Performance multiplier						2
Vesting period						3 years
Weighted average fair value of options granted (in dollars per share)						25.38

PENSION_AND_OTHER_POSTRETIREME2

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
Noncurrent liability	($318)	($246)
Estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year
Employer contribution	49	57
Projected benefit obligation in excess of plan assets at end of year:
Projected benefit obligation	919	876
Fair value of plan assets	584	612
Accumulated benefit obligation in excess of plan assets at end of year:
Projected benefit obligation	798	778
Accumulated benefit obligation	797	777
Fair value of plan assets	572	611
Weighted-average assumptions used to determine net cost:
Discount rate (as a percent)			4.15%
Receivable related to additional cash contributions	11	11	11
Qualified Domestic Plans
Funded status, end of year:
Fair value of plan assets	570	595	814
Benefit obligations	652	623	1,040
Net amount recognized	-82	-28
Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
Noncurrent liability	-82	-28
Net amount recognized	-82	-28
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial loss/(gain)	269	219
Net amount recognized	269	219
Estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year
Amortized losses from AOCL	14
Total amortization cost (credit)	14
Employer contribution	14	20
Projected benefit obligation in excess of plan assets at end of year:
Discretionary contributions	10
Expected Benefit Payments:
2015	46
2016	46
2017	45
2018	45
2019	44
2020-2024	207
Defined benefit plans net periodic benefit (credit) cost
Service cost			1
Interest cost	28	30	43
Expected return on plan assets	-41	-45	-54
Amortization of actuarial losses	11	14	14
Settlement loss recognized	21	32
Net periodic benefit cost (credit)	19	31	4
Weighted-average assumptions used to determine net cost:
Discount rate (as a percent)	4.60%	3.80%	4.60%
Expected return on plan assets (as a percent)	7.50%	7.50%	7.50%
Rate of compensation increase (as a percent)	3.00%	3.00%	4.00%
Qualified Domestic Plans | Discontinued operations
Defined benefit plans net periodic benefit (credit) cost
Net periodic benefit cost (credit)		1	2
International and Non-Qualified Plans
Funded status, end of year:
Fair value of plan assets	455	408	370
Benefit obligations	542	519	499
Net amount recognized	-87	-111
Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
Noncurrent assets	57	30
Current liability	-7	-9
Noncurrent liability	-137	-132
Net amount recognized	-87	-111
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial loss/(gain)	130	120
Net amount recognized	130	120
Estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year
Amortized losses from AOCL	6
Total amortization cost (credit)	6
Employer contribution	24	27
Expected Employer Contributions:
2015	3
Expected Benefit Payments:
2015	21
2016	21
2017	22
2018	25
2019	26
2020-2024	130
Defined benefit plans net periodic benefit (credit) cost
Service cost	2	3	3
Interest cost	21	20	21
Expected return on plan assets	-26	-23	-22
Amortization of actuarial losses	4	5	2
Curtailment loss recognized		1
Net periodic benefit cost (credit)	1	6	4
Weighted-average assumptions used to determine net cost:
Discount rate (as a percent)	4.20%	3.89%	4.64%
Expected return on plan assets (as a percent)	6.68%	6.53%	6.71%
Rate of compensation increase (as a percent)	2.85%	2.77%	3.22%
UK pension plans
Estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year
Cash contributions by entity as per definitive agreements with the trustees	12	12
Post-Retirement Health Care Plans
Funded status, end of year:
Benefit obligations	108	96	124
Net amount recognized	-108	-96
Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
Current liability	-9	-9
Noncurrent liability	-99	-87
Net amount recognized	-108	-96
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial loss/(gain)	49	31
Prior service cost/(credit)	-35	-40
Net amount recognized	14	-9
Estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year
Amortized losses from AOCL	3
Prior service credit	-5
Total amortization cost (credit)	-2
Employer contribution	11	10
Expected Employer Contributions:
2015	9
Expected Benefit Payments:
2015	9
2016	9
2017	8
2018	8
2019	8
2020-2024	33
Defined benefit plans net periodic benefit (credit) cost
Service cost			1
Interest cost	4	4	5
Amortization of prior service cost	-5	-5	-6
Amortization of actuarial losses	3	2	3
Net periodic benefit cost (credit)	2	1	3
Weighted-average assumptions used to determine net cost:
Discount rate (as a percent)	4.45%	3.71%
Legacy pension plan
Defined benefit plans net periodic benefit (credit) cost
Settlement loss recognized		-6
Legacy pension plan | SG&A
Defined benefit plans net periodic benefit (credit) cost
Settlement loss recognized		-2
Legacy pension plan | Discontinued operations
Defined benefit plans net periodic benefit (credit) cost
Settlement loss recognized		4
Antioxidant Business Divestiture
Defined benefit plans net periodic benefit (credit) cost
Settlement loss recognized		40
Consumer Products Business Divestiture
Defined benefit plans net periodic benefit (credit) cost
Settlement loss recognized		$2

PENSION_AND_OTHER_POSTRETIREME3

PENSION AND OTHER POST-RETIREMENT PLANS (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Significant Unobservable Inputs (Level 3)
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	$92
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at beginning of year	106
Purchases	4
Realized gains	2
Unrealized gains	4
Disbursements	-24
Fair value of plan assets at end of year	92
Significant Unobservable Inputs (Level 3) | Alternative Collective funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	75
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at beginning of year	91
Realized gains	2
Unrealized gains	6
Disbursements	-24
Fair value of plan assets at end of year	75
Significant Unobservable Inputs (Level 3) | Other instruments
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	17
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at beginning of year	15
Purchases	4
Unrealized gains	-2
Fair value of plan assets at end of year	17
Qualified Domestic Plans
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	570	595	814
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at beginning of year			814
Fair value of plan assets at end of year	570	595	814
Qualified Domestic Plans | Pooled equity
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	164	141
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	164	141
Qualified Domestic Plans | U.S. government bonds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	72	71
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	72	71
Qualified Domestic Plans | Pooled fixed income funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	258	287
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	258	287
Qualified Domestic Plans | Alternative Collective funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	75	91
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	75	91
Qualified Domestic Plans | Other instruments
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	1	1
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	1	1
Qualified Domestic Plans | Cash & cash equivalents
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets		4
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year		4
Qualified Domestic Plans | Level 1
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	423	433
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	423	433
Qualified Domestic Plans | Level 1 | Pooled equity
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	164	141
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	164	141
Qualified Domestic Plans | Level 1 | Pooled fixed income funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	258	287
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	258	287
Qualified Domestic Plans | Level 1 | Other instruments
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	1	1
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	1	1
Qualified Domestic Plans | Level 1 | Cash & cash equivalents
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets		4
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year		4
Qualified Domestic Plans | Significant Observable Inputs (Level 2)
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	72	71
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	72	71
Qualified Domestic Plans | Significant Observable Inputs (Level 2) | U.S. government bonds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	72	71
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	72	71
Qualified Domestic Plans | Significant Unobservable Inputs (Level 3)
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	75	91
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	75	91
Qualified Domestic Plans | Significant Unobservable Inputs (Level 3) | Alternative Collective funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	75	91
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	75	91
International and Non-Qualified Plans
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	455	408	370
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at beginning of year			370
Fair value of plan assets at end of year	455	408	370
International and Non-Qualified Plans | Pooled equity
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	152	146
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	152	146
International and Non-Qualified Plans | International government bonds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	20	2
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	20	2
International and Non-Qualified Plans | Pooled fixed income funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	268	247
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	268	247
International and Non-Qualified Plans | Other instruments
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	14	11
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	14	11
International and Non-Qualified Plans | Cash & cash equivalents
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	1	2
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	1	2
International and Non-Qualified Plans | Level 1
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	9	14
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	9	14
International and Non-Qualified Plans | Level 1 | Pooled equity
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	8	12
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	8	12
International and Non-Qualified Plans | Level 1 | Cash & cash equivalents
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	1	2
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	1	2
International and Non-Qualified Plans | Significant Observable Inputs (Level 2)
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	429	379
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	429	379
International and Non-Qualified Plans | Significant Observable Inputs (Level 2) | Pooled equity
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	144	134
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	144	134
International and Non-Qualified Plans | Significant Observable Inputs (Level 2) | International government bonds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	20	2
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	20	2
International and Non-Qualified Plans | Significant Observable Inputs (Level 2) | Pooled fixed income funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	265	243
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	265	243
International and Non-Qualified Plans | Significant Unobservable Inputs (Level 3)
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	17	15
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	17	15
International and Non-Qualified Plans | Significant Unobservable Inputs (Level 3) | Pooled fixed income funds
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	3	4
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	3	4
International and Non-Qualified Plans | Significant Unobservable Inputs (Level 3) | Other instruments
PENSION AND OTHER POST-RETIREMENT PLANS
Fair value of plan assets	14	11
Investments transferred into pooled equity and fixed income funds due to the change in asset management
Fair value of plan assets at end of year	14	11
UK pension plans
PENSION AND OTHER POST-RETIREMENT PLANS
Cash contributions by entity as per definitive agreements with the trustees	$12	$12

PENSION_AND_OTHER_POSTRETIREME4

PENSION AND OTHER POST-RETIREMENT PLANS (Details 3)	12 Months Ended																					1 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2014	31-May-11	31-May-11	Sep. 30, 2014	Mar. 31, 2014	Mar. 31, 2014	Jun. 30, 2013	Dec. 31, 2011
	USD ($)	USD ($)	Antioxidant Business Divestiture	Consumer Products Business Divestiture	Qualified Domestic Plans	Qualified Domestic Plans	Qualified Domestic Plans	Qualified Domestic Plans	Qualified Domestic Plans	Qualified Domestic Plans	International and Non-Qualified Plans	International and Non-Qualified Plans	International and Non-Qualified Plans	International and Non-Qualified Plans	International and Non-Qualified Plans	International and Non-Qualified Plans	Post-Retirement Health Care Plans	Post-Retirement Health Care Plans	Post-Retirement Health Care Plans	Post-Retirement Health Care Plans	Post-Retirement Health Care Plans	UK pension plans	UK pension plans	UK pension plans	UK pension plans	UK pension plans	UK pension plans	UK pension plans
			USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	Fixed income securities	Other types of investments	Equity securities	USD ($)	USD ($)	USD ($)	Fixed income securities	Other types of investments	Equity securities	USD ($)	USD ($)	USD ($)	Minimum	Maximum	USD ($)	GBP (£)	USD ($)	USD ($)	GBP (£)	USD ($)	USD ($)
																					USD ($)	item
Pension and other post-retirement benefit plans
Number of UK subsidiaries that entered into a definitive agreement with Great Lakes U.K. Limited Pension Plan																						1	1
Cash contributions by foreign subsidiary																						$96	£ 60		$12	£ 8
Expense recognized based on the results of the evaluation of additional benefit obligations																												8
Gain related to adjustment for plan to SG & A																								4			2
Reduction in projected benefit obligation	52
Amortized losses from AOCL					14						6						3
Change in projected benefit obligation:
Projected benefit obligation at beginning of year					623	1,040					519	499					96	124
Service cost							1				2	3	3						1
Interest cost					28	30					21	19					4	4
Plan participants' contributions												1
Actuarial (gains) losses					99	-69					64	11					20	-20
Benefits paid					-46	-51					-20	-19					-11	-10
Business divestitures			-315	-12		-327
Settlements	21				-52						-3	-6
Foreign currency exchange rate changes											-41	11					-1	-2
Projected benefit obligation at end of year					652	623	1,040				542	519	499				108	96	124
Accumulated benefit obligation at end of year					651	622					506	506
Weighted-average year-end assumptions used to determine benefit obligations:
Discount rate (as a percent)					3.80%	4.60%					3.28%	4.18%					3.70%	4.35%
Rate of compensation increase (as a percent)					3.80%	3.00%					2.41%	2.85%
Health care cost trend rate (as a percent)																	6.16%	6.27%
Ultimate health care cost trend rate (as a percent)																	5.00%
Period over which health care cost trend rate was assumed to be decreased																				5 years	7 years
Effect of one percentage point increase (decrease) in assumed health care cost trend rates on accumulated post-retirement benefit obligation
Effect of one percentage point increase in assumed health care cost trend rates on accumulated post-retirement benefit obligation																	5
Effect of one percentage point decrease in assumed health care cost trend rates on accumulated post-retirement benefit obligation																	4
Effect of one percentage point increase in assumed health care cost trend rates on service and interest cost components	1
Effect of one percentage point decrease in assumed health care cost trend rates on service and interest cost components																					1
Change in plan assets:
Fair value of plan assets at beginning of year					595	814					408	370
Actual return on plan assets					59	51					75	30
Employer contribution	49	57			14	20					24	27					11	10
Plan participants' contributions												1
Benefits paid					-46	-51					-20	-19					-11	-10
Business divestitures			-233	-6		-239
Settlements					-52						-3	-6
Foreign currency exchange rate changes											-29	5
Fair value of plan assets at end of year					$570	$595	$814				$455	$408	$370
Target allocations
Target allocations (as a percent)								58.00%	10.00%	32.00%				53.00%	14.00%	33.00%

FINANCIAL_INSTRUMENTS_AND_FAIR1

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value Measurements
Disposal Group Shares Of Common Received As Consideration	2
Amount of transfer of assets out of Level 1 into Level 2	$0
Amount of transfer of assets out of Level 2 into Level 1	0
Amount of transfer of liabilities out of Level 1 into Level 2	0
Amount of transfer of liabilities out of Level 2 into Level 1	0
Recurring basis | Level 1
Fair Value Measurements
Fair value of asset	3	3
Fair value of liability	3	3
Recurring basis | Significant Unobservable Inputs (Level 3)
Fair Value Measurements
Face value of investment in non-public preferred equity securities	9
Investment in non-public preferred equity securities	$4

LEGAL_PROCEEDINGS_AND_CONTINGE1

LEGAL PROCEEDINGS AND CONTINGENCIES (Details) (Environmental, USD $)	12 Months Ended			0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 06, 2013
Environmental Liabilities that Have Not Been Discharged or Settled
Period for accrual of probable and reasonable remediation costs on an undiscounted basis	10 years
Amount accrued for environmental liabilities	$76	$93
Environmental liabilities reflected as accrued expenses	17	18
Environmental liabilities reflected as other liabilities	59	75
Reasonably possible ongoing environmental liabilities	87
Pre-tax charge for clean-up costs	6	29	7
Payments for clean-up costs	18	15	12
Receivables based on contractual agreement	0
Maximum
Environmental Liabilities that Have Not Been Discharged or Settled
Penalty				$1

LEGAL_PROCEEDINGS_AND_CONTINGE2

LEGAL PROCEEDINGS AND CONTINGENCIES (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Guarantees
Outstanding letters of credit	$15	$14
Guarantees provided to financial institutions
Guarantees
Outstanding guarantees	10	12
Maximum potential future principal and interest payments due under guarantees	$2	$3

BUSINESS_SEGMENTS_Details

BUSINESS SEGMENTS (Details) (USD $)	3 Months Ended								12 Months Ended			1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2013
BUSINESS SEGMENT DATA
Term of supply contract									6 years
Disposal Group Including Discontinued Operation Extension Term of Supply Contracts									2 years
Net Sales
Net Sales	$467	$558	$609	$556	$544	$569	$590	$528	$2,190	$2,231	$2,196
Operating Income
OPERATING INCOME									619	98	179
General corporate expense, including amortization									-80	-97	-101
Amortization									13	15	16
Facility closures, severance and related costs	-19		-4	-2	-14	-3	-11	-14	-25	-42	-11
Gain on sale of business	-529								-529
Interest expense									-45	-60	-64
Loss on early extinguishment of debt	-7					50			-7	-50	-1
Other income, net									12	8	15
Reorganization items, net									1	1	5
(Loss) earnings from continuing operations before income taxes									579	-4	129
Depreciation and amortization									102	123	139
Equity income (loss)											-4
Assets	2,667				2,704				2,667	2,704	3,030
Capital expenditures									113	170	149
Operating segments
Operating Income
OPERATING INCOME									208	252	307
Antioxidant Business Divestiture
BUSINESS SEGMENT DATA
Cash consideration on sale of business												97
Antioxidant and Consumer Product businesses
Operating Income
Amortization										8	14
Continuing operations
Operating Income
Depreciation and amortization									102	101	100
Capital expenditures									113	159	136
Continuing operations | Operating segments
Operating Income
Depreciation and amortization									86	83	81
Assets	1,425				1,619				1,425	1,619	1,526
Capital expenditures									111	153	126
Discontinued operations
Operating Income
Depreciation and amortization										22	39
Assets											654
Capital expenditures										11	13
Industrial Performance Products | Operating segments
Net Sales
Net Sales									987	979	891
Operating Income
OPERATING INCOME									106	109	102
Industrial Performance Products | Continuing operations | Operating segments
Operating Income
Depreciation and amortization									34	28	25
Assets	642				591				642	591	514
Capital expenditures									54	73	52
Industrial Performance Products | Petroleum additives
Net Sales
Net Sales									687	689	600
Industrial Performance Products | Urethanes
Net Sales
Net Sales									300	290	291
Industrial Engineered Products | Operating segments
Net Sales
Net Sales									800	803	896
Operating Income
OPERATING INCOME									16	55	140
Industrial Engineered Products | Continuing operations | Operating segments
Operating Income
Depreciation and amortization									44	43	43
Assets	696				743				696	743	693
Capital expenditures									51	73	69
Industrial Engineered Products | Bromine based & related products
Net Sales
Net Sales									641	639	730
Industrial Engineered Products | Organometallics
Net Sales
Net Sales									159	164	166
Chemtura AgroSolutions | Operating segments
BUSINESS SEGMENT DATA
Number of major product lines									6
Net Sales
Net Sales									403	449	409
Operating Income
OPERATING INCOME									86	88	65
Chemtura AgroSolutions | Continuing operations | Operating segments
Operating Income
Depreciation and amortization									8	12	13
Assets	87				285				87	285	319
Capital expenditures									6	7	5
Corporate
Operating Income
General corporate expense, including amortization										-12	-12
Assets	1,242				1,085				1,242	1,085	850
Corporate | Antioxidant and Consumer Product businesses
Operating Income
Amortization										8	14
Corporate | Continuing operations
Operating Income
Depreciation and amortization									16	18	19
Capital expenditures									2	6	10
Corporate | Continuing operations | Antioxidant and Consumer Product businesses
Operating Income
General corporate expense, including amortization										($20)	($26)
Minimum | Antioxidant Business Divestiture
BUSINESS SEGMENT DATA
Term of supply contract												2 years
Minimum | Chemtura AgroSolutions | Platform
BUSINESS SEGMENT DATA
Term of supply contract									2 years
Maximum | Antioxidant Business Divestiture
BUSINESS SEGMENT DATA
Term of supply contract												5 years
Maximum | Chemtura AgroSolutions | Platform
BUSINESS SEGMENT DATA
Term of supply contract									4 years

BUSINESS_SEGMENTS_Details_2

BUSINESS SEGMENTS (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$467	$558	$609	$556	$544	$569	$590	$528	$2,190	$2,231	$2,196
Property, plant and equipment	704				717				704	717	645
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									888	944	878
Property, plant and equipment	338				336				338	336	341
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									48	42	39
Property, plant and equipment	54				61				54	61	69
Latin America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									174	194	159
Property, plant and equipment	10				13				10	13	13
Europe/Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									639	624	676
Property, plant and equipment	181				216				181	216	187
Asia/Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									441	427	444
Property, plant and equipment	121				91				121	91	35
Parent Company
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									1,346	1,443	1,477
Property, plant and equipment	$116				$121				$116	$121

GUARANTOR_CONDENSED_CONSOLIDAT2

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed consolidating statement of operations and comprehensive loss
Net sales	$467	$558	$609	$556	$544	$569	$590	$528	$2,190	$2,231	$2,196
Cost of goods sold									1,682	1,721	1,615
Selling, general and administrative									255	229	246
Depreciation and amortization									102	101	100
Research and development									36	40	41
Facility closures, severance and related costs	19		4	2	14	3	11	14	25	42	11
Gain on sale of business	-529								-529
Equity loss											4
OPERATING INCOME									619	98	179
Interest expense									-45	-60	-64
Loss on early extinguishment of debt	-7					50			-7	-50	-1
Other income (expense), net									12	8	15
Earnings (loss) from continuing operations before income taxes									579	-4	129
Income tax benefit (expense)									192	-18	-26
Earnings (loss) from continuing operations									771	-22	103
Earnings (loss) from discontinued operations, net of tax									1	25	-3
Gain (loss) on sale of discontinued operations, net of tax			-4	-5	-31	-3	-146		-9	-180
Net earnings (loss)									763	-177	100
Less: Net earnings attributed to non-controlling interests											-1
Net earnings (loss) attributable to Chemtura									763	-177	101
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Net (loss) earnings									763	-177	100
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments net of income tax benefit (expense) of $10, $(3) and $(4)									-73	-60	-6
Unrecognized pension and other post-retirement benefit costs - net of income tax benefit (expense) of $39, $(16) and $14									-39	208	-76
Unrealized loss on available for sale securities									-5
Comprehensive income (loss) income									646	-29	18
Comprehensive loss (income) attributable to the non-controlling interest											1
Comprehensive income (loss) income attributable to Chemtura									646	-29	19
Eliminations
Condensed consolidating statement of operations and comprehensive loss
Net sales									-1,878	-1,813	-1,623
Cost of goods sold									-1,878	-1,813	-1,623
Equity in net earnings of subsidiaries									-145	-85	-81
Earnings (loss) from continuing operations before income taxes									-145	-85	-81
Earnings (loss) from continuing operations									-145	-85	-81
Net earnings (loss)									-145	-85	-81
Net earnings (loss) attributable to Chemtura									-145		-81
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Net (loss) earnings									-145	-85	-81
Other comprehensive (loss) income, net of tax
Comprehensive income (loss) income											-81
Comprehensive income (loss) income attributable to Chemtura									-145	-85	-81
Parent Company
Condensed consolidating statement of operations and comprehensive loss
Net sales									1,346	1,443	1,477
Cost of goods sold									1,112	1,235	1,192
Selling, general and administrative									150	109	121
Depreciation and amortization									25	29	27
Research and development									14	15	16
Facility closures, severance and related costs									3	21	8
Gain on sale of business									-399
OPERATING INCOME									441	34	113
Interest expense									-50	-69	-69
Loss on early extinguishment of debt									-7	-50	-1
Other income (expense), net									-11	-21	-22
Equity in net earnings of subsidiaries									145	85	81
Earnings (loss) from continuing operations before income taxes									518	-21	102
Income tax benefit (expense)									244
Earnings (loss) from continuing operations									762	-21	102
Earnings (loss) from discontinued operations, net of tax									1	-3	-1
Gain (loss) on sale of discontinued operations, net of tax										-153
Net earnings (loss)									763	-177	101
Net earnings (loss) attributable to Chemtura									763		101
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Net (loss) earnings									763	-177	101
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments net of income tax benefit (expense) of $10, $(3) and $(4)									45	-18	-11
Unrecognized pension and other post-retirement benefit costs - net of income tax benefit (expense) of $39, $(16) and $14									-32	202	-44
Unrealized loss on available for sale securities									-5
Comprehensive income (loss) income											46
Comprehensive income (loss) income attributable to Chemtura									771	7	46
Guarantor Subsidiaries
Condensed consolidating statement of operations and comprehensive loss
Net sales									437	449	454
Cost of goods sold									370	389	383
Selling, general and administrative									16	15	17
Depreciation and amortization									32	35	44
Research and development									6	8	7
Facility closures, severance and related costs									2	1
OPERATING INCOME									11	1	3
Interest expense											2
Other income (expense), net									2
Earnings (loss) from continuing operations before income taxes									13	1	5
Income tax benefit (expense)									-4
Earnings (loss) from continuing operations									9	1	5
Earnings (loss) from discontinued operations, net of tax										23	28
Gain (loss) on sale of discontinued operations, net of tax									-8	14
Net earnings (loss)									1	38	33
Net earnings (loss) attributable to Chemtura									1		33
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Net (loss) earnings									1	38	33
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments net of income tax benefit (expense) of $10, $(3) and $(4)										2	1
Comprehensive income (loss) income											34
Comprehensive income (loss) income attributable to Chemtura									1	40	34
Non-Guarantor Subsidiaries
Condensed consolidating statement of operations and comprehensive loss
Net sales									2,285	2,152	1,888
Cost of goods sold									2,078	1,910	1,663
Selling, general and administrative									89	105	108
Depreciation and amortization									45	37	29
Research and development									16	17	18
Facility closures, severance and related costs									20	20	3
Gain on sale of business									-130
Equity loss											4
OPERATING INCOME									167	63	63
Interest expense									5	9	3
Other income (expense), net									21	29	37
Earnings (loss) from continuing operations before income taxes									193	101	103
Income tax benefit (expense)									-48	-18	-26
Earnings (loss) from continuing operations									145	83	77
Earnings (loss) from discontinued operations, net of tax										5	-30
Gain (loss) on sale of discontinued operations, net of tax									-1	-41
Net earnings (loss)									144	47	47
Less: Net earnings attributed to non-controlling interests											-1
Net earnings (loss) attributable to Chemtura									144		48
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Net (loss) earnings									144	47	47
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments net of income tax benefit (expense) of $10, $(3) and $(4)									-118	-44	4
Unrecognized pension and other post-retirement benefit costs - net of income tax benefit (expense) of $39, $(16) and $14									-7	6	-32
Comprehensive income (loss) income											19
Comprehensive loss (income) attributable to the non-controlling interest											1
Comprehensive income (loss) income attributable to Chemtura									$19	$9	$20

GUARANTOR_CONDENSED_CONSOLIDAT3

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified
ASSETS
Current assets	$1,216	$1,525
Property, plant and equipment	704	717	645
Goodwill	172	179
Other assets	575	283
Total Assets	2,667	2,704	3,030
LIABILITIES AND EQUITY
Current liabilities	405	484
Long-term debt	556	781
Other long-term liabilities	652	440
Total liabilities	1,613	1,705
Total equity	1,054	999	1,068	1,046
Total Liabilities and Equity	2,667	2,704
Eliminations
ASSETS
Intercompany receivables	-6,937	-7,671
Investment in subsidiaries	-4,923	-7,277
Total Assets	-11,860	-14,948
LIABILITIES AND EQUITY
Intercompany payables	-6,937	-7,671
Total liabilities	-6,937	-7,671
Total equity	-4,923	-7,277
Total Liabilities and Equity	-11,860	-14,948
Parent Company
ASSETS
Current assets	539	571
Intercompany receivables	3,094	2,681
Investment in subsidiaries	822	1,530
Property, plant and equipment	116	121
Goodwill	93	93
Other assets	448	137
Total Assets	5,112	5,133
LIABILITIES AND EQUITY
Current liabilities	155	244
Intercompany payables	2,971	2,944
Long-term debt	541	764
Other long-term liabilities	391	182
Total liabilities	4,058	4,134
Total equity	1,054	999
Total Liabilities and Equity	5,112	5,133
Guarantor Subsidiaries
ASSETS
Current assets	113	121
Intercompany receivables	2,752	2,349
Investment in subsidiaries	1,134	1,135
Property, plant and equipment	222	215
Goodwill	3	3
Other assets	36	44
Total Assets	4,260	3,867
LIABILITIES AND EQUITY
Current liabilities	44	39
Intercompany payables	3,031	2,583
Other long-term liabilities	83	54
Total liabilities	3,158	2,676
Total equity	1,102	1,191
Total Liabilities and Equity	4,260	3,867
Non-Guarantor Subsidiaries
ASSETS
Current assets	564	833
Intercompany receivables	1,091	2,641
Investment in subsidiaries	2,967	4,612
Property, plant and equipment	366	381
Goodwill	76	83
Other assets	91	102
Total Assets	5,155	8,652
LIABILITIES AND EQUITY
Current liabilities	206	201
Intercompany payables	935	2,144
Long-term debt	15	17
Other long-term liabilities	178	204
Total liabilities	1,334	2,566
Total equity	3,821	6,086
Total Liabilities and Equity	$5,155	$8,652

GUARANTOR_CONDENSED_CONSOLIDAT4

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Details 3) (USD $)	3 Months Ended							12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)								$763	($177)	$100
Adjustments to reconcile net earnings to net cash (used in) provided by operations:
Loss on sale of discontinued operations		4	5	31	3	146		9	180
Gain on sale of business	-529							-529
Agrochemical Manufacturing supply agreements								-6
Impairment charges							11		7	47
Reclass of cumulative translation adjustment from liquidation of entities									-13	-21
Loss on early extinguishment of debt	7				-50			7	50	1
Depreciation and amortization								102	123	139
Stock-based compensation expense								14	14	24
Deferred tax (benefit) expense								-274	1	3
Excess tax benefit from share-based payment arrangements								-5
Other non-cash transactions								8	-1
Non Cash Reorganization Items										3
Changes in assets and liabilities, net								-159	-105	-75
Net cash (used in) provided by operating activities								-78	79	218
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net								984	357	9
Payments for acquisitions, net of cash acquired									-3
Capital expenditures								-113	-170	-149
Net cash provided by (used in) investing activities								871	184	-140
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt								19	481	125
Payments on long term debt, includes premium on tendering of notes								-350	-502
(Payments on) proceeds from other short-term borrowings, net								-1	-1	-3
Payments for debt issuance and refinancing costs									-12	-2
Common shares acquired								-618	-54	-20
Proceeds from the exercise of stock options								10	8	5
Excess tax benefit from share-based payment arrangements								5
Net cash (used in) provided by financing activities								-935	-80	105
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents								-15	1	2
Change in cash and cash equivalents								-157	184	185
Cash and cash equivalents at beginning of year			549					549	365	180
Cash and cash equivalents at end of year	392			549			365	392	549	365
Eliminations
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)								-145	-85	-81
Adjustments to reconcile net earnings to net cash (used in) provided by operations:
Changes in assets and liabilities, net								145	85	81
Parent Company
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)								763	-177	101
Adjustments to reconcile net earnings to net cash (used in) provided by operations:
Loss on sale of discontinued operations									153
Gain on sale of business								-399
Agrochemical Manufacturing supply agreements								-5
Impairment charges										12
Loss on early extinguishment of debt								7	50	1
Depreciation and amortization								25	33	36
Stock-based compensation expense								14	14	24
Deferred tax (benefit) expense								-278
Excess tax benefit from share-based payment arrangements								-5
Non Cash Reorganization Items										2
Changes in assets and liabilities, net								-213	-84	-106
Net cash (used in) provided by operating activities								-91	-11	70
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net								964	255
Capital expenditures								-18	-20	-21
Net cash provided by (used in) investing activities								946	235	-21
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt									457	125
Payments on long term debt, includes premium on tendering of notes								-342	-499
Payments for debt issuance and refinancing costs									-12	-1
Common shares acquired								-618	-54	-20
Proceeds from the exercise of stock options								10	8	5
Excess tax benefit from share-based payment arrangements								5
Net cash (used in) provided by financing activities								-945	-100	109
CASH AND CASH EQUIVALENTS
Change in cash and cash equivalents								-90	124	158
Cash and cash equivalents at beginning of year			317					317	193	35
Cash and cash equivalents at end of year	227			317			193	227	317	193
Guarantor Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)								1	38	33
Adjustments to reconcile net earnings to net cash (used in) provided by operations:
Loss on sale of discontinued operations								8	-14
Impairment charges									7
Depreciation and amortization								32	45	51
Deferred tax (benefit) expense								4
Changes in assets and liabilities, net								-27	-27	-37
Net cash (used in) provided by operating activities								18	49	47
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net								15	-2
Capital expenditures								-33	-47	-47
Net cash provided by (used in) investing activities								-18	-49	-47
Non-Guarantor Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings (loss)								144	47	47
Adjustments to reconcile net earnings to net cash (used in) provided by operations:
Loss on sale of discontinued operations								1	41
Gain on sale of business								-130
Agrochemical Manufacturing supply agreements								-1
Impairment charges										35
Reclass of cumulative translation adjustment from liquidation of entities									-13	-21
Depreciation and amortization								45	45	52
Non Cash Reorganization Items										1
Changes in assets and liabilities, net								-64	-79	-13
Net cash (used in) provided by operating activities								-5	41	101
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net								5	104	9
Payments for acquisitions, net of cash acquired									-3
Capital expenditures								-62	-103	-81
Net cash provided by (used in) investing activities								-57	-2	-72
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of long term debt								19	24
Payments on long term debt, includes premium on tendering of notes								-8	-3
(Payments on) proceeds from other short-term borrowings, net								-1	-1	-3
Payments for debt issuance and refinancing costs										-1
Net cash (used in) provided by financing activities								10	20	-4
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents								-15	1	2
Change in cash and cash equivalents								-67	60	27
Cash and cash equivalents at beginning of year			232					232	172	145
Cash and cash equivalents at end of year	$165			$232			$172	$165	$232	$172

SUMMARIZED_UNAUDITED_QUARTERLY2

SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
Net sales	$467	$558	$609	$556	$544	$569	$590	$528	$2,190	$2,231	$2,196
Gross profit	96	134	158	120	133	121	146	110
(Loss) earnings from continuing operations	703	15	43	10	13	-44	27	-18	771	-22	103
(Loss) earnings from discontinued operations, net of tax				1	-3	7	26	-5	1	25	-2
Loss on sale of discontinued operations, net of tax			-4	-5	-31	-3	-146		-9	-180
Net earnings (loss)	703	15	39	6	-21	-40	-93	-23
BASIC PER SHARE INFORMATION - ATTRIBUTABLE TO CHEMTURA:
(Loss) earnings from continuing operations, net of tax (in dollars per share)	$8.57	$0.17	$0.46	$0.10	$0.13	($0.45)	$0.27	($0.18)	$8.55	($0.23)	$1.04
(Loss) earnings from discontinued operations, net of tax (in dollars per share)				$0.01	($0.03)	$0.07	$0.26	($0.05)	$0.01	$0.26	($0.02)
Loss on sale of discontinued operations, net of tax (in dollars per share)			($0.04)	($0.05)	($0.32)	($0.03)	($1.48)		($0.10)	($1.84)
Net earnings (loss) attributable to Chemtura	$8.57	$0.17	$0.42	$0.06	($0.22)	($0.41)	($0.95)	($0.23)	$8.46	($1.81)	$1.02
DILUTED PER SHARE INFORMATION - ATTRIBUTABLE TO CHEMTURA:
(Loss) earnings from continuing operations, net of tax (in dollars per share)	$8.44	$0.17	$0.46	$0.10	$0.13	($0.45)	$0.27	($0.18)	$8.43	($0.23)	$1.04
(Loss) earnings from discontinued operations, net of tax (in dollars per share)				$0.01	($0.03)	$0.07	$0.26	($0.05)	$0.01	$0.26	($0.02)
Loss on sale of discontinued operations, net of tax (in dollars per share)			($0.04)	($0.05)	($0.32)	($0.03)	($1.46)		($0.10)	($1.84)
Net earnings (loss) attributable to Chemtura (in dollars per share)	$8.44	$0.17	$0.42	$0.06	($0.22)	($0.41)	($0.93)	($0.23)	$8.34	($1.81)	$1.02
Basic weighted - average shares outstanding (in shares)	82	89.4	93.2	96.3	96.6	97.5	98.6	98.2	90.2	97.7	98.2
Diluted weighted - average shares outstanding (in shares)	83.3	90.7	94.4	97.8	98.1	97.5	99.7	98.2	91.5	97.7	98.8
Restructuring Charges	19		4	2	14	3	11	14	25	42	11
Accelerated depreciation of certain fixed assets		4							4	1
Pre-tax charges for gain on sale of the agrochemical manufacturing business									-9	-188
Gain on sale of business	529								529
Loss on early extinguishment of debt	($7)					$50			($7)	($50)	($1)